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ABSTRACT OF DISERTATION 
 
 
 
THE ROLE of SYNTAXIN AND TOMOSYN  
IN PLATELET SECRETION 
 
 
Platelet secretion is important for hemostasis and thrombosis.  The components 
released are also involved in atherosclerosis, inflammation, angiogenesis, and tumor 
growth.  Though the exact mechanism(s) of platelet secretion is still elusive, 
accumulating evidence demonstrates that SNAREs (Soluble N-ethylmaleimide Sensitive 
Factor Associated Receptor) and their regulatory partners are critical for platelet 
exocytosis.  Formation of a trans-bilayer complex composed of one v-SNARE (i.e. 
VAMPs) and two t-SNAREs (i.e. syntaxin and SNAP-25-type) is minimally required for 
membrane fusion.  Regulatory proteins control the rate and specificity of the complex 
assembly.  VAMP-8 and SNAP-23 (a SNAP-25-type t-SNARE) are clearly important; 
however, the identity of the functional syntaxin has been controversial.  Previous studies, 
using anti-syntaxin antibodies in permeabilized platelets, suggested roles for both 
syntaxin-2 and -4.  These conclusions were experimentally tested using platelets from 
syntaxin knockout mice and from a Familial Hemophagocytic Lymphohistiocytosis type 
4 (FHL4) patient that lacks syntaxin-11.  Platelets from syntaxin-2 and syntaxin-4 single 
or double knockout mice had no significant secretion defect.  However, platelets from the 
FHL4 patient had a robust defect, though their morphology, activation, and cargo levels 
appeared normal.  Semi-quantitative western blotting showed that syntaxin-11 is the most 
abundant syntaxin in both human and murine platelets.  Co-immunoprecipitation 
experiments showed that syntaxin-11 forms SNARE complexes with VAMP-8 and 
SNAP-23.  These data conclusively demonstrate that syntaxin-11, but not syntaxin-2, or -
4, is required for platelet exocytosis.   
We also show that a syntaxin binding protein, tomosyn-1, is important for platelet 
exocytosis and hemostasis.  Tomosyn-1 was identified from platelet extracts using 
affinity chromatography, RT-PCR analysis, and western blotting analysis.  Tomosyn-1 
was co-immunoprecipitated with syntaxin-11/SNAP-23 from both resting and activated 
 iv 
 
platelet extracts.  Platelets from tomosyn-1-/- mice displayed a secretion defect, but their 
morphology and activation appeared normal.  Tomosyn-1-/- mice showed impaired 
thrombus formation in two different injury models.  Given the importance of platelet 
secretion to hemostasis, it is hoped that the insights gained from these studies in this 
dissertation will help to identify new and more valuable therapeutic targets to control clot 
formation. 
 
 
 
KEYWORDS: PLATELET EXOCYTOSIS, SNARE, SYNTAXIN-11, TOMOSYN-1, 
Familial Hemophagocytic Lymphohistiocytosis 4 (FHL4) 
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Chapter One 
Introduction 
 
 
Platelet Overview:  
Platelets are small, anucleated blood cells produced from megakaryocytes in bone 
marrow [1].  Their structures are simple: they contain plasma membrane, microtubules, 
mitochondria and three types of storage granules: dense granules, α-granules and 
lysosomes.  Platelets respond to vascular damage via surface receptors that directly bind 
to agonists exposed or produced at the site of damage.  The resulting activation leads to 
increases in intracellular Ca2+, dramatic changes in cell shape and release of granule 
contents.  These steps help to attract more platelets which aggregate to form a thrombus, 
which stops bleeding.  Hypoactive platelets lead to bleeding problems [2]; hyperactive 
platelets cause spurious thrombosis which leads to occlusive events such as heart attack 
or stroke [3, 4].  Thus, regulating and controlling platelet function has significant 
therapeutic value for preventing cardiovascular diseases. 
Secretion of the cargo from the platelet’s three stores is critical for hemostasis [1, 
5-7] and important for other diseases [8-10].  Hemostasis is a physiological process to 
stop bleeding from an injured vessel. Platelets first adhere and aggregate to the damaged 
site to form a platelet rich thrombus.  ADP release from dense granules serves as 
secondary agonists to activate and recruit other circulating platelets, thus it is important 
for secretion dependant platelet aggregation.  Followed by the coagulating cascade 
activation and thrombin generation, a fibrin rich clot is formed to temporarily seal the 
vessel wall.  Fibrinogen and Factor V from α-granules participate in fibrous clot 
formation, clot retraction, and coagulation [1, 11, 12].  Finally, the released growth 
factors from α-granules initiate the wound repair.  Lysosomal proteins are thought to 
assist in clot remodeling.  Platelet secretion defects have been shown to ablate or at least 
delay thrombogenesis in murine models [13].  Platelet secretion is not only important for 
hemostasis and thrombosis but it is also associated with many pathological processes 
such as inflammation, atherosclerosis, angiogenesis and tumor growth.  Platelets are 
thought to contribute to the initiation and propagation of the inflammatory process 
  2 
through secretion of bioactive components such as chemokines, cytokines, and 
procoagulants from α-granules [7, 14].  Platelets with dense granule secretion defects 
show reduced formation of platelet-leukocyte aggregates and arterial [15].  
Atherosclerosis is a chronic inflammatory disease on the arterial walls characterized by 
the infiltration of immune cells [8, 9].  Accumulating evidence demonstrates that platelets 
play a role in both the initiation and progression of atherosclerosis [16, 17].  Chemokines 
and P-selectin from α-granules are thought to be the factors. Specific knockout of platelet 
P-selectin reduces plaque lesion development in apoE null mice [18].  Inhibition of the 
interaction between platelet chemokines decreases the progression of atherosclerosis [19-
21].  Upon stimulation, platelets release a variety of pro-angiogenic proteins, such as 
vascular endothelium growth factor (VEGF), platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF), and epidermal growth factor (EGF) [5].  These 
angiogenic activators promote vessel wall permeability and proliferation of endothelial 
cells and fibroblasts, thus facilitating tumor growth [10, 22].  Understanding the 
mechanism of platelet secretion and secretory machinery has the potential to lead to the 
development of new drug targets for bleeding problems, thrombosis, atherosclerosis, 
heart attack, stroke, cancer, and inflammation. 
 
Platelet Structure and Function 
Platelets contain mitochondria, microtubules, granules, plasma membrane and a 
specialized region of the plasma membrane called the open canalicular system (OCS).  
On the plasma membrane, there are receptors including protease activated receptors 
(PAR1, 3, 4), GPVI, and purinergic receptors (P2Y1 and P2Y12) which are involved in 
platelet activation [1, 23].  The OCS is an invagination of the plasma membrane which is 
thought to be an important site for granule secretion and endocytosis [24].  There are 
three types of granules (Figure 1): α-granules, dense granules, and lysosomes.  The most 
abundant granules, α-granules, contain polypeptides such as platelet derived growth 
factor (PDGF), cytokines, von Willebrand factor, P-selectin, fibrinogen, GPIIb/IIIa and 
platelet factor IV (PF4).  The cargo released from α-granules are important for platelet 
aggregation, wound repair, and inflammation.  Dense granules contain small molecules 
such as ADP, calcium, magnesium, and 5-hydroxytryptamine (5-HT, serotonin), which 
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serve as signaling molecules or ligands to recruit and activate other platelets to the lesion 
site.  Lysosomes contain hydrolytic enzymes such as β-hexosaminidase, cathepsin D, and 
acid phosphatases, which are thought to be important for clot remodeling.  Platelets also 
contain cytoskeletal structures which are necessary for maintaining the resting platelet 
and changing its shape during activation.   
The primary function of platelets is the maintenance of pressurized vasculature 
integrity.  When the receptors on the platelet surface detect vascular damage, such as 
exposed matrix collagen or von Willebrand factor (vWF) from damaged endothelial cells, 
platelets are activated.  Initially, the activated platelet undergoes a rearrangement of its 
actin-based cytoskeleton sending out filopoida then lamellipodia, centralizing its granules 
and spreading onto the damaged area.  This increases the surface contact sites.  The 
centralized granules fuse with the OCS, resulting in the release of components from the 
dense granules, α-granules, and lysosomes.  Once released, these components propagate 
thrombus formation and activate other circulating platelets to aggregate at the damaged 
site.  Finally, the granule membrane becomes part of the exterior platelet membrane, 
which further increases surface contacts.  Platelet activation and aggregation for 
hemostasis is a tightly regulated process, small changes in this process can result in 
diseases.  Given the central role played by platelet secretion, understanding the 
mechanisms of the platelet secretory machinery might be useful in controlling and/or 
regulating platelet functions.  Such knowledge might direct the development of 
therapeutics that could reduce spurious thrombosis and related vascular diseases. 
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Figure 0-1-1.  The Platelet Ultrastructure. 
Figure 1-1. Platelet Ultrastructure.  (A) A transmission electron micrograph of a 
washed murine platelet.  (B) A cartoon image (made by Dr. Wangsun Choi) of the 
structural components of a platelet: α-granules (blue), dense-core granules (purple), and 
lysosomes (grey).  Microtubules are located at each pole.  The open canalicular system 
(OCS) is the invaginated plasma membrane structure.   
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Platelet Granule Cargo 
To date, hundreds of proteins and small molecules have been shown to be 
secreted from activated platelets [25].  This “secretome” can be classified by granular 
source or proposed function.  Dense granules are the source of small molecules, such as, 
ADP, serotonin, and calcium, which are critical for platelet activation.  α-Granules 
contain proteinaceous components.  Platelets also release lysosomal enzymes i.e. 
cathepsins and β-hexosaminidase, which may facilitate clot remodeling.  Functionally, 
the “secretome” can be divided into even more categories.  The most obvious class is the 
adhesive proteins e.g. fibrinogen, von Willebrand Factor and thrombospondin, which are 
released from α -granules and function in platelet-platelet binding.  The most diverse 
category is the mitogens i.e. IGF-1, VEGF, and bFGF, which promote wound healing and 
vessel regrowth.  Platelets also release chemokines and cytokines i.e. RANTES, IL-8, and 
MIP1α/β which activate passing leukocytes and lead to a range of inflammatory 
responses.  This catalog suggests that platelet secretion may be pivotal in establishing the 
microenvironment at a vessel wound site. Understanding more about how the secretion 
process works may yield a unique tool to control the microenvironment at vascular 
lesions. 
 
Platelet and Granules Biogenesis 
Platelets are produced by precursor cells, megakaryocytes, which are descended 
from pluripotent stem cells in the bone marrow [1].  In the early stages of megakaryocyte 
development, the premegakaryocytes differentiate from pluripotent stem cells and then 
undergo endomitosis and maturation.  Maturation includes four stages: megakayoblasts, 
stage I; basophilic megakaryocytes, stage II; granular megakaryocytes, stage III; and 
platelet-producing megakaryocytes, stage VI.  At the early stages of maturation, this 
progenitor cell gradually acquires distinct structures, including a demarcation membrane 
system, dense tubular system, and granule precursors.  Platelet-specific proteins such as 
platelet factor IV (PF4), and β-thromboglobulin (β-TG) are synthesized and packaged 
into α-granules at the late stages of maturation.  Platelets are then produced from the 
matured megakaryocytes and begin to circulate [26].  Circulating platelets live about 10 
days and are primarily destroyed in the liver and spleen.  Blood platelets have three types 
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of granules with distinct ultra-structure, content, and release kinetics.  The ontogeny of 
these granules and their relationships are unknown.  Both dense core granules and α-
granules originate from trans-Golgi network (TGN) elements in megakaryocytes [5] 
Little is known about the lysosome biogenesis.  Depending on the source, the cargo in all 
three granules can be characterized as endocytic cargo, such as fibrinogen and de novo 
synthesized cargo, such as PF4, β-TG, vWF, and PDGF.  Most cargo are packed into 
granules via one of the two routes.   
 
SNARE Hypothesis 
In 1993, Söllner et al. [27] suggested that the soluble N-ethylmaleimide-sensitive-
factor (NSF) Attachment Protein (SNAP) receptors (SNAREs) are involved in 
neurotransmitter exocytosis.  SNAREs are membrane proteins that contain conserved 
heptad repeat regions which associate to form coiled-coils.  The crystal structures [28] 
show that the SNARE complex is a parallel four-helix bundle with SNARE motifs 
assembled into parallel, twisted coiled-coil four-helix bundles by burying the 
hydrophobic residues inside.  Analysis of this structure shows that it is composed of 
fifteen hydrophobic layers, arranged perpendicular to the axis of the bundle, with a 
central hydrophilic zero-layer containing one R- and three Q-residues connected by 
highly polar bonds.  Accordingly, the contributing SNARE motifs are classified as Qa-, 
Qb-, Qc- and R-SNAREs [29-31] (Figure 1-2).  The endosomal SNARE complex [32], 
which contains syntaxin-7 (Qa), Vti1b (Vps ten interacting-1b, Qb), syntaxin-8 (Qc) and 
VAMP-8 (R), has a similar structure, suggesting that the hydrophobic layers that 
surround the “0” layer are highly conserved. The formation of SNARE complexes is 
thought to make membrane fusion energetically favorable. 
 
Reconstituted proteoliposome experiments confirm that SNAREs are minimally 
sufficient for membrane fusion [33].  According to the original definition, SNAREs that 
reside on vesicles (or granules) are referred to as v-SNAREs (also called vesicle 
associated membrane proteins, VAMPs, R-SNAREs) and SNAREs that reside on target 
membranes are t-SNAREs (Q-SNAREs).  VAMPs and syntaxins are generally type II 
integral membrane proteins with their SNARE motifs facing the cytoplasm [30].  The 
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core SNARE complex is comprised of one helical domain each from syntaxin (Qa) and v-
SNARE (R-SNARE) and two from SNAP-25 (Qb,c).  Therefore, functional SNARE 
complexes bridge the two fusing bilayers as hetero-oligomer, requiring one of each of the 
Qa-, Qb-, Qc- and R-SNAREs.  There are several v-SNAREs (R-SNARE): cellubrevin, 
VAMP1-12, etc [34], and two types of t-SNAREs: syntaxin-like (Qa) and SNAP-25-like 
(Qbc).  Numerous syntaxin-like homologues have been reported (syntaxin-1 to -19) [35], 
while there are only a few SNAP-25-like t-SNAREs (SNAP-23, SNAP-25, SNAP-29, 
Sec9p) [34].   
Although most SNAREs have a standard integral-membrane protein structure, 
there are some exceptions.  SNAP-25-like t-SNAREs lack transmembrane domains 
(TMD) and are generally anchored to the membrane through thiolester-linked acyl 
groups.  A stretch of cyteines in the linker between SNARE motifs are through to be 
modified.  A subset of VAMPs lacks TMD but have hydrophobic post-translational 
modifications that mediate membrane anchorage.  For example, Ykt6, a S. cerevisiae 
VAMP, has a C-terminal CAAX box that is farnesylated [36].  Similarly, the mammalian 
syntaxin-11 does not contain a TMD, but instead has a cluster of six cysteine residues, 
which are predicted to anchor to the membrane through palmitoylation.  Studies by using 
transfected NRK cells and human B lymphocytes have demonstrated that syntaxin-11 
behaves like an integral membrane protein [37, 38].  Though the hydrophobicity of these 
TMD surrogates is critical for in vitro fusion of proteolipisomes [39], it not clear what 
degree of modification is required in vivo. 
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Modified from Jahn et al. [30] 
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Figure 0-2: The Structure of SNAREs and SNAREs 
Figure 1-2. The Structure of SNAREs.  Qa-SNAREs have N-terminal three-helix 
bundles (called the Habc domain).  The N-terminal domains of Qb-, Qc- and R-SNAREs 
are represented by an oval shape.  SNARE motifs are shown as rectangles. 
Transmembrane domains are shown as gray rectangles.  Qbc-SNAREs represent a small 
subfamily of SNAREs (the SNAP-25-like t-SNAREs), that contain one Qb-SNARE 
motif and one Qc-SNARE motif.   
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SNARE Machinery in Platelets 
To date, four VAMPs (-2, -3, -7, -8), four syntaxins (-2, -4, -7, -11), and SNAP-
23, SNAP-25, and SNAP-29 have been demonstrated to be present in platelets [40-47].  
Studies involving in vitro permeabilized platelet secretion assay, genetic manipulation 
and ex vivo platelet secretion assays, in vivo studies, and human genetic disorders have 
helped to identify many important proteins associated with platelet exocytosis.  In this 
thesis, we show a role for syntaxin-11.  Biochemical studies have also identified potential 
SNARE regulators that interact with t-SNAREs or t-SNARE complexes.  Some of these 
proteins have been shown to be important (i.e. Munc13-4, Rab27) [48-50] and others 
have yet to be characterized (i.e. granuphilin and tomosyn), which will be described in 
this thesis (i.e. tomosyn) [Figure 4-1 and Table 4-1].   
Proteins interacting with t-SNAREs or t-SNARE complexes are potential SNARE 
regulators.  With this notion, several components have been identified, such as Munc18b, 
Munc13-4, tomosyn-1, and granuphilin [Figure 4-1 and Table 4-1].  Some of them have 
been shown to be important secretory regulators in platelets [48-50]. 
 
Platelet v-SNAREs 
Four v-SNAREs: synaptobrevin/VAMP-2, cellubrevin/VAMP-3, TI-
VAMP/VAMP-7, and endobrevin/VAMP-8 [43-47] have been detected in platelets.  For 
the sake of simplicity, only the VAMP nomenclature will be used.  VAMP-8 is the most 
abundant v-SNARE in both murine and human platelets [46].  Oddly, VAMP-2 is almost 
as abundant in murine platelets but is almost undetectable in human platelets.  VAMP-3 
and VAMP-7 are detected at approximately similar levels and a per platelet basis. 
VAMP-3, a homolog of VAMP-1 and -2, was first identified in human platelets in 
1999 by PCR and cloning [43] and reported to play a role in α-granule secretion [44].  It 
was thought that VAMP-3 was required for platelet secretion since other VAMPs had not 
been identified in platelets at that time and a commercial preparation of VAMP-1/2/3-
cleaving Tetanus toxin inhibited secretion from permeabilized platelets [44, 51].  
Consistently, studies using an anti-VAMP-3 peptide antibody [52] inhibited Ca2+-
induced alpha-granule secretion by approximately 50%, and the cytoplasmic domain of 
VAMP-3 affected both dense and α-granule secretion [45].  Although in vitro 
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permeabilized platelet studies using antibodies, toxins, and peptides have potential 
drawbacks such as steric hindrance by antibodies, contaminants in the commercial 
preparations and cytoplasmic-domain-binding promiscuity.  It was surprising when 
platelets from VAMP-3 null mice had no secretion defect [53].  These ex vivo studies 
demonstrated that VAMP-3 was not absolutely required.  During the analysis of VAMP-3 
null platelets, VAMP-2 was detected in both human and murine platelets.  Considering 
that VAMP-2 is important for neurotransmitter release [54, 55], and Tetanus toxin had 
affected permeabilized-platelet secretion, it could play a role in platelet secretion.  
However, partial deletion of VAMP-2 (~50% reduction) had no defect on murine platelet 
secretion nor did deletion of VAMP-3 and reduction of VAMP-2.  These results indicated 
that neither VAMP-2 nor VAMP-3 were essential for platelet secretion.  VAMP-7 was 
found in platelets using western blot analysis, however there was no evidence, using 
antibodies and inhibitor peptides, to show that VAMP-7 is involved in platelet secretion.  
VAMP-7 was first identified in epithelial cells as a TeNT-insensitive VAMP (TI-VAMP) 
involved in exocytosis [56].  Its unique amino-terminal regulatory Longin domain was 
thought to be involved in post-Golgi and endosomal trafficking [57].  VAMP-8, was 
originally identified as an endosomal v-SNARE involved in fusion between early and late 
endosomes [58], [58], but subsequent studies suggested a role in many regulatory 
secretion processes [59-62].  The cytosolic domain of VAMP-8 did not have a dominant 
negative effect on platelet secretion [45].  More conclusive studies by Ren at al. [46] 
clearly showed that VAMP-8 is required for platelet secretion.  In comparative analysis 
of platelets from VAMP-3-/-, VAMP-2+/-, VAMP-2+/- /VAMP-3-/-, and VAMP-8-/- mice, 
only those lacking VAMP-8 had attenuated secretion.  Permeabilized VAMP-8-/- mouse 
platelets further treated with Tetanus toxin showed no release; all three secretion events 
were totally abolished.  These findings indicate that VAMP-8 is required for normal 
granule secretion though VAMP-2 and -3 do appear to compensate, in a less efficient 
manner, when VAMP-8 is absent.  This suggested that perhaps there is a hierarchy in 
VAMP usage with VAMP-8 being the primary v-SNARE required for rapid and efficient 
release and VAMP-2 or-3 play a secondary role.  This ranked redundancy of v-SNARE 
usage has been seen in neuroendocrine chromaffin cells from the studies of VAMP-2 KO 
mice [55].  Alternatively, this differential usage could imply distinct fusion steps leading 
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to release: primary granule-plasma membrane vs. granule-granule (compound) fusion  
Studies by Jonnalagadda and co-workers (Jonnalagadda et al, in preparation) suggest that 
granule cargo release is best described as a mixture of single and compound fusion 
processes that have distinct rates.  Clearly more experimentation will be required to 
understand the precise kinetics of VAMP usage and granule secretion.  That said, it is 
clear that among the four VAMPs (-2, -3, -7, -8), VAMP-8 is the primary v-SNARE 
required for platelet secretion and VAMP-2 and -3 play some less efficient compensatory 
role.  It is possible that such ranked redundancy in SNARE usage might be common for 
many important physiological processes. 
 
Platelet t-SNAREs 
Fusogenic SNARE complex in platelets is thought to be formed by one v-SNARE 
and two different t-SNAREs, which include a SNAP-25-type and a syntaxin-type.  
Although reports indicate that all three SNAPs (SNAP-23, -25, -29) [5, 63] are present in 
platelets, we have only detected SNAP-23 in significant quantities.  This family of t-
SNAREs does not contain classical TMD’s but instead is anchored in the membrane via 
thioester linked palmitates attached to a series of cysteines between the two SNARE 
motifs.  Perhaps between of the type of membrane anchor, SNAP-23 rapidly relocalizes 
to lipid rafts upon platelet activation (Karim et al, in preparation).  Studies using 
inhibitory antibodies and peptides in permeabilized platelets suggest that SNAP-23 is 
required for all three granule secretion events [40, 41, 44, 45, 63-65].  Co-
immunoprecipitation experiments indicate that SNAP-23, in platelet extracts, can 
associate into complexes with most of the platelet syntaxin (-2, -4, -11) and with at least 
VAMP-3 and -8.  SNAP-23 is phosphorylated upon activation, suggesting SNAP-23 
might be an important link between the platelet activation signaling event and the 
regulatory secretion process [45, 66].  A study by Polgar et al [45], revealed that human 
platelet SNAP-23 is phosphorylated at Ser23/Thr24 and Ser61 after platelet activation by 
thrombin.  In murine mast cells and platelets, SNAP-23 is phosphorylated at Ser95 or 
Ser120 [66].  SNAP-23 is also a substrate for calpain in activated platelets.  Calpains are 
calcium-dependent, non-lysosomal, neutral, cysteine proteases present in most 
mammalian tissues.  Several inhibitors, i.e. calpeptin, calpastatin, and E64d, block 
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SNAP-23 cleavage in heavily activated platelets [67, 68].  It is not clear what role SNAP-
23 cleavage plays since calpain inhibitors had limited effects on release of soluble cargo.  
Given the caveats of the described experiments, it seems reasonable to conclude that 
SNAP-23 is important for platelet secretion.  Studies with knockout murine strains or 
humans with SNAP-23 defects will be required to confirm this conclusion.  However, 
global deletion of SNAP-23 is embryonic lethal and attempts to make condition deletion 
strains have been unsuccessful [69] (Dr. Roche, NCI, personal communication with Dr. 
Whiteheart). 
In addition to the SNARE motif, syntaxins contain an additional N-terminal 
helical domain (the Habc domain), which is thought to serve a regulatory and/or auto-
inhibitory function.  Initial studies focused on syntaxin that had predominantly plasma 
membrane localization in nucleated cells.  Syntaxin-2 and -4 were first detected in 
platelets but syntaxin-1, -3, and -5 were not [5, 64].  Both syntaxin-2 and -4 had been 
shown to be involved in other secretion events [38, 70-72] and studies using 
permeabilized platelets suggested that syntaxin-2 was important for all three granule 
release events while syntaxin-4 played a role in only alpha granule and lysosome release 
[40, 41, 44].  These early data suggested that syntaxin-2 and -4 was important for platelet 
secretion.  Strikingly, platelets from mice lacking either syntaxin-2 and -4 alone or 
together showed no secretion defect [Chapter 3, this thesis].  As with the studies with 
VAMPs, these conflicting data showed that syntaxin-2 and -4 are not required for 
secretion from mouse platelets.  As shown for the VAMPs, using antibodies as inhibitors 
can lead to ambiguous results.  Considering that the syntaxin-2 polyclonal antibody used 
as an inhibitor in the permeabilized platelets [40, 41] was generated against full length 
recombinant protein, it is possible that this antibody was not as isoform-specific as was 
thought.  The experiments in this thesis directly address the question of which syntaxin 
isoform(s) is/are required for platelet secretion.  
Syntaxin-7 is localized to an intracellular compartment instead of the plasma 
membrane in nucleated cells [38] and thus was not considered a likely candidate to 
mediate platelet exocytosis.  Although syntaxin-7 was found in platelets over 10 years 
ago [40], the role of syntaxin-7 is still unclear.  Introducing specific syntaxin-7 antibodies 
into permeabilized platelets had no effect on any of the three granule secretion events 
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[42].  This is the only data to suggest that syntaxin-7 is not required for platelet 
exocytosis.   
Finally, proteomics studies were the first to show that syntaxin-11 is present in 
platelets [73].  Syntaxin-11 is a unique member of syntaxin family which has the Habc 
and SNARE motifs but lacks a classical TMD.  It appears to be anchored to membranes 
via, yet to be defined modifications of its C-terminal cysteine residues [74] [37].  
Syntaxin-11 is associated with late endosomes and the trans-Golgi network in Hela cells 
[37].  Interestingly syntaxin-11 mutations are associated with Familial Hemophagocytic 
Lymphohistiocytosis type 4 (FHL4).  FHL4 is a rare autosomal recessive disorder of 
immune dysregulation associated with uncontrolled T cell and macrophage activation.  
Patients usually present with fever, hepatosplenomegaly, and cytopenias.  Syntaxin-11 
deficient NK-cells exhibit a defect in cytotoxic granules degranulation .ndicating that 
syntaxin-11 could be involved in fusion to the plasma membrane.  However, other studies 
show that activation of syntaxin-11 deficient T-cells with IL-2 does restore degranulation 
[75, 76].  Comparative analysis  of wild type and syntaxin-11 deficient CD8+ T-cells 
suggested that syntaxin-11 affects the granule-granule fusion step before final fusion with 
the plasma membrane [76].  These data suggest that syntaxin-11 is important for T-cell 
degranulation although its mode of action is not clear. Moreover, syntaxin-11 also has 
been shown to play a negative regulatory role in macrophage [77].  Syntaxin-11 regulates 
Vti1b-containing SNARE complex formation by directly binding to Vti1b (Qb-SNARE), 
thus controlling late endosome to lysosome fusion.  Considering that cytotoxic T-
lymphocyte (CTL) and natural killer (NK) cell require syntaxin-11 for membrane fusion 
and degranulation, this negative role for syntaxin-11 in macrophage suggests that the 
function of syntaxin-11 may be tissue- or SNARE-specific.  Further studies are required 
to demonstrate the different roles of syntaxin-11 in these immune cells. Work in this 
thesis shows that syntaxin-11 is important for platelet exocytosis (Chapter 3). 
 
SNARE Regulators in Platelets 
Regulated platelet secretion happens only in respond to external signals, but how 
these signaling pathways are coupled to the SNARE machinery is still not clear.  Based 
on the number of binding partners identified and the presence of the Habc domain, it has 
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been thought that most regulation of SNAREs is through the syntaxins.  Very few VAMP 
and SNAP-23/25 regulators have been identified.  In addition, post-translational 
modifications, such as phosphorylation of SNAREs and SNARE regulators could provide 
links from signaling to secretion.  Several potential SNARE regulators have been 
identified in platelets and most are associated with t-SNARE heterodimers or t-SNARE 
containing complexes.  We will discuss what is known about the following: Munc18b, 
Munc13, granuphilin, and tomosyn. 
 
Munc18s 
Munc18s belong to the evolutionally conserved Sec1/Munc18 (SM) family, which 
is a critical component of the secretory machinery [30].  There are three mammalian 
Munc18 isoforms and all (Munc18a, b, and c) have been detected in human and murine 
platelets by immunoblotting and/or PCR [47, 63, 78].  It has been thought that different 
SM proteins are required for specific secretion steps through their interactions with 
specific syntaxins.  Munc18a is almost exclusively expressed in neurons where it binding 
to syntaxin-1 while Munc18c is ubiquitous expressed in other tissues and appears to 
interact with syntaxin-4 [79].  In platelets, Munc18a was shown to interact with syntaxin-
2, Munc18c with syntaxin-4, and Munc18b was found associated with SNARE 
complexes [47] and with syntaxin-11 (Al Hawas et al. in preparation).  Early studies 
suggested that Munc18c phosphorylation and Munc18c/syntaxin-4 complex formation 
could be important for platelet secretion [63, 78].  Monoclonal antibodies that disrupted 
Munc18c/syntaxin-4 complexes had a positive effect on release from permeabilized 
platelets [63].  Further, introduction of peptides, based on conserved regulatory domain 
of Munc18s, peptides into permeabilized platelets inhibited Ca2+-stimulated release from 
all three granule release events [47].  These in vitro studies suggest that Munc18s was 
important for platelet secretion.  Surprisingly, platelets from Munc18c heterozygous mice 
(with a ~50% reduction in Munc18c) exhibited normal stimulus-induced release [80].  
Double deletion of Munc18c died either in utero or within 6 hours after birth [81].  Based 
on that the syntaxin-4 level is reduced ~50% in Munc18c heterozygous mouse platelets, it 
is consistent with Munc18c being the chaperone for syntaxin-4.  The association between 
Munc18c and syntaxin-4 is required for the stability of both proteins [47, 80].  Although 
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in vitro studies [47] suggest Munc18c plays a role in platelet secretion, the lack of 
secretion defect could be attributed to functional compensation by other Munc18s.  
Munc18a levels are low in human and murine platelets and though it is phosphorylated 
and binds syntaxin-2 [47, 63], it is not clear if it plays any role in exocytosis.  The most 
promising candidate for a functional Munc18 in platelets is Munc18b.  Munc18b is the 
most abundant isoform and it was found to interact with syntaxin-11.  Munc18b was also 
detected in pull-down experiments using SNARE complexes [47] and t-SNARE 
heterodimers (Figure 4-1A and Table 4-1).  Most importantly, Sandrock et al [50] and 
our unpublished data (Al Hawas et al. in preparation) showed that Munc18b deficient 
platelets from Familial Hemophagocytic Lymphohistiocytosis type 5 (FHL5) patients 
have a robust secretion defect suggest that Munc18b is required for platelet secretion.  
The fact that heterozygous patients have a partial secretion defect might suggest that 
Munc18b is a limiting factor in the secretion process remains to be tested.  Syntaxin-11 
levels were affected in these patients. 
 
Rab Proteins 
The Rab subfamily of small Ras-like GTPase includes over 60 members in 
mammals and regulates intracellular membrane traffic [82].  Several Rab proteins have 
been identified in platelets, such as Rab3B, Rab4, Rab6, Rab8, and Rab27 [83-86].  It is 
generally thought that different Rabs regulate different secretion routes through 
associations with specific effectors.  It has been shown that Rab6 and Rab8 are 
preferentially targeted to the plasma membrane and α-granules [83].  Studies using a 
dominant negative mutant of Rab4 suggested that Rab4 regulates α-granule but not dense 
granule secretion [85].  Biochemical studies have shown that the majority of Rab27 is 
associated with dense granules while a small portion is located on the plasma membrane 
[49].  Rab27ab are involved in both dense granule biogenesis in megakaryocytes and in 
platelet secretion.  Deficiency of Rab27a in ashen mice exhibits “ghost” dense granules 
(with normal number but defective contents) [84] while  loss of Rab27b shows around 
50% reduction in both dense granule number and serotonin content [86] with normal α-
granule contents and secretion. This data suggest that the Rab27 family is critical for 
dense granule biogenesis, but not important for α-granule and lysosome biogenesis.  
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Further Rab27 double KO murine platelets display more severe defect in serotonin 
secretion than single Rab27b KO, indicating that Rab27a can partially compensate for 
dense granule secretion [86].  The exact role of Rab27 in dense granules remains unclear.  
Presumably the distinct functions of Rab27 require different effectors.  The fact that one 
of Rab27b effectors, Munc13-4, is required for platelet secretion [48, 49] could explain 
why Rab27b plays a role in exocytosis.  It is also possible that Rab27s interacts with 
unknown factors, which are important for dense granule package and trafficking.  On the 
other hand, Munc13-4 is not required for granule biogenesis since there is no granule 
defects observed in Munc13-4 depleted murine platelets [48].  Further exploration of the 
mechanisms for Rab27 function in platelet secretion will clarify whether different granule 
secretion requires specific sets of Rab proteins, effectors, or even secretory machinery 
components in platelets.   
 
Munc13s 
The Munc13 family has four members: Munc13-1, -2 and -3 are expressed in 
neuron tissue; Munc13-4 is ubiquitously expressed.  Munc13s are widely believed to be 
key vesicle priming factors.  The strongest evidence is from genetic ablation of both 
Munc13-1 and Munc13-2 in neurons.  This completely abolishes synaptic vesicle priming 
and release [87, 88].  Munc13-4 was first identified in platelets as a Rab27a binding 
partner [49] and is essential for platelet secretion.  Mice lacking Munc13-4 have a severe 
bleeding diathesis and the release from dense granules is totally abolished while release 
from α-granules and lysosomes is severely impaired [48]. This shows that Munc13-4 
mediates at least one step that is uniquely required for rapid dense granule release, a step 
that is also critical for hemostasis in vivo.  The residual secretion from α-granules and 
lysosomes could be due to compensation by another Munc13 family member considering 
that both Munc13-1 and Munc13-4 can interact with Munc18a/syntaxin-2 complex in 
platelets (Figure 4-8).  Compared to other Munc13s, Munc13-4 does not contain a 
diacylglycerol-binding C1 domain, but does have two calcium/phosphatidylserine-
binding C2 domain (C2A and C2B) and Munc Homology Domains (MHD).  Mutations 
in the MHD domain or deletion of C2B result in FHL3 in humans [89].  Recombinant 
Munc13-4 lacking C2B potently inhibits platelet secretion from permeabilized cells [48] 
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suggests that both the MHD domain and C2B domain are important for its function.  It is 
possible that the MHD domain is required for interactions with important secretory 
machinery components while C2B is important for anchoring to the plasma membrane or 
regulating membrane fusion in response to Ca2+ signaling.  Identification of key Munc13-
4 interacting partners will be an important step in understanding the SNARE complex 
formation and membrane fusion upon stimulation.  Clearly Rab27 is a possible 
candidates as is another Rab27 effector called granuphilin since they are present in 
platelets.. Another possible candidate Munc13-4 effector is DOC2α because it have been 
shown to interact with other Munc13 isoforms. In summary, Munc13-4 is an essential 
component in dense granule secretion pathway.  Further exploration of its mechanism 
will not only identify new elements of the secretory machinery, but also clarify whether 
secretion of different granules requires specific sets of secretory machinery in platelets.   
 
Synaptotagmin-Like Proteins (Slps):  
Slps possess a C-terminal synaptotagmin-like domain with C-terminal tandem C2 
domains (putative Ca2+-dependent phospholipid binding sites) and an N-terminal Rab27-
binding domain.  There are five Slp isoforms (Slp1 to 5) in mammals [90].  Slp1 and Slp4 
(or granuphilin) are present in platelets [91].  Studies by Neumuller et al [91] 
demonstrated that purified Slp1 can partially inhibit dense granule secretion from 
permeabilized platelets.  Endogenous Slp1 forms a trimetric complex with Rap1GAP2 
and Rab27, suggesting Slp1 is a Rab27 effector that regulates dense granule secretion.  
Though little is known about granuphilin in platelets, it has been well studied in other 
secretory cells.  Granuphilin is abundantly expressed in beta cells and considered to be 
essential for the stable attachment of insulin granules to the plasma membrane where it 
acts by linking Rab27a on the granule membrane with the syntaxin-1a/Munc18a complex 
on the plasma membrane [92].  Loss of granuphilin causes a decrease in docked granules 
in these cells [93].  Granuphilin can bind to both syntaxin-1a and Munc18a [94-96].  The 
enhanced insulin secretion from granuphilin deficient beta cells [97], despite the docking 
defect, argues for it being a negative regulator.  Granuphilin could have a negative effect 
on a step just prior to the final fusion reaction.  It is possible that a local signal such as 
increased [Ca2+]i after stimulation may cause dislocation of granuphilin from the 
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Munc18a-syntaxin-1a complex and allow SNARE assembly.  This is consistent with the 
ability of both Slp and Munc13 families binding Rab27 and containing C-terminal Ca2+ 
binding C2 domains.   
 
Tomosyn-1 
Tomosyn-1 belongs to a family of WD-40 repeat containing proteins associated 
with exocytosis including Sro7/Sro77 in yeast, Tom1 in c.elegans, amisyn and lethal 
giant lavea (lgl) in mammalian [98-101].  Two genes, tomosyn-1 and tomosyn-2, were 
found in mammalian but alternative splicing can produce a total of seven isoforms [102, 
103].  Little is known about the exact role of tomosyn-2 in secretion [102] while 
tomosyn-1 is well studied in neuron and endocrine cell exocytosis.  Tomosyn-1 has three 
isoforms (b-, m-, s-) and has several predicted phosphorylation sites (Figure 1-3).  m-
tomosyn-1 was originally identified as a syntaxin-1 binding partners from rat brain tissue 
cell [104].  The s-tomosyn-1 and m-tomosyn-1 isoforms are enriched in synapse-specific 
domains while b-tomosyn-1 is ubiquitously expressed [105].  Structurally, mammalian 
tomosyn-1 contains an N-terminal WD40 repeat, a small highly variable linker region, 
and a C-terminal R-SNARE (v-SNARE) motif [103].  Both the R-SNARE motif and N-
terminal WD40 repeat have been shown to inhibit secretion from PC12 cells [106] and 
neurons [107].  Thus tomosyn-1 has been thought as a negative regulator for 
neurotransmitter release events.  Consistently, deletion of tomosyn-1 enhances secretion 
[107].  Over-expression of tomosyn-1, in PC12 cells, reduces the ready-release pool and 
resident time of secretory vesicles [108].  This observation is consistent with the 
hypothesis that tomosyn-1 functions by disrupting vesicle priming.  It has also been 
suggested that the N-terminal WD-40 domain may catalyze the formation of 
nonfunctional SNARE complexes [109] or through its loop region by interactions with 
unknown factors [110].  Alternatively, the SNARE domain could block v-SNARE 
binding to t-SNAREs, thus inhibiting membrane fusion and exocytosis.  Post-
translational modifications such as phosphorylation have been suggested to regulate this 
process [111].  Despite these data, the exact mechanism of tomosyn-1 as negative 
regulator is still unclear. 
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Figure 0-3.  Tomosyn-1 isoforms in rat and human.   
Figure 1-3. Tomosyn-1 Isoforms in Rat and Human.  The domain structure of the 
three isoforms of Tomosyn-1.  b-tomosyn-1 is a full length isoform.  m-tomosyn-1 skips 
exon 20 and 21, and s-tomosyn-1 skips exon 20-22.  The WD40 repeats are in cyan, R-
SNARE coiled-coil motif is in blue, and variable region is in gray.  The bottom panel 
shows the predicted phosphorylation sites in the variable region.  The labels represent 
sites of phosphorylation by PKA as A, PKC as C, PKG as G, casein kinase II as K, GSD3 
and DNAPK as X. 
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Although data supports a negative role for tomosyn-1, it has also been shown to 
function permissively in exocytosis.  Over-expression of tomosyn-1 in SCG neurons 
enhances release [111].  The long term potential (LTP) of mossy fiber without tomosyn-1 
is not inhibited.  Moreover, depletion of both Sro7/Sro77 [100] inhibits secretion while a 
deletion of tomosyn-1 in β-cell causes a secretion defect [112].  In light of our 
observation that tomosyn-1 can form a complex with the t-SNARE heterodimers, 
Munc18C [113], and Munc18b [Figure 4-1], tomosyn-1 could control secretion by 
activating t-SNARE complex and thus facilitating t-/v-SNARE complex formation.  
Experiments in this thesis address the role of tomosyn in platelets. 
 
Cytoskeletal Polymerization and Platelet Secretion 
Upon vascular damage, human platelets become activated and dramatically 
change their shape through cytoskeleton rearrangement.  This precedes granule 
centralization and content release mediated by membrane fusion [114].  Disruption of the 
actin cytoskeleton by latrunculin A or inhibition of actin polymerization with 
cytochalasin E [115] inhibits alpha-granule secretion induced by different agonists.  This 
connects actin polymerization with platelet secretion.  In a recent paper, Woronowicz et 
al. [115] show that the actin cytoskeleton can associate with t-SNAREs and actin 
polymerization is important for alpha-granule secretion.  Further interactions between the 
platelet cytoskeleton and the secretory machinery are yet to be identified. 
 
Platelet Activation and Secretion 
Platelet activation occurs through signaling cascades [116].  Different agonists 
bind to the diverse platelet surface receptors, ultimately leading to common intracellular 
signaling events that activate a phospholipase C (PLC).  Activated PLC catalyzes the 
hydrolysis of phosphatidylinositol 4,5-bisphosphate to release inositol trisphosphate (IP3) 
and diacyglycerol (DAG), which activate calcium mobilization and protein kinase C 
(PKC), respectively.  The hallmark of platelet activation is activation of integrin αIIbβ3 to 
mediate aggreagation [116-118].  Platelet secretion is also one of the end steps of these 
signaling cascades, but how they are connected and how secretion is regulated is still not 
clear.  One hypothesis is that post-translational modification plays an important role. 
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Phosphorylation, S-nitrosylation, or sumoylation of SNARE proteins or their regulatory 
proteins has been suggested to be important.  Another possibility is that secondary signal 
molecules, such as calcium, may remove inhibitory proteins or activate SNAREs.  
Calcium is clearly an important factor in the activation of the secretory machinery, and it 
alone can initiate release from permeabilized platelets.  Calcium influx can also regulate 
actin-binding proteins and caused dissolution of the cortical F-actin, which can affect 
granule localization and and give granules freer access to exocytic sites on the plasma 
membrane.  Depolymerization of cortical F-actin or polymerization of F-actin, or myosin 
Va might mediate the recruitment of secretory granules near the plasma membrane (OCS) 
since granule centralization is observed. 
 
Thesis Overview 
Understanding the molecular mechanism of platelet exocytosis requires the 
identification and characterization of the important core SNARE proteins and their 
regulatory molecules.  The demonstration that VAMP-8 is the primary v-SNARE 
required for platelet secretion and that platelet secretion is mediated by SNARE 
complexes, led to the central hypothesis of this thesis; platelet secretion and hemostasis 
are controlled by primary t-SNAREs and t-SNAREs regulators.  The focus of this thesis 
is to determine the primary t-SNARE(s) required for platelet secretion and the t-SNARE 
regulating proteins.  The answer to this question will not only define the core SNARE 
components required for platelet secretion, but also expand the possible ways to regulate 
platelet function and hemostasis.   
The original anti-syntaxin-2 polyclonal antibody was found to cross react with 
syntaxin-11 and it also immunoprecipitated syntaxin-11 from platelet extracts.  This 
partially explains why syntaxin-2 antibodies inhibited permeabilized platelet secretion 
while syntaxin-2/4 double KO mice have no secretion defect.  The syntaxin-11 deficient 
platelets from a FHL4 patient showed significant defects in dense granule and α-granule 
secretion while lysosome secretion was partially.  The aggregation defect from these 
same platelets is likely caused by an ADP release defect, which is required for a second 
wave of aggregation through activation of integrin αIIbβ3.  Taken as a whole these data 
show that syntaxin-11 is required for platelet secretion. 
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A specific role for tomosyn-1 in platelets has also been studied.  Tomosyn-1 was 
first identified in platelets by mass spectrometry as a specific binding partner of 
recombinant t-SNARE complexes [Chapter 4].  Additionally, we showed that tomosyn-1 
is phosphorylated and associated with SNAP-23 in both resting and activated platelets.  
The role of endogenous tomosyn-1 has been investigated using tomosyn-1 KO mice.  
Tomosyn-1 deficient platelets have a normal aggregation phenotype, but a partial 
secretion defect. The partial nature of the defect suggests that other members from 
tomosyn-1 family may play a compensatory role when tomosyn-1 is missing.  Most 
interestingly, tomosyn-1 deficient mice display a robust bleeding phenotype in two in 
vivo thrombosis models: prolonged bleeding times and impaired thrombosis tail bleeding 
and FeCl3 carotid injury.  These data demonstrate tomosyn-1 is important for hemostasis 
and thrombosis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Shaojing Ye 2012  
  25 
Chapter Two 
Materials and Methods 
 
Materials 
Antibodies 
Anti-syntaxin-2, -4, -7, and SNAP-23 polyclonal antibodies were generated in the 
Whiteheart laboratory as described previously [40, 41].  Anti-syntaxin-11 rabbit 
polyclonal antibody (110113) was purchased from Synaptic System GmbH (Gottingen, 
Germany) while murine monoclonal antibody (611282) was obtained from BD 
Transduction Laboratories (San Jose, CA).  Anti-Munc18a (clone131.1) was from 
Synaptic System (Goettingen, Germany).  Anti-Munc18b antibody (sc-14563) was from 
Santa Cruz Inc.  (Santa Cruz, CA).  Anti-Munc18c polyclonal antibody was produced in 
the Whiteheart laboratory as described previously [47].  Anti-synaptobrevin/VAMP-2 
monoclonal antibody (CL69.1), anti-endobrevin/VAMP-8 polyclonal antibody, anti-rat-
Munc13-1 monoclonal antibody (CL266B1), and anti-cellubrevin/VAMP-3 polyclonal 
antibody were generous gifts from Dr. Jeffery Pessin (Albert Einstein College of 
Medicine).  Anti-TI-VAMP/VAMP-7 monoclonal antibody (TG158.2) was a generous 
gift from Dr. Thierry Galli (Institut Pasteur, Paris, France).  Polyclonal rabbit-anti-human 
VAMP-8 antibody were generated in our laboratory using recombinant versions of the 
cytoplasmic domain of human VAMP-8 (1-73 aa) and the Longin domain of human 
VAMP-7 (1-120 aa) as antigen, respectively.  Anti-RabGDI polyclonal antibody was 
generated in our laboratory by Dr. Tara Rutledge using recombinant RabGDIα as 
antigen.  Anti-tomosyn-1 monoclonal antibody (611296) was purchased from BD 
Transduction Laboratories (San Jose, CA) while anti tomosyn-1 polyclonal antibody (H-
55, sc-98350) was from Santa Cruz Inc.  (Santa Cruz, CA).  Anti-Munc13-4 monoclonal 
antibody (designated as Munc13-4 mAb C) was also generated using the domain C as 
antigen as generous gift from Dr. Christian Wimmer (Basel Institute for Immunology, 
Basel, Switzerland).  Anti-human PF4 monoclonal antibody was obtained from R&D 
Systems (R&D Systems, Minneapolis, MN).  Anti-human LAMP-1 monoclonal antibody 
was obtained from the Developmental Studies Hybridoma Bank (University of Iowa, 
Iowa City, IA).  Anti-fibrinogen monoclonal antibody was purchased from Innovative 
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Research (Southfield, MI).  The monoclonal anti-phospho-tyrosine (pY) antibody (4G10) 
was from Upstate (Lake Placid, NY).  Fluorescein isothiocyanate (FITC)-conjugated 
PAC-1 (recognizes activated αIIb/β3 complex) and phycoerythrin (PE)-conjugated anti-
human CD41a (integrin αIIb) monoclonal antibody were purchased from BD Biosciences 
(San Jose, CA).  FITC-labeled anti-human P-selectin monoclonal antibody (AK-4), 
FITC-conjugated PECAM1 (553372), and FITC-conjugated anti-murine P-selectin 
(553744) were from BD PharmingenTM (BD Bioscience, San Jose, CA).  FITC-
conjugated anti-murine GPVI (M011-1), FITC-conjugated GPIbbeta (M050-1), PE-
conjugated GPIIb/IIIa (M023-2, active form) were purchased from Emfret Analytics 
(Germany).  Anti-phosphotyrosine (clone 4G10) monoclonal antibodies were purchased 
from Upstate Biotechnology (Lake Placid, NY).  Anti-integrin β3 rabbit polyclonal 
antibody was obtained from Cell Signaling (Danvers, MA).  For the sandwich Enzyme-
Linked ImmunoSorbent Assay (ELISA) of human and murine PF4, two sets of paired 
antibodies were used: for human PF4, a monoclonal anti-human PF4 antibody was used 
as the capture antibody (R&D systems) while a biotin conjugated rabbit-anti-human PF4 
polyclonal antibody was used as the detection antibody (Leinco Technologies Inc., St.  
Louis, MO); for murine PF4, a monoclonal, anti-murine PF4 antibody  (R&D systems) 
was used as the capture antibody to bind murine PF4 while a biotin conjugated rabbit-
anti-murine PF4 antibody was used as the detection antibody (R&D systems).  Alkaline 
phosphatase conjugated secondary anti-murine, anti-rabbit, anti-sheep, and anti-goat IgGs 
were from Sigma.  FITC or TexasRed conjugated anti-murine, anti-rat and anti-rabbit 
IgGs were purchased from Vector Laboratories (Burlingame, CA).  HRP conjugated 
streptoavidin was from R&D systems.   
 
General Reagents 
Apyrase, benzamidine, poly-D-lysine, type I bovine plasma fibrinogen, 
glutathione-conjugated agarose, 2-methyl-2-butanol, 2,2,2, tribromoethanol, tetramethyl 
rhodamine isothiocyanate (TRITC)-conjugated phalloidin, and Ferric chloride (FeCl3) 
were obtained from Sigma (St Louis, MO).  Ortho-[32P]-phosphoric acid was purchased 
from MP Biochemicals Inc.  (Irvine, CA).  HisProbeTM-HRP and BCATM Protein Assay 
kit were purchased from Pierce (Rockford, IL).  Complete, EDTA-free protease inhibitor 
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cocktail was obtained from Roche (Indianapolis, IL).  Acid citrate dextrose (ACD) blood 
collection tubes (BD Vacutainer) were purchased from BD Diagnostics (Sparks, MD).  
Formaldehyde (37%) and glutaraldehyde (70%) were purchased from Electron 
Microscopy Sciences (Hatfield, PA).  Type I collagen (equine tendon), human plasma 
thrombin, and ADP were purchased from Chrono-log (Havertown, PA).  Convulxin, a 
snake venom toxin, was purchased from Centerchem Inc.  (Norwalk, CT).  A23187, Ca2+ 
ionophore, was obtained from Calbiochem (San Diego, CA).  Thrombin-activated 
receptor peptide (known as PAR4 peptide, AYPGKF) was purchased from Anaspec (San 
Jose, CA).  Whatman filter paper (VWR, San Francisco, CA), 1 mm disc shape was used.   
 
Methods 
 
Murine Strains, Genotyping, and FHL4 Patient 
Epimorphin/Syntaxin-2-/- Mice (Syntaxin-2 KO Mice) 
Epimorphin/Syntaxin-2+/- mice on a C57/BL6 background were kindly provided 
and generated by Dr. Deborah C. Rubin (Washington Univ. School of Medicine) [119].  
The mutant mice were maintained by crossing with C57/BL6 mice.  Murine genomic 
DNA was extracted from murine tail.  Genotyping was performed using primers: 
For the wild type gene: 
forward primer: 5’-GACAGTGTGTTAACTAGTCAAGC-3’  
reverse primer: 5’TTAGATTCCCTCCTAGAGACGC-3’  
For the mutated gene: 
forward primer: 5’-GACAGTGTGTTAACTAGTCAAGC-3’  
reverse primer: 5’-GGACACGCTGAACTTGTGGC-3’  
PCR conditions were as follows: 1 cycle at 94 °C for 7 min, then 35 cycles at (94 
°C for 1 min, 60 °C for 0.5 min, 72 °C for 3.5 min) and 1 cycle at 72 °C for 10 min. 
Syntaxin-4flox/flox/PF4-Cre+ Mice (Syntaxin-4 KO Mice) 
 Syntaxin-4flox/flox mice on a C57/BL6 background were kindly provided by Dr. 
Jeffery Pessin (Albert Einstein College of Medicine).  Genotyping was carried out with 
two sets of reactions.   
For the LoxP site: 
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forward primer, 22F: 5’-GTTGAGGCAGGTGAGAAACC-3’  
reverse primer, 25R: 5’-ATCACCAAGAGGGCTGAAGA-3’.   
PCR conditions were as follows: 1 cycle at 94 °C for 7 min, then 30 cycles at (94 
°C for 1 min, 60 °C for 1.0 min, 72 °C for 1.5 min) and 1 cycle at 72 °C for 10 min. 
For the neo cassette: 
forward primer, 58F: 5’-AGCCCAGTTGCTGGTGTATC-3’  
reverse primer, 55R: 5’-AGGAGGAAGAGGTGGAGGAG-3’.   
PCR conditions were as follows: 1 cycle at 94 °C for 7 min, then 30 cycles at (94 
°C for 1 min, 60 °C for 1.0 min, 72 °C for 1.5 min) and 1 cycle at 72 °C for 10 min. 
PF4-Cre+ mice were kindly provided by Dr. Radek Skoda (University Hospital 
Basel, Switzerland).  Genotyping was performed using the following primers.  
For the wild type gene: 
forward primer, 5’-CCCATACAGCATACCTTTTG-3’  
reverse primer, 5’-GAAACAACAGGCCCAGAAGC-3’ 
For the Cre transgene: 
forward primer, 5’-CCCATACAGCATACCTTTTG-3’  
reverse primer, 5’- TGCACAGTCAGCAGGTT-3’).  
PCR conditions were as follows: 1 cycle at 94 °C for 7 min, then 30 cycles at (94 
°C for 1 min, 50 °C for 1.0 min, 72 °C for 1.5 min) and 1 cycle at 72 °C for 10 min. 
Syntaxin-4 platelet specific syntaxin-4 deletion mice (syntaxin-4 KO mice) were 
generated by a cross of the above two murine strains.  
 
Syntaxin-2-/-/Syntaxin-4flox/flox/Cre+ (Syntaxin-2/4 Double KO Mice) 
Syntaxin-2/4 double KO mice were generated by crossing above three strains: 
syntaxin-2 KO mice, Syntaxin-4flox/flox mice, and PF4-Cre+ mice. 
 
Tomosyn-1-/- Mice 
 Heterozygous Embryos of tomosyn-1 were kindly provided by Dr. 
Yoshimi Takai (Kobe University Graduate School of Medicine, Japan) and Dr. Jun 
Miyoshi (Osaka Medical Center, Japan).  The genetic background of tomosyn-1 
knockouts is the mixture of 129 50%, C57BL6 25% and DBA2 25%.  The Embryos were 
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recovered into live mice by the Jackson Laboratory.  Genotyping of tomosyn-1 KO mice 
was performed by PCR using primers: for KO mice: 
forward primer, 5'-GGGCGCCCGGTTCTTTTTGTC-3'  
reverse primer, 5'-GCCATGATGGATACTTTCTCG-3' 
for wild type mice:  
forward primer, 5'-TTCTGCTCCCCGCTGCTCCTT-3' 
reverse primer, 5'-TCCCCGCTCCCTTCACCTTGC-3'.   
PCR conditions were as follows: 1 cycle at 94 °C for 7 min, then 40 cycles at (94 
°C for 1 min, 57 °C for 1 min, 72 °C for 1.5 min) and 1 cycle at 72 °C for 10 min. The 
expected PCR products are 224 bp for tomosyn-1 KO and 300 bp for the wild type. 
All procedures and usage of mice were approved by the DLAR at the University 
of Kentucky. 
 
Syntaxin-11 Deficient Platelets from FHL4 Patient 
15 mL of whole blood was collected from a FHL4 patient who displayed bleeding 
problems and a profound defect of NK cell degranulation (Dr. Filipovich Cincinnati 
Children’s’ Hospital, personal communication with Dr. Whiteheart).  The platelets from 
the patient were isolated using standard procedures.  The genotype of the patient was 
determined by standard sequencing methods: Allele 1 - 173T>C (D58R), Allele 2 - 
173T>C (D58R).  All procedures were approved by the IRBs at the Cincinnati Children’s 
Hospital and at the University of Kentucky. 
 
Platelet Preparation from Mice and Human Blood 
 Mice were euthanatized by CO2 inhalation.  After the heart was exposed, a 1 mL 
syringe filled with ~100 µL of 3.8% sodium citrate and attached to a 26 G needle was 
used to collect blood from the right ventricle.   
In order to accurately measure the individual murine platelets and erythrocytes, 
whole blood without dilution from syntaxin KO mice and wild type mice were counted 
with Hemvet (DREW Scientific Inc., Oxford, Connecticut) for all three blood cells at the 
same time.  
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The citrated blood was then mixed with an equal volume of PBS and adjusted to 
0.38% sodium citrate final concentration.  Human blood were collected into Acid citrate 
dextrose (ACD) blood collection tubes and then diluted with an equal volume of PBS.  
Both murine and human blood was first centrifuged at 250 × g for 10 minutes (min) at 
RT.  The Platelet Rich Plasma (PRP) was carefully removed (avoiding the buffy coat 
between the PRP and the red blood cell layer).  After adding 100 ng/mL prostaglandin I2 
(PGI2, Sigma) for 5 min at RT, the platelets were harvested by centrifugation at 900 × g 
for 15 min.  The pellet was gently resuspended in HEPES/Tyrode’s Buffer (10 mM 
HEPES/NaOH, pH 7.4, 5.56 mM glucose, 137 mM NaCl, 12 mM NaHCO3, 2.7 mM 
KCl, 0.36 mM KH2PO4, 1 mM MgCl2) containing 0.3 U/mL apyrase (Sigma). 
 
Measurement of Secretion from Intact Murine Platelet 
 Washed platelets were labeled with 2 µCi/mL [3H]-5-HT (Perkin-Elmer Cetus 
Life Sciences, Boston, MA) for 45 min at 30°C.  After washing twice with 
HEPES/Tyrode’s Buffer (pH 7.4) in the presence of 0.3 U/mL apyrase, the platelets were 
resuspended with HEPES/Tyrode’s Buffer (pH 7.4).  Platelet concentration was 
determined by Z2 Coulter particle counter and size analyzer (Beckman Coulter, 
Fullerton, CA) and adjusted to 2.5 × 108 platelets/mL.  A final concentration of 0.7 mM 
CaCl2 was added to the platelet suspension before stimulation.   
 For thrombin titrations, a concentration series of thrombin (Chrono-Log, 
Havertown, PA) was added to stimulate platelets (50 µL of resuspension) at RT.  
Reactions were stopped by adding a twofold excess of hirudin (Sigma) and then placed 
on ice.  For the time course experiments, 0.05 U/mL of thrombin was added for the 
indicated time periods, and 0.1 U/mL of hirudin was added to stop the reaction.  When all 
reactions were finished, the samples were subjected to centrifugation at 13,000 × g for 1 
min.  The supernatant was recovered to another tube.  The pellet was lysed with an equal 
volume of lysis buffer (PBS, pH 7.4, 1% Triton X-100) for 1 hr on ice.  An equal volume 
of the supernatant and the pellet was assayed for the three granule cargo markers: [3H]-5-
HT for dense core granules, PF4 for α-granules.  and β-hexoaminidase for lysosomes, as 
described previously [53].  For the dense core granule release assay, 25 µL of the 
supernatant or the pellet was added to 3 mL of scintillation cocktail solution.  The 
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samples were analyzed using a Tri-Carb 2100TR liquid scintillation analyzer (Beckman, 
Fullerton, CA).  For α-granule secretion, a sandwich ELISA method was used to detect 
the specific α-granule marker, PF4.  This ELISA assay was performed according to the 
manufacturer’s instruction (R&D systems).  To assay for lysosomal secretion, the 
enzymatic activity of β-hexosaminidase was measured.  Six microliters of supernatant 
and 3 µL of the pellet samples was added to 100 µL of citrate-phosphate buffer (53.4 mM 
citric acid, 93.2 mM Na2HPO4, pH 4.5) containing 10 mM p-nitrophenyl-N-acetyl-β-D-
glucosaminide.  The reactions were incubated at 37°C in a sealed, 96 well plate for 18 hrs 
and stopped with 100 µL of 0.08 N NaOH.  The optical density of each well was 
measured at 405 nm using a Biotek Elx808 plate reader (BioTek Instruments Inc., 
Winooski, VT).  The percent release for each marker at each data point was calculated by 
using the supernatant fraction divided by the supernatant plus the pellet fraction (total).   
 
Platelet Aggregometry 
 Washed platelets or PRP were centrifuged at 13,000 rpm for 1 minute in a 
tabletop centrifuge to obtain platelet-poor plasma (PPP) which was used to set the 
baseline.  Platelet suspension (500 µL) was warmed at 37°C in a siliconized glass cuvette 
(Chrono-log, Havertown, PA) containing a metal stir bar (Chrono-log) with stirring (800 
rpm) using a Model 460Vs Lumi-Dual aggregometer (Chrono-log) for 2-3 minutes.  
Agonists were added to initiate platelet activation.  Aggregation traces were monitored 
using a Model 810 Aggro/Link computer interface and Aggro/Link software (Chrono-
log). 
Platelet ATP Release 
ATP release from platelet dense-core granules was monitored by the 
luciferin/ATP-mediated luminescence using an aggregometer.  Washed platelets (475 
µL) were preincubated with 25 µL of Chrono-Lume reagent (Chrono-log) containing 
luciferin and luciferase for 2 minutes at 37°C. Addition of thrombin, collagen (Chrono-
Log), or A23187 (Calbiochem, La Jolla, CA), initiated ATP release from platelets, ATP-
driven activation of luciferase, followed by production of luciferin which were monitored 
by absorption at 560 nm.  Luminescence traces along with aggregation were using the 
same interface and software. 
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Flow Cytometry Analysis 
Washed murine or human resting or thrombin activated platelets (20 µL) at a 
concentration of 1 × 108 platelets/mL were incubated with 2.5 µL FITC-conjugated or 
PE-conjugated antibodies for 15 minutes at RT.  Platelet samples were then fixed with 
700 µL of 0.5% formaldehyde in phosphate-buffer saline (PBS) at RT for 30 minutes.  
Samples for flow cytometry were moved in a polystyrene FalconTM tube (BD 
Biosciences, San Jose, CA).  Fluorescent intensity was measured using FACScanTM flow 
cytometer (BD Biosciences).  Platelet population was detected by adjusting the voltages 
for forward light scattering (FSC; E-01/linear) and side light scattering (SSC; 450/linear).  
Fluorescent intensity was optimized by adjusting the voltages for excitation of blue 
(FITC) and red (PE) channels.  Platelet fluorescent intensities were monitored using an 
acquisition and analysis application, CellQuestTM (BD Biosciences).  A total of 10,000 
platelets were analyzed and fluorescent intensities were plotted as a histogram with 
statistical values. 
 
Western Blotting and Quantification 
Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) [120, 121].  The separated proteins were transferred 
electrophoretically [122] to Immobilon-P polyvinylidene fluoride membrane (PVDF, 
Milipore, Bedford, MA) with constant voltage (100 V) for 1 hour.  Blotted membranes 
were then blocked with blocking solution containing 5% nonfat milk in TBS-T (Tris-
buffered saline:  50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20 (Sigma)) 
containing 0.02% sodium azide (Thermo Fisher Scientific Inc., Waltham, MA) for 1 hour 
at room temperature.  The blocking solution was replaced with primary antibody diluted 
into blocking buffer and membranes were incubated at room temperature for 1-2 hours or 
at 4°C overnight.  Membranes were washed with TBS-T three times and incubated with 
AP-conjugated secondary antibody diluted into blocking buffer for 1 hour at room 
temperature.  Following three washes with TBS-T, membranes were incubated with 
enhanced chemofluorescence (ECF) substrate (GE Healthcare, Piscataway, NJ) for 5 
minutes.  Membranes were covered with a piece of transparency film (3M, St.  Paul, MN) 
and substrate fluorescences were detected using TyphoonTM 9400 Phosphoimager (GE 
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Healthcare).  Quantification of bands was performed using ImageQuant 5.2 software (GE 
Healthcare).   
 
Metabolic Labeling of Human Platelets 
 To metabolically label proteins in human platelets with o-[32P]-phosphoric acid, 
PRP from banked human platelets was centrifuged at 900 × g for 10 minutes at room 
temperature, followed by resuspension with phosphate-free HEPES-Tyrode’s buffer (20 
mM HEPES/KOH, pH 6.5, 128 mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 5 mM D-glucose, 
12 mM NaHCO3) containing 0.37 units/mL apyrase, 100 ng/mL PGI2, and 1 mM EGTA 
in a final platelet concentration of 8 × 108 platelets/mL.  The platelet suspension was 
labeled with 0.5 mCi/mL o-[32P]-phosphate at 37°C for 1 hour.  Labeled platelets were 
recovered by centrifugation at 900 × g for 7 minutes and resuspended in an equal volume 
of HEPES-Tyrode’s buffer (pH 7.4), the estimated final platelet concentration is 
approximately 4 × 108 platelets/mL (50% recovery of resuspension). 
 
Immunoprecipitation of Platelet Proteins  
 Washed unlabeled or [32P]-labeled platelets (500 µL) were warmed at 37°C for 5 
minutes in either a heat block or in the aggregometer, followed by stimulation with the 
agonist, thrombin (0.1 U/mL) for 5 minutes.  The reaction was stopped by adding equal 
volume of 2 × ice-cold IP-lysis buffer (20 mM HEPES/KOH, pH 7.4, 128 mM NaCl, 9 
mM MgCl2, 2% Tx-100, 20% glycerol, 2 mM sodium orthovanadate, 2 mM 
benzamidine, 2 mM EGTA, 2× EDTA-free protease inhibitor cocktail) and the lysates 
were incubated for 30 minutes to 1 hr on ice.  The insoluble cytoskeleton was removed 
by centrifugation at 13,000 × g for 5 minutes and the supernatant (500 µL) was 
precleared with 10 µL Protein A or Protein G-Sepharose beads at 4°C for 30 minutes on 
the rotator.  The beads were spun down at 500 × g for 10 seconds and the clarified 
supernatant was incubated with 5 µg of antibody bound to 10 µL Protein A or Protein G-
Sepharose beads at 4°C for 2 hours on the rotator.  Non-specific binding was eliminated 
by three washes with 1 mL of 1× ice-cold IP-lysis buffer without protease inhibitor 
cocktail at 500 × g for 10 seconds and the bound proteins were eluted with 2× SDS 
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sample buffer by boiling for 10 minutes.  Proteins were resolved by SDS-PAGE, 
transferred to PVDF membrane, and then analyzed with a specific antibody by western 
blotting.  For storage phosphor detection of [32P]-labeled proteins, the resolved PVDF 
membrane was covered and then exposed to a storage phosphor screen (GE Healthcare) 
overnight.  The screen was excited at 600 nm and detected the emission intensity peaked 
at 390 nm using TyphoonTM 9400 Phosphoimager and analysis of bands was performed 
using ImageQuant 5.2 software.  For detection of coimmunoprepitates, western blotting 
was performed using an antibody for the protein of interest. 
 
Electron Microscopy of Platelets 
 Washed human or murine platelets were warmed in a 37°C metal block for 5 
minutes.  Platelets were either kept resting or stimulated with 0.1 U/mL of thrombin for 5 
minutes.  The platelets were then processed for electron microscopy as described 
previously [42, 46] with slightly modification.  An equal volume of 0.1% glutaraldehyde 
in White’s saline (120 mM NaCl, 5 mM KCl, 2.3 mM MgSO4, 3.2 mM Ca(NO3), 6.5 
mM NaHCO3, 0.42 mM Na2HPO4, 0.19 mM KH2PO4, 0.0005% phenol red) was added to 
the platelet suspension for 15 minutes at 37°C.  The platelets were centrifuged at 3,000 × 
g for 2 minutes and incubated in ice-cold 3% glutaraldehyde in White’s saline at 4°C for 
1 hour.  After three washes with White’s saline, the platelets were osmicated in 1% OsO4 
in White’s solution.  This modification was known to generate a stable fixation of granule 
contents and provides a better identification of dense-core granules osmicated platelets 
were washed twice with 0.1 M Sorenson’s buffer (16.2 mg/mL KH2PO4, 3.76 mg/mL 
Na2HPO4, pH 8.0) and dehydrated in a serial ethanol washes (50%, 70%, 80%, 90%, 
100%, and previously unopened absolute ethanol) for 5 minutes.  The platelets were 
rinsed twice with propylene oxide and infiltrated overnight in a 1:1 mixture of propylene 
oxide and Spurr’s resin (10g vinyl cyclohexane dioxide (VCD), 6g DER epoxy resin, 26g 
nonenyl succine anhydride (NSA) with final addition of 0.4g dimethylaminoethanol 
(DMAE)).  After one wash in Spurr’s resin for 1 hour, samples were embedded in 200 µL 
Spurr’s resin and polymerized in a 60°C incubator for 48 hours.  Polymerized blocks 
were sectioned and mounted on copper grids.  Following counterstaining with uranyl 
acetate, samples were examined using a Philips Tecnai 12 transmission electron 
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microscope (FEI, Hillsboro, OR) and images were obtained with Gatan 
Digitalmicrograph software (Pleasanton, CA). 
 
Platelet Membrane Fractionation 
 Platelet membrane fractions were isolated using sonication.  Platelets were 
resuspended in sonication buffer (50 mM Tris/HCl, pH 7.4, 250 mM sucrose, 1× protease 
inhibitor cocktail) and the concentration was adjusted to 4 × 108/mL.  Resting and 
stimulated platelets were placed in an ultrasonic dismembrator Model 100 (Thermo 
Fisher Scientific) and disrupted by three rounds of 10 seconds pulses with 50 W output.  
The samples were chilled on ice for 10 minutes and the membrane and cytosolic fractions 
were separated by ultracentrifugation at 186,000 × g for 1 hour.  The membrane fraction 
was washed three times with sonication buffer in order to remove cytosol components.  
The final membrane pellet (membrane fraction) and cytosol fraction were dissolved in 
SDS sample loading buffer.  The equivalent amount of platelets for membrane fraction 
and cytosol were loaded 
 
Isolation of Platelet Lipid Rafts 
 Resting and stimulated platelets (1 × 109/mL) were lysed in 2× Raft lysis buffer 
(50 mM MES, pH 6.5, 150 mM NaCl, 1% Tx-100, 2× protease inhibitor cocktail), and 
mixed with 80% sucrose solution in MES saline (50 mM MES, pH 6.5, 150 mM NaCl).  
Final 40% sucrose/platelet lysates (2 mL) were layered into 15 mL ultracentrifuge tubes 
(Beckman Coulter), with 30% (6 mL) and 5% (2 mL) sucrose layers added on top.  
Samples were centrifuged at 200,000 × g for 18 hours without a break and the tubes were 
snap frozen in an ethanol-dry ice chamber for 10 minutes.  Nine fractions (1 mL each) 
were collected as a frozen entity using a graduated platform for cutting with a hacksaw 
(named ‘Raftolator’) and tube debris were removed by centrifugation at 1,000 × g for 2 
minutes.  Protein concentration was measured in each fraction using BCATM assay and 
proteins were concentrated using trichloroacetic acid (TCA) precipitation, followed by 
boiling with 2× SDS sample buffer. 
 
Identification of Unknown Proteins by Mass Spectrometry 
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Stained specific protein bands were visualized on a UV light box and the gel 
image was captured using Molecular Imager Gel Doc XR System and Quantity One 4.6 
image analysis software (Bio-Rad).  Bands of interest were excised either using the Gel 
Doc System or a ProteomeWorksTM automated spot cutter with PDQuest 7.2 software 
(Bio-Rad).  Digestion with trypsin and peptide analysis by mass spectrometry using 
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) method were 
performed at the University of Kentucky, Center for Structural Biology Protein Core 
Facility (Lexington, KY).  Peptide fragments were analyzed for identification of protein 
using the web-based search engine MASCOT (Matrix Science Inc., Boston, MA). 
 
Streptolysin-O (SLO) Permeabilized Human Platelet Secretion 
 This assay was established in the laboratory [123].  Human PRP was obtained 
from the Kentucky Blood Center as units (Lexington, KY).  Twenty five milliliters of 
human PRP were first labeled with 0.4 µCi/mL [3H] 5-HT for 45 min at 37°C.  After 
centrifugation at 150 × g for 10 min, the supernatant was moved to another conical tube 
and centrifuged at 500 × g for 15 min.  The pellet was washed twice with Ca2+-free 
Tyrode’s Buffer (154 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5.6 mM D-glucose, 7 mM 
NaHCO3, 0.6 mM NaH2PO4, 5 mM sodium PIPES, pH 6.5, 5 mM EGTA, 0.35% BSA) 
containing 3 µg/mL apyrase and finally resuspended in Buffer A (120 mM sodium 
glutamate, 5 mM potassium glutamate, 20 mM HEPES, pH 7.4, 2.5 mM EGTA, 2.5 mM 
EDTA, 3.15 mM MgCl2, 1 mM DTT).  The platelet concentration was determined by Z2 
Coulter particle counter and size analyzer and adjusted to 5 × 108/mL.  Fifty microliters 
of platelet suspension were mixed with 50 µL of Buffer A containing 8 mM ATP, 1.6 
U/mL SLO (Corgenix, Peterborough, United Kingdom) and the effectors (recombinant 
proteins, antibodies, etc.).  The reaction was first incubated at RT for 10 min and then 30 
min on ice.  The samples were then warmed to 25°C using a RT water bath for 5 min and 
stimulated with calcium for 5 min.  The reaction was stopped by centrifugation at 13,800 
× g for 1 min to separate the supernatant from the pellet.  The pellet samples were lysed 
with 100 µL lysis buffer (PBS, pH 7.4, 1% Triton X-100) for 1 hr on ice.  The assay for 
secretion from all three granules is similar to the assay used to analyze mice platelet 
secretion (see above).  The only difference is the usage of an ELISA assay, specific for 
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human PF4.  This assay was developed in the laboratory by Dr. Todd Schraw and 
described in detail in [124].   
 
Cloning of DNAs and Recombinant Protein Production 
Proteins Tagged with His6 or GST 
The coding region of each protein was amplified by polymerase chain reaction 
(PCR) using forward and reverse primers.  PCR products and prokaryotic expression 
plasmids (pProEX-HTb (Invitrogen, Carlsbad, CA) for His6-tagged protein and pGEX-
KG for GST-tagged protein) were digested with corresponding endonuclease restriction 
enzymes and separated on a 1% low-melting agarose gel (ISC BioExpress, Kaysville, 
UT) in TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA).  DNA bands were 
excised and eluted in sterile water using a Gel Extraction kit (Qiagen, Valencia, CA).  
Inserts (PCR products) and vectors (pProEX-HTb or pGEX-KG) were ligated in a 3:1 
molar ratio using T4 DNA ligase (Invitrogen) and the ligates were transformed into 
DH5α E.coli strain by 45 seconds heat shock at 42°C.  Transformed bacteria were 
recovered by incubating in 1 mL Luria-Bertani (LB) media at 37°C for 1 hour and grown 
on LB/agar plate containing 100 µg/mL ampicillin overnight at 37°C.  Each colony was 
screened with cloning PCR and double digestion testing with the corresponding enzymes 
after purification of plasmid DNA Miniprep kit (Qiagen).  The clones were further 
confirmed by DNA sequencing at Davis Sequencing (Davis, CA).   
 For production of recombinant proteins, purified plasmid DNAs were transformed 
into the RosettaTM(DE) E coli strain which harbors a plasmid (pRARE) containing rare 
tRNA sequences (Novagen, Gibbstown, NJ).  The colonies were amplified by culturing 
in 100 mL LB media containing 100 µg/mL ampicillin and 35 µg/mL chloroamphenicol 
(LB/amp/cam) and the culture was further scaled to 2 L.  Recombinant protein production 
was induced by adding 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 4 hours at 
37°C or overnight at 16°C.  The cells were harvested by centrifugation at 6,000 × g for 5 
minutes and washed once in ice-cold PBS.  The bacterial pellet was weighed and 
resuspended in breaking buffer.  The cells were broken by three passages using French 
Press cell disruptor at 12,000 psi and centrifuged at 100,000 × g for 1 hour.  The 
supernatant was filtered using 0.2 µm nylon filter (Fisher Scientific) and applied to 
  38 
column purification using either Ni2+-NTA agarose or glutathione agarose.  The purified 
recombinant proteins were dialyzed in HEPES buffer (20 mM HEPES/KOH, pH 7.4, 100 
mM NaCl, 2 mM MgCl2, 1 mM DTT, 5% glycerol) overnight at 4°C and the aliquots 
were stored at -80°C.   
 
Syntaxin-Containing Complexes Production 
 Dual expression plasmids for full-length SNAP-23, Munc18a, and Munc18c, 
syntaxin-2 (residues 1-251, representing the cytoplasmic region), and syntaxin-4 
(residues 1-265, representing the cytoplasmic region) were constructed using pRSFDuet-
1.  Amino acid substitutions were introduced using the site-directed mutagenesis 
(Strategene).  All syntaxin-containing complexes were overexpressed in the Rosetta 
Escherichia coli cells (Novagen) and purified from cell lysates by both Ni2+-affinity 
chromatography and S-protein affinity chromatograph. 
 
Production of His6-Tomosyn-1 from Sf9 Cells 
 His6-tomosyn-1 full length and fragments were generated in Sf9 (Spodoptera 
frugiperda) cells according to the manufacturer’s instruction.  Full-length tomosyn-1 
cDNA was inserted into the pFastBac-HTB and the sequence was confirmed by 
commercial dideoxy sequencing.  The pFastBac-HTB-tomosyn-1 plasmid was then 
transformed into DH10Bac competent cells (Invitrogen) and tomosyn-1-Bacmid was 
purified according to the manufacturer’s instructions.   
 Tomosyn-1-Bacmid was used to transfect Sf9 cells which had been previously 
adapted to serum-free suspension culture (SF-900 II SFM medium, Invitrogen).  After 
two days, the supernatant of the transfected Sf9 cells was collected (containing secreted 
baculovirus, P1 virus) and used to directly infect a new culture of Sf9 cells to produce P2 
virus.  P2 virus titer was determined by a virus plaque assay according to the 
manufacturer’s instructions.  P2 virus was then used to infect 200 mL mid log-phased Sf9 
cells (1~2 × 106/mL) at the indicated multiplicity of infection (1 to 5) for 3 days.  The 
whole cell pellet was collected, washed twice with cold PBS, and resuspended in 20 mL 
cold Lysis Buffer (50 mM Tris, pH 8.0) in the presence of 1 mM 
phenylmethanesulphonylfluoride (PMSF) and protease inhibitor cocktail (Roche Applied 
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Science, Indianapolis, IN).  The cell suspension was sonicated 10 times, 30 sec each on 
ice.  The lysate was first centrifuged at 500 × g for 10 min to remove unbroken cells and 
disrupted cell debris, then at 13,800 × g for 20 min at 4°C.  The supernatant was loaded 
to a 1 mL Ni2+-NTA column pre-equilibrated with 50 mM Tris (pH 8.0).  The column 
was washed sequentially with 10 volumes of Buffer I (50 mM Tris, 500 mM NaCl, pH 
8.0) and of Buffer II (50 mM Tris, 500 mM NaCl, 5 mM imidazole, pH 8.0), then eluted 
with 5 mL of Elution Buffer (50 mM Tris, 500 mM NaCl, 0.5 M imidazole, pH 8.0). 
 
Generation of the Tomosyn-1 and Syntaxin-11 Antibodies 
DNAs encoding the rat tomosyn-1 and murine syntaxin-11were inserted into the 
pProEX-HTB vector and used to transform Rosetta DE3 competent E. coli.  The His6-
tagged insoluble proteins were dissolved in 8 M urea then purified under denaturing 
conditions.  The eluted proteins were dialyzed extensively with PBS in order to remove 
residue imidazole and urea.  The protein concentration was analyzed using SDS-PAGE 
with BSA as a standard. 
To generate antibodies, 1 mg of protein was emulsified in 1 mL Freund’s 
complete adjuvant (Sigma) and injected subcutaneously into a total of ten sites along the 
back of a New Zealand Rabbit (100 µL/site).  Two weeks later, the rabbit was boosted 
with 0.25 mg of protein emulsified with Freund’s incomplete adjuvant (Sigma) using a 
similar pattern of injection sites.  Two weeks following the boost, 35 mL of blood was 
collected from the rabbit ear vein.  Following the first bleed, the rabbit was boosted then 
bled every two weeks for 15 cycles.  Sera were prepared, and stored as aliquots at -20°C. 
To affinity purify the antibodies, purified protein was coupled to 2 mL GSH-
Agarose beads.  The column was washed with 20 volumes of PBS to remove unbound 
protein, then 20 volumes of 200 mM HEPES (pH 8.5).  The column was incubated with 
10 mL of 20 mM dimethyl pimelimidate (DMP) in 200 mM HEPES (pH 8.5) at RT for 1 
hr with gently rocking.  After removing the crosslinking solution, 10 mL of 200 mM 
ethanolamine (pH 8.2) was added and incubated for 30 min at RT with gently rocking to 
terminate any residual crosslinker.  After washing the column with 10 volumes of Elution 
Buffer (150 mM NaCl, 200 mM Glycine/HCl, pH 2.0), the column was washed with TBS 
(25 mM Tris, 150 mM NaCl, pH 7.5).  Ten milliliters of sera were diluted, 1:1, with TBS 
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and filtered through a 0.2 µm filter.  The filtered sera was loaded onto the column and 
incubated overnight at 4°C.  The column was sequentially washed with 10 volumes of 
TBS, 10 volumes of Wash Buffer (500 mM NaCl, 20 mM Tris/pH 7.4, 0.1% Triton X-
100), and 10 volumes of TBS.  The column was eluted with 10 volumes of Elution 
Buffer.  One milliliter fractions were collected into 1.5 mL microtubes containing 100 µL 
the Neutralizing Buffer (2 M Tris, pH 8.5).  Antibody was collected, concentrated, 
dialyzed against PBS, and stored as aliquots at -20°C.  The antibody concentration was 
determined by Bicinchoninic acid (BCA) assay (Pierce, Rockford, IL).  The affinity-
purified anti-tomosyn-1 antibodies immunoprecipitate endogenous tomosyn-1 from 
platelet extracts (Figure 2-1).   
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Figure 0-1Figure 2-1 Generation of Tomosyn-1 Antibodies 
Figure 2-1. Generation of Tomosyn-1 Antibodies.  Tomosyn-1 antibodies were 
generated by immunizing rabbit with purified recombinant tomosyn-1 fragments.  (A) 
Denaturing purified recombinant His-tagged B-fragment and F-fragment of tomosyn-1 
were separated on a 10% SDS-PAGE gel and visualized by Commassie Brilliant Blue R-
250 staining.  These two recombinant protein preps were pure as determined by western 
blotting for tomosyn-1 monoclonal antibody and mass spectrometry (the lower bands are 
fragments of corresponding proteins) and used as antigen for antibody production.  Two 
fragments of rat tomosyn-1 are indicated as B and F of tomosyn-1.  B-fragment was 
cloned from N-teriminal sequence (1-390 aa) of rat tomosyn-1, which is predicated to 
form the first β-propeller structure, while the F-fragment is from the C-terminal region 
(670-1056 aa) and has a flexible predicated structure.  (B) Antibodies generated against 
both B and F-fragments of tomosyn-1 are able to immunoprecipitate endogenous 
tomosyn-1 protein from platelet extracts.  (C) Anti-tomosyn-1 polyclonal antibodies also 
recognize the endogenous tomosyn-1 protein from resting, PGI2 treated, and thrombin 
activated platelet extracts. 
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Tail Vein Bleeding Time 
Tail vein bleeding time was determined as described by Broze et al. [125].  
Briefly, mice 5-6 weeks of age were anesthetized with ketamine 75 mg/kg i.p.  A 
transverse incision was made with a scalpel at a position around 3 mm from the tip of 
murine tail.  Then the tail was immediately immersed into a 15 mL tube filled with 37°C 
normal saline.  The time from incision to bleeding cessation was recorded as the bleeding 
time.  Animals with prolonged bleeding times greater than 10 min were stopped 
manually. 
 
FeCl3-Induced Arterial Thrombosis in vivo Model 
FeCl3-induced arterial thrombosis is a method to analyze platelet functional 
defects in vivo [126, 127].  This model is believed to be one of the better models to mimic 
thrombotic disease in vivo because it generates a controlled and localized vascular 
damage that the platelets respond to.  Mice 8-12 weeks of age were anesthetized with 
Avertin (0.2 g/kg, i.p.) in a supine position on a 37°C heating pad.  The toe-pinch reflex 
was used to monitor the anesthesia state.  A segment of the left carotid artery was 
exposed using blunt dissection under a dissecting microscope.  A miniature Doppler flow 
probe (0.5VB, Transonic system Inc., Ithaca, NY, USA) was placed on the carotid artery 
to monitor blood flow.  Thrombus formation was induced by placing a small piece of 
filter paper saturated with 5% FeCl3 solution in saline on the top of the vessel for 3 min 
and then removed.  Time from application to cessation of flow, defined as flow stopped 
for more than 1 min, was measured.  Experiments were terminated at 30 min. 
 
Statistics Analysis 
 All statistical analysis was performed using ANOVA (GraphPad Prism 5).  P 
values less than 0.05 were considered significant.   
 
 
 
 
Copyright © Shaojing Ye 2012  
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Chapter THREE 
The Role of Syntaxins in Platelet Secretion 
 
 
Introduction 
 It is generally accepted that secretion is mediated by formation of trans-
membrane SNARE complexes which drive two lipid bilayers to fuse together, leading to 
the release of granule contents.  The minimal functional SNARE complex is formed by 
one v-SNARE and two t-SNAREs.  According to the original SNARE hypothesis, 
specificity for different membrane fusion events is provided by specific interaction of t-
SNARE/v-SNARE pairs [33, 128].  This has been challenged in recent years.  A more 
modern version of the hypothesis posits that only certain SNARE complex combinations 
are fusogenic [30, 79]. In platelets, it has been demonstrated that VAMP-8 is required for 
platelet secretion. VAMP-8 is the primary VAMP among the four known platelet 
VAMPs (VAMP-2, -3, -7, -8); only VAMP-8 null mouse platelets have a secretion 
defect.  Since this defect is not complete, unless Tetanus toxin is added, VAMP-2 and -3 
must serve some compensatory, secondary role with lower efficacy [46].  It has been 
demonstrated that SNAP-23 is required for platelet secretion [40, 41].  The role of the 
syntaxins has been more equivocal and has not been determined definitively.  
Several syntaxins (-2, -4, -7, -11, and Vti1b) are present in platelets.  Of the 
known syntaxins in platelets, syntaxin-2 and -4 were the only two that were found on the 
plasma membrane [38]. Thus, they were the most likely candidates to mediate exocytosis.  
Consistently, introduction of a syntaxin-2 polyclonal antibody into SLO-permeabilized 
human platelets inhibited release from α-granules, dense granules, and lysosomes [40, 
41].  In vitro studies have also shown that syntaxin-2 can interact with SNAP-23 and 
VAMP-8 [129], suggesting that syntaxin-2 can form SNARE complexes.  In parallel, 
studies of syntaxin-4 suggested that it also played a role in platelet exocytosis.  
Introduction of a syntaxin-4 monoclonal antibody into SLO-permeabilized human 
platelets inhibited release from α-granules and lysosomes and co-immunoprecipitation 
experiments showed that syntaxin-4 could form complexes with VAMP-8 and SNAP-23 
[41, 44].  These results were consistent with other studies showing a role for syntaxin-4 
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in exocytosis; syntaxin-4 is required for insulin secretion from pancreatic beta-cells [70, 
130].  However, there were inconsistencies.  A syntaxin-4-specific polyclonal antibody 
had no effect on platelet secretion (Lemons et al unpublished) and reduction of the 
syntaxin-4 chaperone Munc18c and concomitant reduction in syntaxin-4 had no effect on 
release from murine platelets [80].  Given the possibility that the antibodies used may not 
be completely isoform-specific or that steric hindrance could account for the inhibitory 
effects of the antibodies, we used transgenic mice to reexamine the roles of syntaxin-2 
and-4 in murine platelets. 
Syntaxin-2 KO mice are viable but the null males are sterile due to abnormal 
testicular development and impaired spermatogenesis [119]. Syntaxin-4 is important for 
embryo development and its global deletion causes early embryonic lethality before day 
7.5 (E7.5). Syntaxin-4 is probably required for glucose transporter 8 transports in 
embryoblasts [131].  These knockout mouse systems make ideal tools to re-examine the 
roles of syntaxin-2 and -4 in platelet exocytosis because that are not subject to the same 
ambiguities as are the permeabilized platelet assays.  Surprisingly, in our analysis (this 
Chapter), platelets lacking both syntaxin-2 and -4 had no secretion defect, suggesting that 
other syntaxins are required for platelet exocytosis.   
Considering that syntaxin-7 is not located on the plasma membrane and 
introduction of syntaxin-7 antibody into platelets did not affect platelet secretion [42], we 
reasoned that that syntaxin-7 may not be critical for platelet secretion.  The syntaxin, 
Vti1b, was found in platelets by western blotting analysis during my thesis preparation.  
Vti1b has been shown to be important in other hematopoietic cells.  Vti1b is necessary 
for the release of secretory lysosomes in cytotoxic lymphocytes [131, 132].  However no 
evidence is available to show that it plays an important role in platelet secretion.  Based 
on the close sequence homology with prototypical t-SNAREs, the mammalian syntaxin 
family can be further divided into Qa (syntaxin-1, -2, -3, -4, -5, -7, -10, -11, -16, etc.), Qb 
(Vti1a, Vti1b, etc.), Qc (syntaxin-6, syntaxin-8, etc.).  SNAP-23/25 t-SNAREs are 
considered Qb/Qc SNAREs.  Since SNAP-23 appears to be required, any candidate 
syntaxin in platelet should be a Qa SNARE.  Since Vti1b is a Qb t-SNARE it is not likely 
to be critical for platelet secretion.   
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Among the five known syntaxins in platelets, syntaxin-11, by default, appears to 
be the most important candidate for a role in platelet secretion [40, 41, 73].  Most 
mammalian syntaxins are type II integral membrane proteins anchored by their C-
terminal TMD [74].  Syntaxin-11 is a non-conventional syntaxin without a TMD.  
Syntaxin-11 has been shown to be associated with late endosomes and the trans-Golgi 
network in Hela cells [37].  Interestingly, syntaxin-11 mutations are associated with 
Familial Hemophagocytic Lymphohistiocytosis Type 4 (FHL4).  FHL4 is a rare 
autosomal recessive disorder of immune dysregulation associated with uncontrolled T 
cell and macrophage activation.  Syntaxin-11 deficient NK-cells exhibit a cytotoxic 
granule degranulation defect.  Thus it has been thought that syntaxin-11 is involved in 
granule-plasma membrane fusion.  However, other studies suggest that syntaxin-11 might 
be involved in granule-granule fusion instead [75, 76].  Moreover, syntaxin-11 has been 
shown to play a negative, regulatory role in macrophages by controlling access to Vti1b 
and thus affecting late endosome to lysosome fusion [77].  Although the exact role of 
syntaxin-11 in immune cell exocytosis is still not clear, the genetic association of 
syntaxin-11 mutations with FHL4 is clear.  We took advantage of this in our analysis of 
platelets from an FHL4 patient that lacked syntaxin-11.  
The goal of the studies described in this Chapter was to determine which syntaxin 
is required for platelet secretion.  We used syntaxin KO mouse models and syntaxin-11 
deficient human platelets.  Deletion of syntaxin-2 or -4 alone or in combination had no 
effect on secretion from murine platelets. Platelet secretion from patients with FHL4, 
which lack syntaxin-11, was severely defective.  Thus, syntaxin-11, but not syntaxin-2 or 
-4, is critical for platelet exocytosis. 
 
 
Results: 
The Effect on Murine Platelets of Deleting Syntaxin-2: 
The syntaxin-2 KO mice were on a C57Bl/6J background.  Compared to wild type 
littermates, the syntaxin-2 null mice had normal size, body weight, and fur color.  The 
males were sterile and for unknown reasons most females had some problems with 
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delivering; thus, producing syntaxin-2 null mice was difficult.  These data are consistent 
with syntaxin-2 being important for certain physiological processes.   
To investigate the specific role of syntaxin-2 in platelets, first we analyzed the 
morphology of platelets from the knockout mice.  The number and size of the circulating 
platelets were in the same range as wild type (Figure 3-7).  The ultrastructure was normal 
with similar shape, granules, OCS, and mitochondria (Figure 3-1), compared to the wild 
type platelets from littermate controls.  There were no overt, morphological differences 
between platelets from wild type and syntaxin-2 null animals. 
To study the specific role of syntaxin-2 in platelet secretion, we first examined 
whether deletion of syntaxin-2 affected the levels of other secretory machinery 
components (Figure 3-2).  There was no obvious effect on VAMP-2, VAMP-3, or 
VAMP-8.  There was no significant effect on other t-SNAREs: syntaxin-4, syntaxin-7, 
syntaxin-11, or SNAP-23.  We confirmed the deletion of syntaxin-2. The protein level of 
syntaxin chaperone proteins, Munc18 (a, b, c), appeared normal when probing with 
Munc18a/b and Munc18c polyclonal antibodies. 
Because a syntaxin-2 polyclonal antibody inhibited secretion in in vitro 
permeabilized platelets, syntaxin-2 was hypothesized to be required for platelet secretion.  
If this hypothesis was correct, a secretion defect should be observed when using syntaxin-
2 KO mouse system.  Surprisingly the depletion of syntaxin-2 has no secretion defect 
(Figure 3-3) from all three granules (α-granules, dense granules, and lysosomes).  For 
analysis, we performed dose response and a time course of release experiments using 
thrombin as agonist [46, 133].  Intact platelets were first loaded with [3H]-5HT, washed 
with HEPES buffer, and then stimulated with increasing concentrations of thrombin for 1 
min (Figure 3-3, left panel).  The platelets were pelleted by centrifugation, and the 
supernatants were assayed for the presence of granule cargo markers: [3H]-5HT from 
dense granules, PF4 from alpha granules, and β-hexosaminidase from lysosomes.  As 
expected, agonist-induced release of dense core and α-granule cargo from wild type 
platelets (black square symbols) was greater than the release from lysosomes.  
Comparison of platelets from wild type and null mice (red circle symbols) showed that 
each responded equally to thrombin and released granular cargo to similar extents.  To 
assess the efficiency of release, the time course of granule release was analyzed by 
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stimulating platelets with 0.05 U/mL thrombin (Figure 3-3, right panel).  Thrombin 
stimulation initiated dense granule release rapidly and appeared to be complete by 45 
seconds.  This same response also was seen for α-granule and lysosome release, although 
the extent of release was not as great as dense granule.  Comparison of release kinetics 
between wild type and syntaxin-2 null platelets showed no significant difference in the 
time course of their granule release.   
Additionally, there was no observable defect in platelet aggregation (Figure 3-11) 
for syntaxin-2 null platelets.  The washed platelets were used after recalcifying with 1 
mM CaCl2.  Under these conditions platelets from wild type (black color) and syntaxin-2 
KO mice (green color) were responsive to thrombin.  The platelets showed an initial, 
agonist-induced shape-change response followed by aggregation as indicated by the 
increase in light transmission.  The kinetics and extent of aggregation to 0.1 U/mL of 
thrombin were essentially identical (Figure 3-11).  The aggregometer measurements are 
consistent with the normal secretion (Figures 3-3).  Thus, the absence of this t-SNARE 
does not result in any gross defect in platelet function.  
Even though the in vitro SLO-permeabilized platelet assay had suggested that 
syntaxin-2 is important for platelet secretion, deletion of syntaxin-2 in mouse platelets 
had no effect on platelet secretion, suggesting that syntaxin-2 is not absolutely required 
for platelet secretion.  It is possible that syntaxin-2 is not required for platelet secretion or 
other syntaxins are compensating for the secretion function when syntaxin-2 is missing.  
In order to exclude the possibility, we used the platelet–specific, syntaxin-4 KO mouse 
model. 
 
The Effect on Murine Platelets of Deleting Syntaxin-4: 
To study the specific role of syntaxin-4 in platelet secretion we used a platelet-
specific knockout mouse model.  Mice carrying a floxed version of the syntaxin-4 gene 
were mated to a Platelet Factor 4 promoter-driven Cre recombinase expressing transgenic 
mouse strain.  Using platelets from the progeny of that cross, first we analyzed their 
morphology.  The number and size of circulating platelets were in the same range as for 
wild type platelets (Figure 3-7).  The ultrastructure was normal with similar shape, 
granules, OCS, and mitochondria (Figure 3-4), compared to the wild type platelets from 
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littermates.  There was no overt difference between the number of granules per platelets 
between wild type and null platelets. 
Western blotting analysis was performed to determine whether deletion of 
syntaxin-4 affects other secretory components.  There were no obvious effects on v-
SNAREs in platelets; VAMP-2, VAMP-7, and VAMP-8 levels were normal (Figure 3-5).  
Similarly there were no significant effects on other t-SNAREs, such as syntaxin-2, -7, -
11, or SNAP-23.  We confirmed the loss of syntaxin-4. The protein levels of the syntaxin 
chaperones, Munc18a and Munc18b, appeared normal while Munc18c levels were 
reduced.  This is consistent with the notion that Munc18c is a syntaxin-4-specific 
chaperone and the stable complex they form is mutually regulated. 
If the assumption is that syntaxin-4 is required for platelet secretion, a secretion 
defect should be observed when syntaxin-4 is deleted. Surprisingly the depletion of 
syntaxin-4 caused no secretion defect (Figure 3-6) from all three granules (α-granules, 
dense granules, and lysosomes).  In Figure 3-6 left panel, a thrombin titration experiment 
was performed using 1 min as the incubation time.  Secretion from each of the three 
granules showed the expected dose dependence.  Comparison of platelets from wild type 
(black square symbols) and null mice (red circle symbols) showed that each responded 
equally to thrombin and released granular cargo to similar extents.  To assess the 
efficiency of release, the time course of granule release was analyzed.  When stimulated 
with 0.05 U/mL of thrombin, release from all three granules is clearly observed (Figure 
3-6 right panel).  Dense granule release was the fastest secretion event, followed by 
release from α-granules and lysosomes.  Dense granule secretion was observed at 15 
seconds when stimulated with 0.05 U/mL of thrombin and completed by 30 sec.  α-
granule secretion and lysosomal secretion were slightly delayed.  They were detectable at 
15 sec and completed by 60 second.  The extent of secretion also differed among these 
three granule secretion events.  Over eighty percent of dense granule cargo was released 
while ~40% of α-granule cargo and lysosome marker were released when platelets were 
stimulated with 0.05 U/mL of thrombin for 1 min.  However, in summary, there was no 
significant defect in the kinetics or extent of secretion from all three granules in the 
syntaxin-4 deficient platelets.   
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Additionally, there was no observable defect of platelet aggregation (Figure 3-11) 
of syntaxin-4 deficient platelets.  Washed platelets were used after recalcification with 1 
mM CaCl2.  Under these conditions platelets from wild type (black color) and syntaxin-4 
KO mice (blue color) were responsive to thrombin.  The platelets showed an initial, 
agonist-induced shape-change response followed by aggregation as indicated by the 
increase in light transmission.  The kinetics and extent of aggregation in response to 0.1 
U/mL of thrombin were essentially identical (Figure 3-11).  The aggregometer 
measurements were consistent with normal secretion (Figures 3-6).  Thus, the absence of 
this t-SNARE does not result in any gross defect in platelet function.  
Even though the in vitro SLO-permeabilized platelet assay has suggested that 
syntaxin-2 and -4 are important for platelet secretion, syntaxin-2 and syntaxin-4 single 
KO mouse platelets have no secretion defect, arguing that neither syntaxin-2 nor 
syntaxin-4 alone is required for platelet secretion.  At the time of these experiments, only 
three syntaxins (syntaxin-2, -4, -7) were known in mouse platelets and it has been 
discussed syntaxin-7 was not felt to be important for platelet secretion [40].  One 
possibility is that syntaxin-2 and -4 could be equally and inter-changeably used.  To 
exclude this possibility, we then generated syntaxin-2/4 double KO platelets by crossing 
syntaxin-2-/- mice and syntaxin-4flox/flox/PF4-Cre+ mice.  If both syntaxin-2 and -4 are the 
primary syntaxins required for platelet secretion, depletion of both should inhibit granule 
secretion. 
 
The Effect on Murine Platelets of Deleting both Syntaxin-2 and -4: 
To investigate whether syntaxin-2 and -4 together are important for platelet 
secretion, we utilized a syntaxin-2/4 double KO murine model. Platelets morphology was 
first analyzed.  The size of circulating platelets is normal while the number is 
significantly reduced compared to wild type littermate (Figure 3-7).  The ultrastructure is 
normal (Figure 3-8), compared to platelets from wild type littermates. There was no 
significant difference between the number of granules per platelets between wild type and 
null platelets. Despite the thrombocytopenia, there was no overt morphological difference 
in the double KO platelets. 
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To study the specific role of syntaxin-2/4 in platelet secretion, we first analyzed 
the levels of known elements of the platelets secretory machinery and found that loss of 
both syntaxin had no effect on the v-SNAREs (VAMP-2, -3, -8), other t-SNAREs 
(syntaxin-7 and -11), or the syntaxin chaperone proteins, Munc18a and Munc18b.  There 
was a loss of Munc18s since syntaxin-4 was missing (Figure 3-9).  Loss of syntaxin-2/4 
also did not affect the expression of several cell surface membrane protein: GPIIb/IIIa, 
GP1bβ, PECAM-1, and GPVI (Figure 3-10), suggesting depletion of syntaxin-2/4 in 
platelets does not overtly affect membrane protein trafficking. 
To determine whether both syntaxin-2 and syntaxin-4 are important for platelet 
aggregation, we tested platelets from the syntaxin-2/4 double KO mice.  Washed and 
recalcified platelets were analyzed for their aggregation activity.  Under these conditions 
platelets from wild type (black color) and syntaxin-2/4 KO mice (red color) were 
responsive to thrombin.  The platelets showed an initial, agonist-induced shape-change 
response followed by aggregation as indicated by the increase in light transmission.  The 
kinetics and extent of aggregation to 0.1 U/mL of thrombin showed no significant defect 
compared to syntaxin-2 KO, syntaxin-4 KO, and wild type platelets from the 
corresponding littermates.  (Figure 3-11). 
Considering the syntaxin-2 polyclonal antibody and syntaxin-4 monoclonal 
antibody could inhibit the in vitro permeabilized platelet secretion, a secretion defect 
should be observed when double deletion of syntaxin-2/4 was used, surprisingly the 
double depletion of syntaxin-2/4 resulted in no secretion defect (Figure 3-12).  As shown 
in Figure 3-12 left panel, in a thrombin titration experiment, using 1 min as the 
incubation time, secretion from each of the three granules showed the expected dose 
dependence.  Comparison of platelets from wild type (black square symbols) and null 
mice (red circle symbols) showed that each responded about equally to thrombin and 
released granular cargo to similar extents.  Interestingly, the release from α-granule was 
significantly enhanced when both syntaxin-2 and -4 were missing, suggesting that 
syntaxin-2 and -4 might compete with the important syntaxin for secretion.  To assess the 
efficiency of secretion, the time course of granule release was analyzed.  When 
stimulated with 0.05 U/mL of thrombin, release from all three granules is clearly 
observed (Figure 3-12 right panel).  Dense granule release is the fastest, followed by 
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release from α-granules and lysosomes.  Dense granule secretion was observed at 15 
second when stimulated with 0.05 U/mL of thrombin and completed by 30 sec.  α -
Granule secretion and lysosomal secretion are slightly delayed.  They were detectable at 
15 sec and completed by 60 second.  The extent of secretion also differs among these 
three granule secretion events.  Over eighty percent of dense core granule cargo was 
released while ~60% of α-granule cargo and lysosome marker were released when 
platelets were stimulated with 0.05 U/mL of thrombin for 1 min.  There is no defect in 
the kinetics or extent of secretion from all three granules in the syntaxin-2/4 double 
deficient platelets, suggesting that neither syntaxin-2 nor -4 are required for platelet 
secretion.  Compared to the wild type platelets, deletion of both syntaxin-2 and -4 seems 
to enhance the secretion from α-granules, indicating the syntaxin-2 and -4 might be 
competing with the real functional syntaxin for formation of functional SNARE complex, 
thus membrane fusion.  A similar enhancement, though subtle, was noticed when 
examining the secretion from VAMP-3 null platelets [53] 
 
Syntaxin-11 is the Most Abundant t-SNARE in Human and Murine Platelets: 
From the data above, it is clear that previous analysis of syntaxin function in 
permeabilized platelets may be flawed.  How previous experiments could have reached 
such different conclusions is an open question that we attempt to resolve in this section.  
Initial experiments sought to determine the relative levels of the different platelet 
SNAREs.  As was shown for VAMP-8, and assumed for SNAP-23, the most abundant 
SNARE appears to be the most functionally relevant.  Additionally, it seems possible that 
the antibodies originally used in the permeabilized platelet could have some cross-
reactivities that were initially undetected (since syntaxin-11 was not know that the time).   
The sequence in each mammalian t-SNARE is highly conserved, for example, the 
sequence identity for syntaxin-11 is 84.67 % between mouse and human.  In terms of 
detectable t-SNAREs, a total of five syntaxins (syntaxin-2, -4, -7, -11 and Vti1b) and 
SNAP-23 have been identified in platelets (notes: Vti1b was found in platelets during the 
preparation of this manuscript, so data presented here do not included Vti1b).  To 
characterize antibody specificity and understand the syntaxin usage in mouse and human 
platelets, we utilized fluorescence-based, quantitative, western blotting of both human 
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and mouse platelet extracts.  The antibodies used for syntaxin-2, -4, -7, and -11 and 
SNAP-23 recognized both human and mouse platelet syntaxins (Figure 3-14).  To 
determine the relative abundance of the five t-SNAREs, recombinant proteins were used 
to generate a standard curve for quantification.  The platelet extracts from known 
numbers of human and mouse platelets were loaded as indicated (Figure 3-15).  The 
protein level of syntaxin-11 was the most abundant t-SNAREs in both human and mouse 
and a molecule per platelet level (Table 3-1).  Syntaxin-11 was ~6 fold more abundant 
than syntaxin-4 and 3 fold more abundant than SNAP-23 in human platelets while in 
mouse platelets syntaxin-11 was 9 fold higher than other t-SNAREs.  Comparing human 
and mouse t-SNAREs, syntaxin-2, -7, and -11, there were ~2000 molecules of syntaxin-2 
per platelet, twice that for syntaxin-7 and 25 fold that syntaxin-11.  However the amount 
of human syntaxin-4 and SNAP-23 were much higher than in mouse.  The specificity of 
each antibody was also assessed by comparing their immuno-reactivities to the various 
recombinant syntaxins (Figure 3-16A).  Among the four syntaxin antibodies, the 
syntaxin-2 polyclonal antibody, which was generated by our group and used for 
previously studies [40, 41], showed some cross reactivity with both syntaxin-4 and 
syntaxin-11.  However, the small amount of cross reactivity does affect the fact that 
syntaxin-11 is the most abundant t-SNARE in both human and mouse platelets.  From 
these data two points are clear, the originally used anti-syntaxin-2 antibody used in 
permeabilized platelets does cross react with syntaxin-11 (also see below) and syntaxin-
11 is the major syntaxin by mass in platelets.  These data would support the hypothesis 
that syntaxin-11 is required for platelet secretion.   
 
Syntaxin-11 is Required for Platelet Secretion: 
Among the four known syntaxins in platelets, all except syntaxin-11 have been 
ruled out as the most important syntaxin required for platelet secretion.  Quantification of 
t-SNAREs (Table 3-1) in platelets shows that syntaxin-11 is the most abundant t-SNARE 
in both human and mouse platelets, suggesting that syntaxin-11 could be the most 
important t-SNARE in platelets.  The fact that syntaxin-2 deficient platelets have no 
secretion defect argues that the inhibition phenotype by the syntaxin-2 polyclonal 
antibody [40, 41] may be caused by a steric effect or more likely by cross reactivity.  
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Indeed, the original syntaxin-2 polyclonal antibody showed cross reactivity to syntaxin-
11 (Figure 3-16A). Additionally, the antibody also recognized endogenous syntaxin-11 
since syntaxin-11 could be co-immunoprecipitated by the syntaxin-2 antibody (Figure 3-
16B).  The syntaxin-2 antibody cross reactivity not only explains the inconsistency 
between permeabilized platelet secretion data and knockout, intact platelet secretion data, 
but also suggests a role for syntaxin-11 in platelet secretion.  To address this question, we 
collaborated with Dr. Alexandra H. Filipovich at Cincinnati Children’s Hospital Medical 
Center to study platelets from a FHL4 patient.  The patient, whose platelets were 
analyzed, had bleeding problems and a profound defect of NK cell degranulation 
(personal communication).  Genetic analysis demonstrated that the patient was 
homozygous for 173T>C mutation in the syntaxin-11 gene.  This point mutation causes a 
reduction in syntaxin-11 protein levels, below the limits of detection.  The levels of 15 
other secretory machinery components are normal (Figure 3-17A).  As perhaps expected 
since Munc18b is a potential chaperone for syntaxin-11, Munc18b levels were negatively 
affected.  The mutation causes a change in D58 to R on the Habc region.  It is possible 
that this point mutation may disrupt the protein folding and/or stability of syntaxin-11. To 
address whether syntaxin-11 is required for platelet secretion, we examined release from 
all three granules in both thrombin-titration and time course experiments.  A thrombin 
titration experiment was performed using 1 min as the incubation time.  Secretion from 
each of the three granules from normal control platelets and lysosome from FHL4 patient 
showed the expected dose-dependence (Figure 3-17B).  Secretion from dense granule and 
α-granule release was almost abolished in the FHL4 patient’s platelets.  To assess the 
efficiency of release, the time course of granule release was analyzed.  The time course of 
[3H]-serotonin from dense granule and PF4 release from α-granule was nearly abolished 
in the syntaxin-11 deficient platelets from the FHL4 patient (Figure 3-17C).  Release of 
β-hexosaminidase from lysosomes was only modestly decreased, suggesting that 
syntaxin-11 is essential for dense and α-granule release while lysosome release is not 
fully dependent on syntaxin-11. 
 
Platelet Aggregation, ATP Release, and P-selectin Exposure are Defective in 
Syntaxin-11 Deficient Platelets from a FHL4 Patient: 
  55 
To confirm that syntaxin-11 is required for platelet exocytosis, we further 
analyzed syntaxin-11 null platelets from the same FHL4 patient.  Figure 3-18A, i-iii 
shows that the aggregation of washed platelets (control, black traces; patient, gray traces) 
stimulated with 0.1 U/mL thrombin, 10 µg/mL collagen, or 100 µM A23187, was 
significantly defective for the syntaxin-11 deficient platelets.  Concomitantly, ATP 
release, as measured with luciferin/luciferase luminescence, from dense granules was 
totally abolished (Figure 4A, iv-vi).  Secretion-dependent aggregation was defective 
when stimulated with thrombin or A23187 (Figure 3-18A, i and iii) by comparison with 
collagen induced aggregation (Figure 3-18A, ii) since collagen induced aggregation is 
less dependent on secondary wave of ADP release [134].  A23187 is an ionphore, which 
increases intracellular calcium and circumvents the need for signaling cascade activation 
[117, 118].  Secretion in the presence of A23187 is impaired, suggesting that the 
secretion defect seen on syntaxin-11 deficient platelets is not in a signaling step but is 
indeed at the fusion step required for secretion (see EM analysis discussion).   
To further confirm the secretion defect in the syntaxin-11 deficient platelets, we 
also performed flow cytometry analysis.  P-selectin is an integral membrane protein in α-
granules and its exposure at the platelet surface is widely used as a metric for α-granule 
exocytosis.  Compared to normal control and resting platelets, the geometric mean 
fluorescence intensity (GMFI) of staining for P-selectin on syntaxin-11 deficient platelets 
only slightly increased upon stimulation with 0.1 U/mL thrombin (Figure 3-18B).  When 
quantified, the P-selectin staining on FHL4 patient’s platelets was 10 fold less than that 
of control, suggesting that α-granule secretion, as measured by P-selection exposure, is 
almost abolished. 
To exclude the possibility that the observed secretion defects could be caused by a 
defect in granule biogenesis or platelet activation, we examined platelet cargo levels and 
other parameters of platelet activation.  The level of PF4, an α-granule-specific cargo 
protein, was similar to wild type (Figure 3-17A).  Based on the secretion experiments 
discussed about, the platelet levels of β-hexosaminidase and PF4 were similar: for PF4 
from α-granules, there were ~2331 ± 184 pg/2.5×108 control platelets and 2220 ± 86 
pg/2.5×108 in the syntaxin-11 deficient patient platelets; for β-hexosaminidase there were 
~37 ± 5 U/2.5×108 control platelets (n=24) and 30 ± 5 U/2.5×108 in the syntaxin-11 
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deficient patient platelets.  We also examined two important platelet activation bench 
marks: platelet cytoskeletal reorganization and integrin αIIbβ3 activation.  A hallmark of 
platelet activation is integrin αIIbβ3 activation [116-118].  The activated αIIbβ3 can be 
measured with the conformation-specific, PAC-1 antibody.  Flow cytometry analysis was 
performed.  The traces of PAC-1 labeling in thrombin activated platelets (grey trace) 
from control and FHL4 patient shift to the right, suggesting that both platelet preparations 
are activated upon thrombin stimulation (Figure 3-18C).  Compared with the control, the 
mean fluorescence intensity (GMFI) of staining for activated αIIbβ3 of syntaxin-11 
deficient platelets from FHL4 patient was slightly decreased but not significantly, 
suggesting that loss of ADP release might contribute to affect integrin activation.  From 
these data it appears that syntaxin-11 depletion does not significantly impair platelet 
αIIbβ3 inside-out signaling.   
Activated platelets undergo dramatic cytoskeletal rearrangement, forming 
filopodia and laminipodia and causing granule centralization, which is necessary for 
platelet exocytosis [135].  If syntaxin-11 deletion only affects the final fusion step, we 
would expect that syntaxin-11 deficient platelets would form filopodia and centralize 
their granules, but the granule membrane would not fuse with the plasma membrane 
because the relevant SNARE is not present.  The expected phenotype would be similar to 
that of VAMP-8 null [46] or Munc13-4 null mouse platelets: visible granules centralized 
and surround by an actin cytoskeleton [48].  Resting and thrombin-activated platelets 
from a control donor and the FHL4 patient were examined by transmission electron 
microscopy.  As shown in Figure 3-18D, i and ii, resting controls and resting FHL4 
platelets have normal shapes with similar arrays of granules, mitochondria, microtubular 
networks, and OCS.  When stimulated with thrombin (0.1 U/mL; 5 min), both platelets 
showed a similar irregular appearance with protruding filopodia.  This is consistent with 
thrombin-induced cytoskeletal rearrangements (Figure 3-18D, iii and iv).  Control 
platelets showed granules depletion while patient platelets showed centralization of the 
granules.  The presence of granules in the middle of the cells suggests that their fusion 
with plasma membrane did not occur.  This is consistent with a lack of secretion seen 
previously [48] and also indicates that the thrombin induced signaling required for 
cytoskeletal rearrangements is still intact in the syntaxin-11 deficient platelets.   
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Syntaxin-11 Has Forms SNARE Complexes with SNAP-23 and VAMP-8: 
It is clear that VAMP-8 is the primary v-SNARE required for platelet secretion 
and SNAP-23 is one of two t-SNAREs to form the core SNARE complex in platelets.  If 
syntaxin-11 is the primary t-SNARE required for platelet secretion, syntaxin-11 should 
be present in SNARE complexes with SNAP-23 and VAMP-8.  Studies by Valdez at al. 
[37] have demonstrated that syntaxin-11 is capable of binding to VAMP-2 and SNAP-23 
in vitro and SNAP-23 in lymphocytes in vivo.  To address this question in platelets, 
experiments were designed to determine if endogenous syntaxin-11 associates with 
endogenous SNAP-23 in platelets in vivo.  Both resting and thrombin-activated human 
platelets were lysed with Triton X-100-containing buffer and immunoprecipitations were 
performed using control IgG and anti-syntaxin-11 polyclonal antibody.  Western blotting 
using a syntaxin-11-specific antibody confirmed that syntaxin-11 was present in both the 
anti syntaxin-11 (Figure 3-19A) and the anti-SNAP-23 immunoprecipitates [Karim et al 
in preparation].  This demonstrates that syntaxin-11 is associated with SNAP-23 in 
platelets.  Moreover, syntaxin-11 co-immunoprecipitated with VAMP-8 in both resting 
and thrombin-activated platelet extracts (Figure 3-19, panel A).  Syntaxin-11 is also 
associated with VAMP-3 in resting platelets but not in activated platelets.  There was no 
association between syntaxin-11 and syntaxin-4, further confirming that the syntaxin-11 
antibody is specific (Figure 3-16).  The observation that syntaxin-11 co-
immunoprecipitated with syntaxin-2 from both resting and activated platelets may be 
caused by the cross-reactivity of syntaxin-2 antibody used for the western blotting.  
However, it is possible that syntaxin-2 was present in a different complex considering 
syntaxin-2 can form complex with SNAP-23 and VAMP-8.  Taken together, syntaxin-11 
is associated with both core SNARE complex components: SNAP-23 and VAMP-8 in 
activated platelets, demonstrating syntaxin-11 can form SNARE complexes with SNAP-
23 and VAMP-8 in vivo.    
 
Discussion: 
It is generally believed that any regulated biological exocytosis is a SNARE–
mediated, membrane fusion process.  We hypothesized that there is a syntaxin required 
for platelet secretion.  The potential candidates were syntaxin-2 and -4 considering they 
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are important for permeabilized platelet exocytosis [40, 41, 44].  The fact that syntaxin-
2/4 double deletion murine platelets had no secretion defect suggests that syntaxin-2 and 
-4 are not the absolutely required for platelet secretion.  But mild secretion enhancement 
from α-granules and lysosomes (Figure 3-12) argues that syntaxin-2/4 may be involved 
somehow.  The similar observation was found with the VAMPs.  A secretion 
enhancement in VAMP-3 KO mice platelets was observed [46].  Perhaps syntaxin-2/4 
may have the similar role to VAMP-3: serving as secondary t-SNARE.  Further 
experiments will we required to make this assessment.  However, it should be noted that 
the defect in secretion in the syntaxin-11 deficient platelets was more severe than that in 
the VAMP-8 null platelets.  This may imply that there are no secondary syntaxins in 
platelets.   
Data presented in this Chapter demonstrated a required role for syntaxin-11 in 
platelet secretion.  Depletion of syntaxin-11 in platelets from a FHL4 patient almost 
totally abolished dense granules and α-granules secretion (Figure 3-17 and Figure 3-18B) 
and severely impaired lysosome secretion (Figure 3-17B). Loss of syntaxin-11 did not 
affect granule biogenesis (Figure 3-17), other SNARE proteins (Figure 3-17A) or platelet 
activation (Figure 3-18C, 4D) indicating that the secretion defect is due a deficit in the 
final fusion step due to a loss of syntaxin-11.  Washed platelets from the syntaxin-11 
deficient patient also displayed a profound aggregation defect in response to stimulation 
with thrombin and A23187 while showing mild defect upon collagen stimulation, 
suggesting the secretion-dependent aggregation is ablated since full aggregation requires 
the secondary agonists (such as ADP from dense granule) additional stimulation and 
more binding surface (such as fibrinogen from α-granules).  Moreover, syntaxin-11 forms 
SNARE complex with SNAP-23 and VAMP-8 [37].  In summary, these data support the 
conclusion that syntaxin-11, but not syntaxin-2 and -4, is the most important t-SNARE 
required for platelet secretion and thus for hemostasis. 
Syntaxin-2 and -4 may not be required for granule biogenesis, based on the 
platelets levels of β-hexosaminidase and PF4, which were similar between wild type and 
syntaxin-2/4 KO mice (Figure 3-12).  Similarly, the level of cell surface integrin αIIbβ3, 
PECAM, GP1bβ, and GPVI (Figure 3-10) from resting platelets were similar, suggesting 
that syntaxin-2/4 may not be required for membrane protein transport through ordinary 
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secretory pathway.  However, whether syntaxin-2 and -4 are important for endocytosis in 
platelets is not clear and will required further analysis.  A preliminary experiment showed 
that platelets from syntaxin-2/4 double KO mice displayed a fibrinogen uptake defect by 
western blotting analysis of the total platelet extracts (Figure 3-13), suggesting that 
syntaxin-2/4 may be involved in the granule biogenesis through the endocytic pathway.  
Western blotting and flow cytometry analysis of other uptake molecules, such as VEGF 
and albumin, using syntaxin-2/4 double KO mice will be a good way to explore this point 
further. 
Syntaxin-2/4 may be important for platelet biogenesis.  Compared to normal wild 
type and single syntaxin-2 or -4 KO, the syntaxin-2/4 double KO mice have lower 
circulating platelet numbers; however, the size and general morphology of platelets was 
unchanged.  Analysis of megakaryocytes from these mice might yield interesting results.  
In sum, syntaxin-2 and -4 are not the most important syntaxins required for platelet 
secretion, but they might be important for other platelet functions or for biogenesis.   
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Table 1Table 3-1.  t-SNAREs in Human and Murine Platelets 
Table 3-1. t-SNAREs in Human and Murine Platelets 
t-SNAREs 
Molecules/Platelet* 
Human (n=4) Murine (n=4) 
Syntaxin-2 1,579 ± 429 1,766 ± 121 
Syntaxin-4 9,633 ± 75 1,625 ± 184 
Syntaxin-7 3,861 ± 564 3,707 ± 372 
Syntaxin-11 51,717 ± 5459 46,966 ± 5516 
SNAP-23 19,374 ± 5384 5,363 ± 798 
 
*Number of molecules per platelet was calculated using the molecular weight for 
Syntaxin-2 (33 kDa), Syntaxin-4 (34 kDa), Syntaxin-7 (30 kDa), Syntaxin-11 (33 kDa), 
SNAP-23 (23 kDa). 
Certain amounts of human or murine platelet extracts were subjected to western blotting 
with the four different syntaxin antibodies and SNAP-23 antibody.  Recombinant human 
syntaxin-2, -4, -7, or -11 were used to generate a corresponding standard curve for 
quantification of the four known syntaxins and SNAP-23. 
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Figure 0-1Figure 3-1 Deletion of Syntaxin-2 Does not Affect Resting Platelet Ultrastructure. 
Figure 3-1. Deletion of Syntaxin-2 Does not Affect Resting Platelet Ultrastructure.  
Washed platelets (4 × 108/mL) from wild type (Wt) and syntaxin-2 platelet specific KO 
mice (Stx2 KO) were kept resting by adding PGI2.  The platelets were fixed in 0.1% 
glutaraldehyde for 15 min at 37°C and 3% glutaraldehyde for 1 hour at 4°C.  After 
osmication, the fixed platelets were dehydrated then polymerized in Spurr’s resin.  The 
thin sections of platelets were counterstained with uranyl acetate and the samples were 
analyzed using transmission electron microscope.  The images were obtained using Gatan 
software and only the brightness and contrast were adjusted in Photoshop (the scale bar is 
indicated in left panel). 
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Figure 0-2Figure 3-2 Deletion of Syntaxin-2 Does not Affect Secretory Machinery Proteins. 
Figure 3-2. Deletion of Syntaxin-2 Does not Affect Secretory Machinery Proteins.  
Platelet extracts (5 × 107 platelets/lane) from wild type and syntaxin-2 KO (Stx2 KO) 
were probed by western blotting with the indicated antibodies.   
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Figure 0-3Figure 3-3 Deletion of Syntaxin-2 Does not Affect Platelet Secretion 
Figure 3-3. Deletion of Syntaxin-2 Does not Affect Platelet Secretion.  Platelets from 
syntaxin-2 KO mice (red circle symbols) and wild type control (black quare symbols) 
were prepared as described in “Materials and methods”.  Aliquots of intact washed 
platelets (2.5 × 108 /mL) were incubated with 0.7 mM CaCl2 at RT for 5 min and then 
incubated with the indicated thrombin concentration at RT for 1 mins (left panel) or 0.05 
U/mL thrombin for the indicated time points (right panel).  Release of [3H]-5HT from 
dense granules, PF4 from α-granules, and β-hexosaminidase from lysosomes was 
measured, and percent secretion was calculated.  The points represent the average of 
triplicate measurements and the standard deviations are indicated. 
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Figure 0-4Figure 3-4 Deletion of Syntaxin-4 Does not Affect Resting Platelet Ultrastructure 
Figure 3-4. Deletion of Syntaxin-4 Does not Affect Resting Platelet Ultrastructure.  
Washed platelets (4 × 108/mL) from wild type (Wt) and syntaxin-4 platelet specific KO 
mice (Stx4 KO) were kept resting by adding PGI2.  The platelets were fixed in 0.1% 
glutaraldehyde for 15 min at 37°C and 3% glutaraldehyde for 1 hour at 4°C.  After 
osmication, the fixed platelets were dehydrated then polymerized in Spurr’s resin.  The 
thin sections of platelets were counterstained with uranyl acetate and the samples were 
analyzed using transmission electron microscope.  The images were obtained using Gatan 
software and only the brightness and contrast were adjusted in Photoshop (the scale bar is 
indicated in left panel). 
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Figure 0-5Figure 3-5 Deletion of Syntaxin-4 Does not Affect Other SNARE Proteins 
Figure 3-5. Deletion of Syntaxin-4 Does not Affect Other SNARE Proteins.  Platelet 
extracts (5 × 107 platelets/lane) from wild type and syntaxin-4 platelet specific knockout 
(Stx4 KO) were probed by western blotting with the indicated antibodies.   
  
  67 
 
  
  68 
 
Figure 0-6Figure 3-6 Deletion of Syntaxin-4 Does not Inhibit Platelet Secretion 
Figure 3-6. Deletion of Syntaxin-4 Does not Inhibit Platelet Secretion.  Platelets from 
syntaxin-4 KO mice (red circle symbols) and wild type control (black square symbols) 
were prepared as described in “Materials and methods”.  Aliquots of intact washed 
platelets (2.5 × 108 /mL) were incubated with 0.7 mM CaCl2 at RT for 5 min and then 
incubated with the indicated thrombin concentration at RT for 1 min (left panel) or 0.05 
U/mL thrombin for the indicated time points (right panel).  Release of [3H]-5HT from 
dense granules, PF4 from α-granules, and β-hexosaminidase from lysosomes was 
measured, and percent secretion was calculated.  The points represent the average of 
triplicate measurements and the standard deviations were indicated. 
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Figure 0-7Figure 3-7 Syntaxin-2/4 Double Deficient Mice Have Lower Circulating Platelets 
Figure 3-7. Syntaxin-2/4 Double Deficient Mice Have Lower Circulating Platelets.   
Whole blood from syntaxin-2 (n=9), syntaxin-4 (n=8), syntaxin-2/4 double KO mice 
(n=28) or wild type littermate (n=20) was collected.  The number of platelets and 
erythrocytes were counted with Hemvet. 
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Figure 0-8Figure 3-8 Syntaxin-2/4 Double Deficient Mice Have Reduced Circulating Platelets 
Figure 3-8. Syntaxin-2/4 Double Deficient Mice Have Normal Ultrastructure. 
Washed platelets (4 × 108/mL) from syntaxin-2/4 double KO mice and wild type litter 
mate were kept resting by adding PGI2.  The platelets were fixed in 0.1% glutaraldehyde 
for 15 min at 37°C and 3% glutaraldehyde for 1 hour at 4°C.  After osmication, the fixed 
platelets were dehydrated then polymerized in Spurr’s resin.  The thin sections of 
platelets were counterstained with uranyl acetate and the samples were analyzed using 
transmission electron microscope.  The images were obtained using Gatan software and 
only the brightness and contrast were adjusted in Photoshop (the scale bar is indicated in 
left panel). 
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Figure 0-9Figure 3-9 Double Deletion of Syntaxin-2/4  Does not Affect Other SNARE Proteins 
Figure 3-9. Double Deletion of Syntaxin-2/4 Does not Affect Other SNARE Proteins.  
Platelet extracts (5 × 107 platelets/lane) from wild type and syntaxin-2/4 double KO 
(Stx2/4 KO) were probed by western blotting with the indicated antibodies.   
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Figure 0-10Figure 3-10 Depletion of Syntaxin-2/4 Mice Platelets Has No Effect on Surface Membrane 
Expression 
Figure 3-10. Depletion of Syntaxin-2/4 Mice Platelets Has No Effect on Surface 
Membrane Expression.  Washed platelets (1 × 108 platelets/mL) from wild type (Wt), 
syntaxin-2/4 double KO (Stx2/4 KO), syntaxin-2 KO (Stx2 KO), and syntaxin-4 KO 
(Stx4 KO) were stimulated with or without 0.1 U/mL thrombin for 1 min and then 
incubated with FITC-conjugated anti-GPIIb/IIIa, GP1bβ, PECAM-1, and GPVI 
antibodies for 15 min at RT.  The reactions were stopped by adding 10 volumes of 1% 
formaldehyde for 30 min and the fluorescent intensities were measured by flow 
cytometry.   
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Figure 0-11Figure 3-11 Syntaxin-2/4 Double Deficient Platelets Have Normal Aggregation Function 
Figure 3-11. Syntaxin-2/4 Double Deficient Platelets Have Normal Aggregation 
Function.  Platelets from wild type control (Wt, in black), syntaxin-2/4 double KO 
(Stx2/4 KO, in red) mice, syntaxin-2 KO (Stx2 KO, in green) mice, syntaxin-4 KO (Stx4 
KO, in blue) mice, were prepared as described in Chapter 2.  Platelets were stimulated 
with 0.1 U/mL of thrombin and aggregation was measured in the aggregometer. 
  
  74 
 
 
 
 
  
  75 
Figure 0-12Figure 3-12 Double Deletion of Syntaxin-2/4 Does not Inhibit Platelet Secretion 
Figure 3-12. Double Deletion of Syntaxin-2/4 Does not Inhibit Platelet Secretion 
Platelets from syntaxin-2/4 double KO (Stx2/4 DKO) mice (red circle symbols) and wild 
type control (black square symbols) were prepared as described in “Materials and 
methods”.  Aliquots of intact washed platelets (2.5 × 108 /mL) were incubated with 0.7 
mM CaCl2 at RT for 5 min and then incubated with the indicated thrombin concentration 
at RT for 1 min (left panel) or 0.05 U/mL thrombin for the indicated time points (right 
panel).  Release of [3H]-5HT from dense granules, PF4 from α-granules, and β-
hexosaminidase from lysosomes was measured, and percent secretion was calculated.  
The points represent the average of triplicate measurements and the standard deviation is 
indicated. 
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Figure 0-13Figure 3-13 Double Deletion of Syntaxin-2/4 Affect Platelet Fibrinogen Storage 
Figure 3-13. Double Deletion of Syntaxin-2 /4 Affects Platelet Fibrinogen Storage.  
Platelet extracts (5 × 107 platelets/lane) from wild type (Wt), syntaxin-2/4 double KO 
(Stx2/4 KO), syntaxin-2 KO (Stx2 KO), and syntaxin-4 KO (Stx4 KO) were probed by 
western blotting with anti-fibrinogen antibody.  The red arrow indicates the position of 
the alpha chain of fibrinogen. 
 
  
  77 
 
 
Figure 0-144 Figure 3-14: Anti-Human Syntaxin Antibodies Recognizes Both Human and Murine Platelet 
Syntaxins 
Figure 3-14. Anti-Human Syntaxin Antibodies Recognize Both Human and Murine 
Platelet Syntaxins.  Equal amounts of human or murine platelet extracts (equivalent to 
5.0 × 107 platelets/lane) were subjected to western blotting with the indicated antibodies. 
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Figure 0-15Figure 3-15: Syntaxin-11 is the Most Abundant t-SNARE in Platelets 
Figure 3-15. Syntaxin-11 is the Most Abundant t-SNARE in Platelets.  Recombinant 
his-tagged human syntaxin-2, -4, -7, -11, and SNAP-23 and GST-tagged murine 
syntaxin-11 were used to generate a standard curve for quantification (using Enhanced 
Chemi-Fluorescence western blotting) of each t-SANREs in the indicated number of 
murine platelets (m) and human platelets (h).  
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Figure 0-16Figure 3-16: Endogenous Syntaxin-11 is Recognized by Syntaxin-2 Polyclonal Antibody 
Figure 3-16. Endogenous Syntaxin-11 is Recognized by Syntaxin-2 Polyclonal 
Antibody.  A) Recombinant his-tagged cytosolic domain of human syntaxin-2 (rStx2, 
lane 1-3), human syntaxin-4 (rStx4, lane 4-6), human syntaxin-7 (rStx7, lane 7-9), and 
GST-tagged human syntaxin-11 (rStx11, lane 10-12) were loaded with a series of 
amount: 20 ng, 10 ng, 2.5 ng per lane and probed by western blotting with the indicated 
antibodies.  B) Human platelet extract was incubated with syntaxin-2 conjugated agarose 
beads.  The specific bound proteins were eluted and subjected to western blotting by 
using indicated syntaxin-11 antibody.  Controls include with or without IgG conjugated 
agarose beads. 
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Figure 0-17Figure 3-17: Syntaxin-11 Deficient Human Platelets Have Secretion Defects 
Figure 3-17. Syntaxin-11 Deficient Human Platelets Have Secretion Defects.  Platelet 
extracts (5.0 × 107 platelets/lane) from control and FHL4 patients were probed by western 
blotting with the indicated antibodies (A). [3H]-5HT labeled and washed platelets from 
FHL4 patient (red circle symbols) and normal control (black square symbols) were 
prepared as described in “Materials and methods”.  Aliquots of intact platelets (2.5 × 108 
/mL) were incubated with 0.7 mM CaCl2 at RT for 5 min and then incubated with the 
indicated thrombin concentration at RT for 1 min (B) or 0.05 U/mL thrombin for the 
indicated time points (C). Release of [3H]-5HT from dense granules, PF4 from α-
granules, and β-hexosaminidase from lysosomes was measured, and percent secretion 
was calculated.  The points represent the average of triplicate measurements and the 
standard deviation is indicated.  The statistical analysis was performed using ANOVA 
(GraphPad Prism 5), p values as indicated. 
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Figure 0-18Figure 3-18: Depletion of Syntaxin-11 in FHL4 Patient Affects Aggregation 
Figure 3-18. Loss of Syntaxin-11 in Platelets Affects Aggregation, ATP Release, and 
P-selectin Exposure.  A) The washed platelets from control (black traces) and patient 
(gray traces) were stimulated with thrombin (0.1 U/mL, i), collagen (10 µg/mL, ii), and 
A23187 (100 nM, iii) for 2-3 min.  The aggregation traces were monitored in the platelets 
(i-iii) concurrently the released ATP monitored by a luciferin/luciferase-induced 
luminescence (iv-vi).  (B) and (C) Washed platelets (1 × 108/mL) from normal control 
(Control) and FHL4 patient (Patient) were stimulated with or without 0.1 U/mL thrombin 
for 1 min and then incubated with FITC-conjugated anti-P-selectin, or FITC-conjugated 
PAC-1 antibodies for 15 min at RT.  The reactions were stopped by adding 10 volumes 
of 1% formaldehyde for 30 min and the fluorescent intensities were measured by flow 
cytometry.  The data from each FACS run were plotted in histogram and graphed using 
Geo Mean Fluorescence Intensity (GMFI): P-selectin (B) and PAC-1 (C).  D) Deficiency 
of syntaxin-11 does not affect resting platelet ultrastructure and cytoskeletonal 
rearrangement.  Washed platelets (4 × 108/mL) were kept resting by adding PGI2 (i-ii) or 
stimulated with 0.1 U/mL thrombin (iii-iv) for 5 min.  The platelets were fixed in 0.1% 
glutaraldehyde for 15 mins at 37°C and 3% glutaraldehyde for 1 hour at 4°C.  After 
osmication, the fixed platelets were dehydrated then polymerized in Spurr’s resin.  The 
thin sections of platelets were counterstained with uranyl acetate and the samples were 
analyzed using transmission electron microscope.  The images were obtained using Gatan 
software and only the brightness and contrast were adjusted in Photoshop.  The 
magnification of images was shown as indicated scale bars.  
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Figure 0-19Figure 3-19: Syntaxin-11 is Associated with Platelet Core SNAREs 
Figure 3-19. Syntaxin-11 is Associated with Platelet Core SNAREs.  Platelet extracts 
from resting (R) or thrombin stimulated platelets (S) were prepared by solubilization with 
1% Triton-100.  After clarification, platelet extracts were incubated with syntaxin-11 
polyclonal antibody or IgG control for 3 h at 4°C, then extension of 1h by adding Protein-
A-Agarose.  The bound proteins were eluted and separated by SDS-PAGE, followed by 
western blotting with the indicated antibodies.   
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Chapter FOUR 
The Role of Tomosyn in Platelet Secretion 
 
 
Introduction 
Platelet secretion is critical for hemostasis and thrombosis.  Hypoactive platelets 
cause bleeding problems while hyperactive platelets cause thrombosis, which eventually 
leads to heart attack or stroke.  Control and regulation of platelet secretion is very 
important for normal platelet function.  It has been generally believed that most regulated 
exocytosis processes are mediated by highly conserved SNARE proteins.  VAMPs (v-
SNARE), interact with two types of target membrane SNAREs: syntaxin-type and 
SNAP-25-type (t-SNAREs), serving as the minimal components to drive bilayer fusion 
[33].  An interaction between the v-SNARE and t-SNAREs is been thought to provide the 
specificity for individual fusion events, with additional accessory proteins regulating 
spatial and temporal aspects of the process [136, 137].  In platelets, the core SNARE 
machinery, which includes VAMP-8, SNAP-23, and syntaxin-11, are defined using 
genetic and biochemical analysis [40, 41, 46] and [Chapter 3].  Further efforts to look for 
t-SNARE interacting proteins are thought to be a method to identify regulatory 
components that control SNARE complex formation. These data will build a detailed 
picture of SNARE machinery necessary for platelet secretion.  By using t-SNARE 
containing complexes as “bait”, we found that tomosyn-1, granuphilin, and Munc18b, 
from platelet extracts, could specifically associate with different set of SNARE 
complexes.  Tomosyn-1 had not been previously identified in platelets.  Tomosyn-1, 
originally identified as a neuronal, syntaxin1A-binding protein, is a 130 kDa, cytoplasmic 
protein.  There are two genes for tomosyn (-1 and -2) in mammals.  Tomosyn-1 contains 
two domains: an N-terminal WD40 repeats and an R-SNARE coiled-coil domain in C-
terminus, which are linked by a hypervariable region.  The WD40 repeat domain is 
predicted to fold into a two, β-propeller structure, which is important for protein-protein 
interactions.  Tomosyn-1 has three splice variants and shares 98% sequence identity 
between human and rat (shown on Fig.1).  Over-expression of tomosyn-1 in neuronal or 
endocrine cells inhibits secretion, this together with its C-terminal, R-SNARE motif 
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suggests that tomosyn-1 plays a negative role in secretion.  Consistently, knockdown of 
tomosyn-1 in β-cells increases insulin secretion [112].  Also, the loss of tomosyn-1 in 
neurons enhances neurotransmitter release [107].  Depletion of tomosyn-1 in C. elegans 
causes an increase in neurotransmitter release by enhancing vesicle priming [138, 139].  
Although data supports a negative role for tomosyn-1 in exocytosis, there are several 
conflicting results from the neuronal field.  Tomosyn-1 knockdown in SCG neurons has 
been shown to inhibit synaptic transmission [111].  Tomosyn-2 shares the same structure 
and alterative splicing pattern with tomosyn-1 and has been thought to have the similar 
function as tomosyn-1 [102, 103, 140].  Although data supports a negative role for 
tomosyn-1 in exocytosis, there are several conflicting results from the neuronal field.  
Tomosyn-1 knockdown in SCG neurons has been shown to inhibit synaptic transmission 
[111].   
The goal in this Chapter was to identify SNARE regulators and characterize their 
function.  To this end, we have identified tomosyn-1 in platelets and determined its novel 
function in platelets and hemostasis.  Our findings suggest tomosyn-1 is a positive 
regulator for platelet secretion, thus important for hemostasis and thrombosis. 
 
 
Results:  
Tomosyn-1 is Present and Associated with SNAREs in Platelets 
Although the core SNARE machinery has been studied in platelets, SNARE 
complex regulation and its coupling to signaling cascades in the platelet has not been as 
well studied.   Among the core SNARE complex components (VAMP, syntaxin, and 
SNAP-23), only syntaxin contains a potential regulatory domain (Habc domain), 
suggesting syntaxin might be important for regulation of t-SNARE activation and/or 
SNARE complex formation.  Thus, it seems logical that components which specifically 
interact with syntaxins may be potential regulatory proteins.  To identify potential 
regulatory proteins from platelet extracts, we performed pulldown assays using syntaxin-
containing complexes as “bait” and then analyzed the bound proteins by mass 
spectrometry.  Four specific bands were resolved by SDS-PAGE and SYPRO Ruby 
staining (Figure 4-1A).  Mass spectrometry identified all four (labeled as T1, T2, T3, T4) 
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(Table 4-1).  Tomosyn-1 (T1 and T2) was found to associate with both syntaxin-2/SNAP-
23 and syntaxin-4/SNAP-23 complexes, which is in agreement with the previous data 
that tomosyn-1 can form high affinity ternary complexes with syntaxin4/SNAP-23 [113].  
To verify expression of tomosyn-1 in platelets, we probed the platelet lysate (Input) and 
pulldown samples with antibodies directed against a peptide sequence in tomosyn-1 (a 
region shared by all three isoforms).  A specific, immunoreactive band was only seen 
when t-SNARE heterodimers were used as “bait” (Figure 4-1B), but not Munc18a and 
Munc18c containing complexes were used.  This indicates that tomosyn-1 might not co-
exist with Munc18a or Munc18c on SNARE complexes (Figure 4-1B), but tomosyn-1 
could be present in the same complex with Munc18b (Figure 4-1A, -1B).  To further 
determine which tomosyn-1 isoform is present in platelets.  RT-PCR was performed 
using b-, m-, and s-tomosyn-1 specific primers.  Only m-tomosyn-1 was detected (Figure 
4-1C), suggesting m-tomosyn-1 is most abundant isoform in platelets.   
Granuphilin, specifically interacted with Munc18a/syntaxin-2 complex, Munc13-
4 and Munc13-1 also specifically bound to this complex but not to the 
Munc18c/syntaxin-2 complex suggesting that Munc18a, but not Munc18c, can interact 
with Munc13-4 and granuphilin in platelets (Figure 4-8).  VAMP-8 and SNAP-23 were 
not shown to be present in Munc18a/syntaxin-2 complex.  This work was begun before 
syntaxin-11’s role was appreciated. Future studies on interacting proteins with syntaxin-
11 containing complexes will be a fruitful direction to pursue to identify other regulatory 
proteins. 
M-tomosyn-1 and Munc18a binding to syntaxin-1 has been shown mutually 
exclusive using recombinant proteins [104]. We found that tomosyn-1 and Munc18b 
were associated with SNAP-23/syntaxin-2 complex (Figure 4-1A, -1B).  Our finding is 
consistent with studies from adipocytes, showing Munc18c and b-tomosyn-1 binding to 
syntaxin-4 [113].  Further studies will need to clarify whether other components are 
required so that Munc18 can co-exist with tomosyn-1 in the same complexes.  It is 
generally thought that tomosyn-1 functions by interacting with t-SNAREs and blocking 
v-SNARE binding, thus prevent the formation of fusogenic SNARE complexes [98].  The 
syntaxin-2/SNAP-23 complex, but not syntaxin-4/SNAP-23, was associated with 
tomosyn-1, Munc18b, and VAMP-8 (R-SNARE).  This data suggests that tomosyn-1 
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could exist in the same complex with VAMP.  Similar observations have been reported 
by Widberg et al. [113].  In adipocytes, Munc18c, but not Munc18b, associates with 
tomosyn-1 and the SNARE complex (syntaxin-4/SNAP-23/VAMP-2), suggesting 
specific tomosyn-1/Munc18s pairings in different tissue are important for fusogenic 
SNARE complex formation. 
VAMP-8, SNAP-23, and syntaxin-11 are the primary v- and t-SNAREs required 
for platelet secretion [40, 41, 46].  In vitro complex pulldown assay showed that 
tomosyn-1 was associated with syntaxin-2/SNAP-23 and syntaxin-4/SNAP-23 
heterodimers (Figure 4-1A, -1B).  Experiments were designed to determine if 
endogenous tomosyn-1 was capable of interacting with endogenous core SNARE 
machinery components, which include syntaxin-11, SNAP-23, and VAMP-8 in platelets.  
Both resting and thrombin-activated human platelets were lysed in Triton X-100 and 
immunoprecipitations were performed using control IgG and anti-tomosyn-1 monoclonal 
antibodies.   Three t-SNAREs, syntaxin-2, syntaxin-4, and SNAP-23, were found in the 
tomosyn-1 immunoprecipitates, suggesting endogenous tomosyn-1 is associated with 
endogenous syntaxin-2 or -4 / SNAP-23 complexes.  This is consistent with our in vitro 
complex pulldown data (Figure 4-2).  Endogenous tomosyn-1 co-immunoprecipitated 
with syntaxin-11 from both resting and thrombin-activated platelet extracts, indicating 
tomosyn-1 might be involved in platelet secretion through interaction with functional t-
SNAREs.  Association with VAMP-3 and VAMP-8 was not detectable, which is 
consistent with the notion that R-SNARE motif of tomosyn-1 blocks v-SNARE binding 
to t-SNAREs.  It is likely that VAMP-8 and tomosyn-1 are present in two different 
complexes since extra t-SNARE complexes were used in the pulldown assay.  Taken 
together, these data demonstrate that tomosyn-1 is associated with core SNARE complex 
components, SNAP-23 and syntaxin-11 in activated platelets, suggesting tomosyn-1 may 
regulate functional SNARE complex formation in vivo.   
 
Tomosyn-1 is Phosphorylated and Partially Associated with Membrane 
Tomosyn-1 can form stable complexes with t-SNARE heterodimers through its C-
terminal R-SNARE domain [141].  It also has been shown that neuronal tomosyn-1 is 
phosphorylated at Ser-724 by PKA and the PKA-catalyzed phosphorylation of tomosyn-1 
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enhances neurotransmitter release through increased formation of the SNARE complex 
[111].  Thus, tomosyn-1 could be regulated by phosphorylation.  In platelets, PKA is 
activated in resting cells while PKC is activated upon.  To address the potential role of 
tomosyn-1 phosphorylation in platelets, we investigated whether tomosyn-1 was 
phosphorylated in vivo by using 32P metabolically-labeled platelets.  Figure 4-3A shows 
that phosphorylated tomosyn-1 was immunoprecipitated from both resting platelets 
treated with or without PGI2 and platelets activated by thrombin.  The phosphorylation 
level is similar in resting and activated platelets.  This result differs from that in neurons, 
suggesting that tomosyn-1 phosphorylation may not be important in platelets.  It is also 
possible that PKA is responsible for tomosyn-1 phosphorylation in resting platelets while 
PKC is associated with tomosyn-1 phosphorylation upon platelet activation, thus the level 
of phosphoryation observed did not change.  Further experiments will be required to 
address this point 
Tomosyn-1 is a cytosolic protein while SNAREs are membrane proteins.  If 
tomosyn-1 regulates SNARE complex formation through direct interaction with t-
SNAREs, a portion of tomosyn-1 should be detected associated with membranes.  If 
tomosyn-1 is a negative regulator in platelet through competing binding site with VAMP, 
tomosyn-1 would expect to translocate from membrane upon platelet activation, which 
allows SNARE complex formation and membrane fusion.  To test this scenario and 
determine whether tomosyn-1 is dissociated from the membranes upon platelet 
activation, we performed membrane fractionation experiments.  Tomosyn-1 was found to 
be present in both membrane and cytosol fraction (Figure 4-3B).  Membrane association 
did not change upon thrombin stimulation, suggesting that tomosyn-1 does not dissociate 
from membranes upon activation and secretion (Figure 4-3C).  The membrane 
association increased upon NEM-treatment, suggesting tomosyn-1 may anchor to 
membrane through association with SNAREs.  This observation is consistent with a 
previous report that tomosyn-1/syntaxin/SNAP-23 complexes can be dissembled by NSF 
(which is NEM sensitive) [104].  As a control, SNAP-23 and syntaxin-4 membrane 
association did not change since both proteins are membrane proteins.  In summary, 
unlike neuronal tomosyn-1, which behaves as a negative regulator through PKA 
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phosphoryation, phosphorylation and membrane association of platelet tomosyn-1 do not 
change upon stimulation, suggesting tomosyn-1 may have a different role in platelets. 
 
Tomosyn-1 is Important for Platelet Secretion 
To address whether tomosyn-1 plays a role in platelet secretion, we examined 
release from intact, tomosyn-1 KO mouse platelets.  To exclude non-specific effects to 
the secretory machinery due to a loss of tomosyn-1, washed platelet extracts from 
tomosyn-1 KO (Tomo KO) and wild type littermates (Wt) were prepared and probed by 
western blotting analysis.  The protein levels of fifteen other secretory components were 
not significantly altered by the deletion of tomosyn-1 (Figure 4-4A).  A thrombin titration 
experiment was performed using a 1 min incubation time (Figure 4-4B).  The secretion 
from α-granules and lysosomes was significantly decreased by the loss of tomosyn-1 
compared with wild type, suggesting that tomosyn-1 is required for release from these 
two granules.  The release from dense granules was slightly inhibited, suggesting that 
other components are compensating for the loss of tomosyn-1 or that it is not required.   
To confirm whether tomosyn-1 is required for platelet exocytosis, we further 
analyzed dense granule secretion from tomosyn-1 null platelets by using lumi-
aggregometry.  Figure 4-5, A-D and F-H shows the aggregation traces for washed 
platelets (control, black traces; patient, gray traces) stimulated with 10 µg/mL collagen, 
100 µM PAR4, 100 nM A23187, convulxin, and thrombin (0.025, 0.05, 0.1 U/mL).  As 
can be seen there is a significant defect in aggregation for the tomosyn-1 deficient 
platelets.  Concomitantly, ATP release from dense granules was significantly inhibited as 
measured with luciferin/luciferase-induced luminescence (Figure 4-5, a-d and f-h).  
Figure 4-5, E and I show in bar graph format, the release of ATP from dense granule 
stimulated with different agonists.  Secretion induced by the calcium ionphore, A23187, 
is impaired, suggesting that the secretion defect seen on tomosyn-1 deficient platelets is 
caused by the final SNARE-mediated fusion step and not at some upstream signaling 
step.   
To further confirm that the secretion defect, we also performed flow cytometry 
analysis.  P-selectin and LAMP-1 are integral membrane proteins in α-granules and 
lysosome.  Their exposure at the platelet surface is widely used as a metric for α-granule 
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and lysosome exocytosis.  Compared to normal control and resting platelets, the 
geometric mean fluorescence intensity (GMFI) of staining for P-selectin and LAMP-1 on 
tomosyn-1 deficient platelets only slightly increased upon stimulation with 0.1 U/mL 
thrombin (Figure 4-6, A-B).  When quantified, the P-selectin and LAMP-1 staining on 
tomosyn-1 null platelets was 2 fold less than those of wild type controls, suggesting that 
release from α-granule and lysosome is significantly inhibited. 
To explore whether loss of tomosyn-1 affects granule biogenesis, we compared 
the levels of several granule markers.  The level of the dense granule marker, serotonin 
and the lysosome marker, β-hexosaminidase was not significantly different (Figure 4-
4B).  There were 2538 ± 66 CPM/2.5×108 from control platelets (n=12) and 3083 ± 91 
CPM/2.5×108 from tomosyn-1 deficient platelets (n=24) for serotonin.  The level of β-
hexosamidase was 64 ± 6 U/2.5×108 (Wt, n=12) vs. 60 ± 4 U/2.5×108 (Tomo KO, n=12).  
The level of α-granule marker, PF4, was reduced 3 fold in tomosyn-1 deficient platelets: 
1771 ± 184 pg/2.5×108 (Wt, n=12) vs. 573 ± 82 pg/2.5×108 (Tomo KO, n=12), 
suggesting loss of tomosyn-1 causes reduction in intra-platelet PF4 storage.  Further 
studies are required to clarify if the observed reduction is caused by biosynthesis or 
trafficking.  Because the secretion assay is determined as percentage secretion, the PF4 
storage level does not affect the result that there is an α-granule release defect in the 
tomosyn-1 KO platelets.   
To exclude that the observed secretion defect is caused by signaling, we examined 
two important platelet activation markers: platelet cytoskeletal reorganization and 
integrin αIIbβ3 activation.  Activated αIIbβ3 was measured by flow cytometry analysis 
using the JonA antibody.  In Figure 4-4C, the histogram displays both JonA binding 
curves for thrombin activated platelets (grey trace) from control and tomosyn-1 KO 
platelets. There was no significant difference between wild type and the tomosyn-1 KO 
platelets, which was confirmed by quantification (right panel of Figure 4-4C), suggesting 
that tomosyn-1 depletion does not impair platelet αIIbβ3 inside-out signaling.  In sum, 
tomosyn-1 deficiency inhibited platelet secretion without affecting integrin activation, 
granule centralization, platelet aggregation, and granule genesis, indicating tomosyn-1 is 
important for platelet exocytosis. 
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Tomosyn-1 is Important for Hemostasis and Thrombosis 
The primary function of platelets is in hemostasis.  To study whether deletion of 
tomosyn-1 affects thrombosis and hemostasis, we used two in vivo assays.  First, tail-
bleeding time tests were performed on 5-6 weeks old littermates generated from 
tomosyn-1 heterozygous siblings.  In Figure 4-7A, among 24 tomosyn-1 KO mice we 
tested, only three mice had short or normal bleeding times, the remaining 21 mice bled 
for more than ten minutes.  The wild type with the same background showed normal 
bleeding time with a median bleeding time of 226.4 ± 37.3 seconds (n=19).  This 
prolonged tail-bleeding time in tomosyn-1 KO mice demonstrates that tomosyn-1 is 
required for hemostasis and suggests that tomosyn-1 plays a positive role in platelet 
secretion and hemostasis. 
To further confirm that this robust in vivo, phenotype was due to loss of tomosyn-
1, we utilized the carotid artery, FeCl3-injury thrombosis model.  The model looks at 
thrombosis in response to endothelial cell damage by FeCl3 and measured to the time 
required for carotid artery occlusion post-damage induction.  In agreement with the 
prolonged tail bleeding times, there was a robust thrombosis defect in tomosyn-1 deletion 
mice as compared to wild type littermates (Figure 4-7B).  The time to occlusion in wild 
type littermates was around 2.7 minutes.  Surprisingly, under the same condition, the 
occlusion time for tomosyn-1 deficient mice was not observed, except one mouse around 
7 minutes.  These in vivo data provide strong evidence that tomosyn-1 is required for 
platelet secretion, hemostasis, and thrombosis. 
 
Discussion: 
In summary, tomosyn-1 is present and phosphorylated in platelets.  Tomosyn-1 
was associated with the endogenous functional t-SNARE heterodimer, syntaxin-
11/SNAP-23 in platelets.  Deletion of tomosyn-1 in platelets reduced platelet secretion 
and thus impaired hemostasis and thrombosis.  It is clear that tomosyn-1 is present in 
platelets and important for platelet secretion, hemostasis, and thrombosis.  In agreement 
with previous studies showing tomosyn-1 interacts with t-SNARE heterodimers [104, 
113, 141], tomosyn-1 was found associated with syntaxin/SNAP-23 heterodimers (Figure 
4-1A, -1B) in vitro.  In particular, tomosyn-1 was found associated with syntaxin-
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11/SNAP-23 heterodimers in platelets (Figure 4-2).  Studies have shown that incubating 
cells with NEM could inhibit NSF [142, 143].  This enzyme has been suggested to 
catalyze the disassembly of tomosyn-1/SNARE complexes.  We observed an increase in 
tomosyn-1 membrane association upon NEM-treatment, supporting the notion that 
tomosyn-1 was associated with membranes through formation stable complexes with t-
SNAREs (Figure 4-3B, -3C).  Tomosyn-1 is believed to be a negative regulator of 
neurotransmitter release through its R-SNARE motif and through its phosphoryation by 
PKA [98].  If this is the case in platelets, we would expect to see tomosyn-1 translocate to 
the cytosol and phosphorylated upon platelet activation.  Surprisingly, we did not find 
that tomosyn-1 dissociated from membrane into the cytosol and tomosyn-1 
phosphorylation was not changed upon stimulation.  These data suggest that tomosyn’s 
function in platelets may be different that in neurons.  Our secretion data support this 
contention.  Taken together, our in vitro data does not support negative role for tomosyn-
1 in platelets. 
Tomosyn-1 is important for platelet secretion from α-granules and lysosomes.  
Further, tomosyn-1 is required for hemostasis and thrombosis.  Overall, tomosyn-1 is 
important for physiological platelet function and hemostasis, suggesting that tomosyn-1 
plays a positive role in platelet exocytosis, possible through interaction with syntaxin-
11/SNAP-23. 
Originally tomosyn-1 was shown to disrupt the neuronal Munc18a/syntaxin-1a 
complex by binding to syntaxin-1a and has thus been proposed to be a positive modulator 
of SNARE complex formation [104].  It is possible that tomosyn-1 is required for 
activating syntaxin by releasing syntaxin-11 from Munc18b into an open stage. Our 
results, in agreement of Widberg et al [113], showed that all the components can still be 
in a fusion complex which probably requires some conformational change for activation 
of fusion.  Another possibility is that tomosyn-2 might be important for neurotransmitter 
release while tomosyn-1 is important for platelets and adipocyte exocytosis.  The 
inhibitory phenotype shown in tomosyn-1 KO mice may reflect tomosyn-1 competition 
with tomosyn-2 [107].  Moreover, there are conflicting results from neuronal field.  
Tomosyn-1 knockdown in SCG neurons inhibits synaptic transmission [111].  It has also 
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been shown that down regulation of tomosyn-1 reduced insulin secretion from an insulin-
secreting INS-1E cell line [144]. 
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Table 4-1. MS of Syntaxin Complex Interacting Proteins 
Sample MS Score Protein 
T1 144 Tomosyn-1 
T2 66 Tomosyn-1 
T3 325 Munc18b 
T4 259 Granuphilin 
 
The specific interacting proteins from Figure 4-1, which were indicated on the top as T1-
T4 were excised from the gel and subjected to trypsin digestion.  The samples were 
spotted onto a matrix-assisted laser desorption ionization (MALDI) target plate.  Both 
mass spectrometry (MS) and tandem time-of-flight (TOF-TOF) spectra were acquired 
and processed.  The data were searched against the database using MASCOT software.  
The MASCOT search results were shown. 
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Figure 0-1Figure 4-1: Tomosyn-1 is Present in Platelets 
Figure 4-1. Tomosyn-1 is Present in Platelets.  A) The indicated complexes were 
produced in E.coli using the pRSFDuet plasmid with a S-tag peptide fused to the C-
terminus of the syntaxin.  Complexes are bound to S-Protein-Agarose beads through the 
S-tag.  After washing, the complex-bound beads were incubated with solubilized platelet 
extracts.  The beads were washed again, and then the proteins were eluted with SDS-
PAGE sample buffer.  The eluted proteins were separated by SDS-PAGE and stained 
with Sypro Ruby.  The specific interacting proteins which were indicated on the top as 
T1-T4 were excised from the gel and subjected to trypsin digestion.  The samples were 
spotted onto a matrix-assisted laser desorption ionization (MALDI) target plate.  Both 
mass spectrometry (MS) and tandem time-of-flight (TOF-TOF) spectra were acquired 
and processed.  The data were searched against the database using MASCOT software.  
The MASCOT search results are shown on the Table 4-1.  B) The indicated complexes 
were produced in E.coli using the pRSFDuet plasmid with a S-tag peptide fused to the C-
terminus of the syntaxin.  Solubilized platelet extracts were incubated with the different 
complexes and the resulting material was recovered on S-Protein-Agarose.  After 
washing, the proteins were eluted and probed by western blotting with the antibodies to 
the indicated proteins.  C) RT-PCR using platelet-derived RNA with tomosyn-1 isoform-
specific primers shows only expression of PCR product corresponding to m-tomosyn-1 
mRNAs while not to b- and s-tomosyn-1 mRNAs in human platelets.  Marker = 1-kb 
DNA ladder.   
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Table 2Table 4-1.  MS of Syntaxin Complex Interacting Proteins 
 
 
 
 
 
 
 
 
Figure 0-2Figure 4-2: Tomosyn-1 is Associated with Platelet Core SNARE Fusion Complexes 
Figure 4-2. Tomosyn-1 is Associated with Platelet Core SNARE Fusion Complexes.  
Platelet extracts (Plt Ext.) from resting (R) or thrombin stimulated platelets (S) were 
prepared by solubilization with 1% Triton-100.  After clarification, platelet extracts were 
incubated with anti-tomosyn-1 murine monoclonal antibody or an IgG (1:1 ratio mixture 
of murine and rabbit IgG) control for 4 h at 4°C.  The immune complexes were recovered 
with Protein-G-Aagarose.  The bound proteins were eluted and separated by SDS-PAGE, 
followed by western blotting with the indicated antibodies.   
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Figure 0-3Figure 4-3: Tomosyn-1 is Phosphorylated in Both Resting and Activatied Platelets and Membrane 
Association Increases upon NEM Treatment 
Figure 4-3. Tomosyn-1 is Phosphorylated in Both Resting and Activated Platelets 
and Membrane Association Increases upon NEM Treatment.  A) Metabolically [32P]-
labeled platelets were stimulated with or without thrombin for 2 min.  Platelets were 
solublized with 1% Triton-100 to make platelet extract.  Protein A Sepharose, conjugated 
with anti-tomosyn-1 monoclonal antibodies were incubated with the labeled platelet 
extract.  After washing, the bound proteins were analyzed with SDS-PAGE, followed by 
Phosphor Imaging and western blot for tomosyn-1.  B) Resting and thrombin activated 
platelets treated with or without NEM were sonicated, followed by centrifugation to 
separate membrane and cytosol fractions.  The equivalent amount of two fractions were 
loaded and analyzed with SDS-PAGE, followed by western blotting for the indicated 
proteins.  ImageQuant 5.2 software was used to analysis of immunolabeled bands.  The 
data are presented as means ± SD. 
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Figure 0-4Figure 4-4: Tomosyn-1 Deficient Murine Platelets Have Secretion Defects  
Figure 4-4. Tomosyn-1 Deficient Murine Platelets Have Secretion Defects.  A) 
Platelet extracts (5.0 × 107 platelets/lane) from wild type (Wt) and tomosyn-1 KO (Tomo 
KO) mice were probed by western blotting with the indicated antibodies.  [3H]-5HT 
labeled and washed platelets from tomosyn-1 null (red circle symbols) and Wt (black 
square symbols) were prepared  and incubated with 0.7 mM CaCl2 at RT for 5 min, prior 
to activation with the indicated thrombin concentration for 1 min.  Release of [3H]-5HT 
from dense core granules, PF4 from α-granules, and β-hexosaminidase from lysosomes 
was measured, and percent secretion was calculated.  The points represent the average of 
triplicate measurements and the standard deviation is indicated.  The statistical analysis 
was performed by ANOVA (GraphPad Prism 5), p<0.001. 
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Figure 0-5Figure 4-5: Deletion of Tomosyn-1 in Platelets Affects ATP Release but Limited Effects on 
Aggregation 
Figure 4-5. Deletion of Tomosyn-1 in Platelets Affects ATP Release but has Limited 
Effects on Aggregation.  Washed platelets from Tomosyn-1 null (Tomo KO) and wild 
type (Wt) mice were stimulated with collagen (5 µg/mL, A), PAR4 peptide (100 µM, B), 
A23187 (10 nM, C), convulxin (10 µg/mL, D), or thrombin (0.025 U/mL, F; 0.05 U/mL, 
G; 0.1 U/mL, H) for 2-3 minutes.  The aggregation traces were monitored (A-D and F-H) 
and concurrently the released ATP monitored by a luciferin/luciferase-induced 
luminescence (a-d and f-h).  The absolute percentage ATP release comparing to 
background PPP was graphed (E and I). 
 
  
  106 
 
 
  
  107 
Figure 0-6Figure 4-6: Depletion of Tomosyn-1 in Platelets Effects P-selectin and LAMP-1 exposure but not 
intergrin activation 
Figure 4-6. Depletion of Tomosyn-1 in Platelets Affects P-selectin and LAMP-1 
Exposure but not Intergrin Activation.  Washed platelets (1 × 108/mL) from wild type 
(Wt) and tomosyn-1 null (Tomo KO) mice were stimulated with or without 0.1 U/mL 
thrombin for 1 min and then incubated with FITC-conjugated anti-P-selectin, or FITC-
conjugated LAMP-1, or FITC-conjugated anti-integrin αIIbβ3, or PE-conjugated JonA 
antibodies for 15 min at RT.  The reactions were stopped by adding 10 volumes of 1% 
formaldehyde for 30 min and the fluorescent intensities were measured by flow 
cytometry.  The data from a representative FACS run are shown and cumulative data was 
graphed using Geo Mean Fluorescence Intensity (GMFI): P-selectin (A), LAMP-1 (B), 
JonA (C), and GPIIbIIIa (D). 
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Figure 0-7Figure 4-7: Tomosyn-1 Deficient Mice Have Bleeding Phenotype 
Figure 4-7. Tomosyn-1 Deficient Mice Have Bleeding Phenotype.  Mice from 
Tomosyn-1 null (Tomo KO) and wild type (Wt) littermates were used for tail-bleeding 
time assay and FeCl3-induced arterial thrombosis.  The animal number, mean and 
standard deviation are indicated (p<0.0001, ANOVA).  A) Tail bleeding times were 
measured after tail transection.  The tail tips were used for genotyping.  B) Occlusion 
time in FeCl3-induced arterial thrombosis test. 
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Figure 4-8. Western Blot Analysis of Interacting Proteins of Syntaxin Containing 
Complexes.  The indicated complexes were produced in E.coli using the pDuet plasmid 
with a S-tag peptide fused to the C-terminus of the syntaxin. Solubilized platelet extracts 
were incubated with the different complexes and the resulting material was recovered on 
S-Protein-Agarose. After washing, the proteins were eluted and probed by western 
blotting with the antibodies to the proteins indicated on the left.  
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Chapter Five 
Conclusions and Future Directions 
 
The research presented in this dissertation demonstrates that syntaxin-11, rather 
than syntaxin-2 or syntaxin-4, is the primary t-SNARE required for platelet secretion.  
The enhanced α-granule secretion from syntaxin-2/4 double KO platelets suggests that 
syntaxin-2 and syntaxin-4 could serve as secondary syntaxins for platelet secretion.  
Given that endogenous syntaxin-11 was associated with SNAP-23 and VAMP-8 in 
platelets, it seems plausible that syntaxin-11 forms fusogenic SNARE complexes 
required for platelet secretion.   
We have also added a novel component, tomosyn-1, to the list of proteins 
involved in platelet secretion.  Tomosyn-1 is associated with syntaxin-11 and SNAP-23 
both in activated platelets and resting platelets, suggesting tomosyn-1 may be interact 
with a fusogenic SNARE complex.  The studies of tomosyn-1 KO mice show that 
tomosyn-1 is important for platelet secretion, at least for α-granule and lysosome release.  
Moreover, tomosyn-1 is required for hemostasis and thrombosis.  Overall, tomosyn-1 is 
important for platelet function and hemostasis, suggesting that tomosyn-1 plays a positive 
role in platelet exocytosis.  My data suggest that its role could be through interactions 
with syntaxin-11/SNAP-23 heterodimers.  The mild defect of dense granule secretion 
contrasts with the robust impairment of hemostasis, suggesting that tomosyn-1 is required 
for normal platelet function and also suggests that there is more to uncover about the role 
of tomosyn-1 in vivo.  Clearly the data presented here show that controlling platelet 
secretion without affecting signaling may be a therapeutic target for anti-platelet therapy 
to control serious cardiovascular diseases, such as heart attack and stroke. 
 
The Core SNARE Machinery in Platelet Secretion 
It is generally believed that most regulated exocytosis is a SNARE-mediated 
membrane fusion process.  SNARE proteins are characterized by a conserved heptad 
repeat region of approximately 60-70 residues in length, referred to as SNARE motif.  
The energy from SNARE complex formation is believed to drive lipid bilayer fusion.  A 
functional SNARE complex comprises four SNARE motifs from synaptic SNARE 
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proteins, forming a four-helix, coiled-coil structure [28, 145].  All physiological SNARE 
complexes cotain one R- and three Q-(a, b, c) SNAREs as described in Chapter 1.  In 
platelets, both VAMP-8 (R) and SNAP-23 (Qbc) are required for platelet secretion, so the 
functional SNARE complex should be the R-Qa-Qbc configuration.  This suggests that 
Vtib (Qb) is not likely to be a component of the functional SNARE complexes in 
platelets.  The studies from Chapter 3 clearly demonstrated that syntaxin-11 is required 
for platelet exocytosis and thus is the most likely Qa-SNARE candidate.  Studies also 
suggested that syntaxin-11, SNAP-23, and VAMP-8 are present in the same complex as 
demonstrate by immunoprecipation with syntaxin-11 antibodies (Chapter 3) and SNAP-
23 antibodies [Karim et al, in preparation].   
Syntaxin-11 is much more important for dense granule and α-granule release than 
for lysosome release, which suggests that syntaxin-11 mediates at least one common step 
that is important for both efficient and rapid dense granule release and less rapid but the 
more abundant α-granule release.  Given the clinical bleeding diathesis observed with this 
patient (Filipovich, personal communication), this step must be vital for hemostasis.  
Syntaxin-11 also must play a role in lysosome release; but, unlike dense granule and α-
granule release, secretion from lysosomes was not completely eliminated in syntaxin-11 
deficient human platelets.  Residual release from lysosomes indicates that a redundant 
syntaxin compensates for the lack of syntaxin-11, though less efficiently.  The potential 
candidates are syntaxin-2 and -4, especially considering that the syntaxin-2/4 double 
depletion mouse platelets had mild secretion enhancement for α-granule and lysosome 
release.  If syntaxin-2 or -4 serve as secondary syntaxins for lysosome release, it may not 
be obvious in the single and double knockouts.  As a comparison, deletion of VAMP-2 
and/or-3 had no overt effect yet they could be shown to play a role when analyzing the 
residual secretion from VAMP-8 KO platelets.   
The data in Chapter 3, showing that syntaxin-2 and -4 are not critical for platelet 
secretion, contradict previous reports from our laboratory and others [40, 41, 44].  The 
discrepancy can be explained by a number of factors that stem from the use of antibodies 
as inhibitors in permeabilized platelets.  The large antibody molecules could sterically 
block a functional SNARE or the antibody could cross react with other SNAREs.  Based 
on the observation that β-hexosaminidase and PF4 levels from syntaxin-2 and -4 double 
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KO and syntaxin-11 deficient platelets are normal, syntaxin-2, -4, and -11 are almost 
certainly not required for granule biogenesis.  Thus the requirement for syntaxin-11 in 
platelet secretion, shown in Chapter 3, could be attributed to a defect of vesicle priming 
and/or fusion.  To define the exact mechanism for syntaxin-11 in platelet exocytosis, 
further studies are required, but clearly it is essential for secretion.  
Platelet exocytosis represents a unique model to study vesicle trafficking because 
platelets have three different granules with the three different types of cargo, release 
rates, and delays post-stimulation.  This might suggest that three different types of 
granule release events may use slightly different sets of SNAREs or regulatory proteins.  
Loss of the primary v-SNARE, VAMP-8, shows differential effects on the three granule 
secretion processes.  Dense granule is the least affected in VAMP-8 deletion murine 
platelets.  However deficiency of syntaxin-11 totally abolishes both α-and dense granule 
release but has a milder effect on lysosome release [Figure 3-17].  This suggests that 
three different granule release processes may use different SNARE regulators or that 
certain t-SNARE regulators are more critical for the rapid release.  The supportive 
evidence for SNARE regulators playing a critical role in granule release comes from the 
studies of Munc13-4 and tomosyn-1.  The loss of Munc13-4 in platelets has a greater 
effect on dense granule secretion than on α-granule and lysosome release [48].  The 
newly described regulatory protein tomosyn-1 (Chapter 4) appears to play a more 
important role for α-granule and lysosome release than dense granule release [Figure 4-
4].  Further studies on regulatory proteins will identify whether different regulatory 
proteins interact with specific SNAREs, thus playing a differential role in specific 
granule release.   
Based on the classic neuronal SNARE complex (syntaxin-1/SNAP-25/VAMP-2), 
it is expected that both Qa and R-SNARE need TMDs.  However, syntaxin-11 does not 
contain a TMD.  Since studies from Chapter 3 demonstrate that syntaxin-11 is required 
for platelet secretion, we hypothesize that the functional SNARE complex in platelets is 
syntaxin-11 (Qa), SNAP-23 (Qbc), and VAMP-8 (R).  This is supported by the fact that 
syntaxin-11 associates with SNAP-23 and VAMP-8 in (Figure 3-19).  Thus it would 
appear that syntaxin-11 forms a functional SNARE complex required for all three granule 
release.  Moreover it has been demonstrated that syntaxin-11 is required for exocytosis 
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from lymphocytes [146].  Although the exact membrane anchoring is still unknown, 
studies [37] have suggested that the majority of syntaxin-11 is anchored to membranes 
and may be so via palmitoylation of C-terminal cysteine residues.  This is significant 
because studies show that t-SNARE membrane anchor activity, and thus fusogenicity, is 
governed by the overall degree of hydrophobicity of the added modification [39].  A t-
SNARE complex anchored only by phosphatidyl-ethanolamine (PE)-linked SNAP-25 
(involving up to four PE molecules per SNAP-25) and syntaxin-1 cytoplasmic domain is 
enough to drive membrane fusion [39].  Studies [36, 39, 147] have suggested that long 
prenyl groups (~C55) can replace the TMD of VAMP-2 in proteoliposome fusion.  To test 
our hypothesis, two types of proteoliposomes: t-SNARE (SNAP-23 and PE-linked 
syntaxin-11 containing different number of C-terminal cysteine residues or a C-terminal 
domain replaced by the TMD of syntaxin-2) containing vesicles and v-SNARE (VAMP-
8) containing vesicles can be tested for fusogenicity [33].  Fusion efficiency is expected 
to be correlated with the number of modified C-terminal cysteine residues of syntaxin-11 
and concentration of cholesterol in liposome.  Considering syntaxin-11, but not syntaxin-
2 and -4, is required for platelet secretion and that platelet secretion is believed to happen 
at the OCS, which is cholesterol rich membrane region, one expectation should be that 
lipid-modified syntaxin-11 is more fusogenic than that with chimeric syntaxin-2 TMD. 
Finally the latest discovery of Vti1b in platelets opens another possibility.  The 
typical core fusion complexes are likely to have a similar parallel four-helical bundle 
structure, but in some cases the two α-helical SNARE domains provided by SNAP-25 
may be replaced by the SNARE domains of other members of the syntaxin family.  For 
example, VAMP-8 complexes with syntaxin-7 (Qa), Vti1b (Qb), and syntaxin-8 (Qc) and 
VAMP-4 complexes with syntaxin-16, Vti1a, and syntaxin-6 [148, 149].  At this point, 
we cannot fully exclude that syntaxin-2 is in the fusion complex for the final step since 
endogenous syntaxin-2 (Qa) might be present in the endogenous syntaxin-11 (Qa) 
precipitates [Figure 3-19].  Another candidate is Vti1b (Qb).  Although Vti1b is 
negatively regulated by syntaxin-11 in macrophage [77], it might be in similar complexes 
in platelets and thereby compensate for the lack of a syntaxin-11transmembrane domain.  
Further studies are required to address these possibilities.   
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Taken together, a model consistent with our data shows the functional core 
SNARE machinery includes VAMP-8 on granule membranes and SNAP-23 and 
syntaxin-11 on plasma membrane in platelets (Figure 5-1).  Syntaxin-11 is the most 
abundant t-SNAREs of four known syntaxins in platelets (Table 5-1); suggesting 
syntaxin-11 could be the critical t-SNARE just like VAMP-8 is the primary v-SNAREs 
[46].  In sum, all the evidence support that syntaxin-11 is the primary t-SNARE required 
for platelet secretion. 
 
The SNARE Complex Regulation for Platelet Secretion 
Munc18s are cytosolic proteins that belong to the evolutionally conserved SM 
family which is required for vesicle trafficking events [79, 136, 150].  SM proteins act as 
syntaxin-specific chaperones and may contribute to matching cognate v- and t-SNARE to 
form fusogenic trans-SNARE complexes [151].  Among the three SM isoforms present 
in platelets: Munc18 (a, b, c) [47, 63, 78], Munc18b is the most abundant [Al-Hawas et 
al. in preparation].  Moreover when using t-SNARE heterodimer [Figure 4-1] or SNARE 
complex [47], Munc18b is the only Munc18 identified in the pull-downs from human 
platelet extracts.  More importantly, human platelets from Munc18b mutant patients 
(FHL5) show a robust secretion defect from all three granules [50].  Data from our 
laboratory show that platelets from Munc18b deficient patients have defects in the release 
of serotonin, PF4, and β-hexosaminidase [Al-Hawas et al. in preparation].  It will be 
interesting to know if the platelet secretion impairment in certain FHL5 patients is caused 
by dominant-negative Munc18b mutations (or loss of the protein due to protein 
instability).  If this is true, inhibitory peptides of based on Munc18b could be a new drug 
candidate to modulate thrombosis.  Consistently, peptides based on a conserved region of 
Munc18 did prove to be effective inhibitors of secretion when introduced into 
permeabilized human platelets [47].   
Since Munc18b is required for all three granule secretion events, further exploring 
the mechanism of Munc18b in platelet secretion will help to identify other SNARE 
machinery components and understand how Munc18b specifically interacts with t-
SNAREs or v-SNARE to promote specific SNARE complex formation.  This might also 
shed light on how secretion is coupled to the platelet signaling pathways.  Munc18b may 
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be a syntaxin-11-specific partner since our unpublished data showed that platelets from 
FHL5 patient (which had no Munc18b) had reduced levels of syntaxin-11.  Syntaxin-11-
deficient platelets from a FHL4 patient display a robust secretion defects while Munc18b 
protein level is only partially reduced [Figure 3-17A].  This prompts speculation that 
syntaxin-11 is an absolutely required component for secretion while Munc18b is required 
for syntaxin-11 stability (Figure 5-1).  This may indicate that Munc18b functions as a 
specific chaperone for syntaxin-11.   
Given that loss of Munc18b affects syntaxin-11, it is formally possible that loss of 
syntaxin-11 contributes to the observed phenotype in FHL5 patients, which lack 
Munc18b.  This would be consistent with the phenotype from syntaxin-11 deficient 
platelets from a FHL4 patient in this thesis.  One hypothesis is Munc18b serves solely a 
syntaxin-11 chaperone.  To test this hypothesis, more characterization of FHL5 platelets 
is required.  A correlation analysis should be performed to link the types of Munc18b 
mutations to the levels of secretion defect to determine whether the severe secretion 
defect is caused by certain Munc18b mutations.  Another experiment could use 
mutagenesis to generate two kinds of Munc18b mutations that differentially affect 
syntaxin-11 protein levels and then introduction into megakaryocytes lacking endogenous 
Munc18b and syntaxin-11.  If our hypothesis is right, we would expect to see the 
secretion defect corrects with the syntaxin-11 protein levels.  However, it should be noted 
that Munc18b heterozygous patients show a partial secretion phenotype and no reduction 
in syntaxin-11, so it seems possible that Munc18b could play other roles as a limiting 
component of the secretion pathway (Al Hawas et al. in preparation).  Further studies are 
required to discriminate whether Munc18b serves solely a chaperone or is also a core 
regulator for functional specific SNARE complex formation in platelet secretion.   
Although syntaxin-11 stability is dependent on Munc18b, Munc18b is not solely a 
syntaxin-11-specific partner.  Loss of syntaxin-11 in platelets did not significantly affect 
Munc18b protein levels as shown in Figure 3-17A, suggesting that syntaxin-11 is not 
required for Munc18b expression and stability.  Moreover Munc18b can specifically 
interact with syntaxin-2/SNAP-23 complex but not the syntaxin-4/SNAP-23 complex 
[Figure 4-1], supporting the idea that Munc18b might also be a chaperone for syntaxin-2. 
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Tomosyn in Platelets 
By using syntaxin-containing complexes, we purified tomosyn-1 from platelet 
extracts.  Tomosyn-1 is a cytosolic protein, was originally identified as a syntaxin-
binding protein.  It has been shown to disrupt the neuronal Munc18a/syntaxin-1a 
complex and thus was proposed to be a positive modulator of SNARE complex formation 
[104].  The results from this work support the hypothesis that tomosyn-1 is a positive 
regulator for platelet granule secretion.  Results in this work clearly show that tomosyn-1 
KO mice have a bleeding diathesis and tomosyn-1 is required for platelet secretion from 
at least α-granules and lysosomes.  Overall, tomosyn-1 is important for platelet function 
and for hemostasis though the mechanism is still elusive.  In agreement with previous 
studies [104, 113, 141], tomosyn-1 is associated with the membrane through interactions 
with syntaxin/SNAP-23 heterodimers in platelets.  Tomosyn-1 has also been thought to 
bridge the fusion machinery to a signaling event.  It has been shown that phosphorylation 
of tomosyn-1 by PKA [98] is important for regulation of SNARE complex formation 
upon stimulation in neuron.  Indeed, tomosyn-1 is phosphorylated in platelets but this 
phosphorylation does not appear to change during platelet activation.  This suggests that 
tomosyn-1 phosphorylation may not be a viable secretion control pathway in platelets.  
Tomosyn-1 also can form complexes with syntaxin-11 and SNAP-23.  Widberg et al 
[113] and our syntaxin-1\SNAP-23 pull down experiments (Figure 4-1A) show that the 
fusion components, which include VAMP-8, syntaxin-11, SNAP23, Munc18b, and 
tomosyn-1 can form a large complex.  It is possible that tomosyn-1 is required for 
activating syntaxins by releasing syntaxin-11 from the Munc18b/closed syntaxin stage 
into an open conformation.   
However, the mechanism that tomosyn-1 plays in different tissues is elusive.  The 
studies of tomosyn-1 KO mice clearly show that tomosyn-1 is a negative regulator of 
neurotransmitter release but a positive regulator for platelet exocytosis.  It is possible that 
this inconsistency is caused by tissue-specific factors that have yet to be identified.  
Consistently, phosphorylation of tomosyn-1 appears different in neuron than in platelets.  
Tomosyn-1 is similarly phosphorylated in both resting and activated platelets while 
neuronal tomosyn-1 is phosphorylated by PKA only upon stimulation.  The difference 
could be caused by the specific kinases in different tissue. Upon stimulation, PKA is the 
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active form in neurons while PKC is activated in platelets.  It is possible that tomosyn-1 
is phosphorylated by PKA in resting platelets and by PKC in activated platelets, but the 
sites of phosphorylation are different.  Another possibility is that tomosyn-2 might be 
important for neurotransmitter release while tomosyn-1 is important for platelets and 
adipocytes exocytosis.  The inhibitory phenotype shown in tomosyn-1 KO mice may be a 
result of tomosyn-1 competition with tomosyn-2 [107].  Future studies should focus on 
the different mechanism for tomosyn-1 as negative role in neurotransmitter release and as 
positive role in platelet exocytosis.  It is important to determine if tomosyn-1 serves as 
place holder for VAMPs and/or is keeping the t-SNAREs in an activated state.  These 
experiments will help us understand the differential roles of tomosyn-1 in different cell 
types.  The phenotype observed from tomosyn-1 KO mice is similar to that in the 
granuphilin KO mice [92].  Finally, it is also possible that tomosyn-1 sequesters t-
SNAREs from the functional fusion complex or secretion active zones using unknown 
mechanisms.   
The last possible mechanism for tomosyn-1 regulating platelet secretion can be 
through interaction with cytoskeletal components.  Future studies are required to 
understand the molecular mechanism of tomosyn-1 on platelet secretion and 
cardiovascular diseases.  Because endothelial cells are another key regulator for initiation 
of thrombus formation by providing vWF for platelet adhesion and activation, bone 
marrow transplantation will allow differentiation of the role of tomosyn-1 in platelets and 
endothelial cells.  We expect that vWF release from Weibel-Palade body (WPB) will be 
defective considering tomosyn-1 is ubiquitously expressed in different tissue.  The robust 
bleeding problem and impaired thrombosis formation could be due to a defect in 
endothelial cells.  
 
Platelet Rabs 
Rab GTPases and their effectors, which coordinate vesicle attachment and the 
subsequent assembly of cognate v- and t-SNARE complexes, play a key role in 
exocytosis [152].  The Rab27 family is involved in both dense granule biogenesis in 
megakaryocytes and platelet secretion [90].  In platelets, it has been shown that the 
majority of Rab27 is associated with dense granules while a smaller portion is associated 
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with the plasma membrane.  Rab27a/b double KO murine platelets display a severe 
defect in serotonin secretion [86].  The exact role of Rab27a/b in the regulation of dense 
granules instead of α-granules remains unclear.  Presumably the multiple-functions of 
Rab27 act through recruiting different effectors.  One of Rab27’s effectors, Munc13-4, is 
required for platelet secretion [48, 49], suggesting Rab27s and their effectors are required 
for dense granule exocytosis.  It is also possible that Rab27s interact with unknown 
factors which are important for dense granule package and trafficking, given the fact that 
deficiency of Munc13-4 also affects α-granule release.  The role of Munc13-4 and 
Rab27s in platelets is not fully understood since Munc13-4 is not required for granule 
biogenesis while Rab27s are[48].  Munc13-4 is also associated with α-granule release 
while Rab27s are not.  Further exploration of the mechanisms for Rabs in platelet 
secretion will clarify whether different granules require specific sets of Rab proteins or 
effectors. 
 
Rab27 Effectors in Platelets 
Munc13s are widely believed to serve as key vesicle priming factors.  The 
strongest evidence for this is from genetic ablation of both Munc13-1 and Munc13-2, 
which completely abolishes the synaptic vesicle priming and release [87, 88].  Mice 
lacking Munc13-4 have a bleeding diathesis and release from dense granules is totally 
abolished while the release from α-granules and lysosomes is severely impaired [48].  
This indicates that Munc13-4 mediates at least one step that is uniquely required for rapid 
dense granule release, and that this step is also critical for hemostasis in vivo.  The 
residual secretion from α-granules and lysosomes could be compensated for by other 
Munc13 family members or other Rab27 effectors.  The syntaxin containing complex 
pull-down experiment in this work (Chapter 4) discovered that both of Munc13-1 and 
Munc13-4 could interact with Munc18a/syntaxin-2 complex specifically in platelets.  
However, only Munc13-4 is critical for platelet secretion [48].  Compared with other 
Munc13s, Munc13-4 does not contain a C1 domain, but does have two C2 domains and a 
MHD domain.  The observations that mutations in the MHD domain or deletion of the 
C2B domain [89] and Munc13-4 peptides without C2B domain potently inhibit platelet 
secretion [48] suggest that both the MHD domain and the C2B domain are important for 
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its function.  It is possible that the MHD domain is required for interaction with important 
secretory machinery components while the C2B domain is important for anchoring to the 
plasma membrane or for regulating membrane fusion in response to Ca2+ signaling.  
Identifying the key interacting partners of Munc13-4 will be an important step for us to 
understand the SNARE complex formation or membrane fusion upon stimulation.  One 
possible candidate is Munc18b since patients with mutations in Munc18b have blocked 
secretion of all three granules.  This suggests that Munc18b is downstream in the 
secretion pathway and is shared by all three granule release events.   
Other Munc13 family members, DOC2α or granuphilin are candidates for 
possible contributors to the steps required for the residual release of α-granule and 
lysosome content upon loss of Munc13-4.  Granuphilin is a known Rab27 effector; its 
presence in platelets was first identified by using Munc18a/syntaxin-2 complex (Chapter 
4).  The role of granuphilin in platelets has not been investigated.  It will be interesting to 
know whether granuphilin is negatively regulating platelet secretion considering 
deficiency of granuphilin enhances β-cell exocytosis [92].  Future studies should 
determine the mechanism of Rab27 effectors on platelet exocytosis.  One expectation is 
that dense granules contain a specific molecule, such as Rab27, which is important for the 
specific release pathway that it is required for.  Identification of new interacting partners 
that are directly or indirectly associated with Rab27 effectors and the SNARE/Munc18 
complex will help us to dissect the molecular mechanism of vesicle priming. 
 
Endocytosis  
Endocytosis is important for platelet function though it is uncharacterized at the 
molecular level. Several granule cargo proteins are taken up by platelets from plasma via 
an endocytic pathway.  Several mechanisms of endocytosis have been suggested. It has 
been shown that plasma proteins can bind to a platelet surface receptor and subsequently 
be internalized via a clathrin-dependent process.  The best example is uptake of 
fibrinogen via integrin αIIbβ3 [153-157].  The endocytosis of factor V by megakaryocytes 
is through a two-receptor system mediating specific endocytosis by binding to a specific 
factor V receptor and then to the low-density lipoprotein receptor-related protein-1 (LRP-
1) [158].  Some plasma proteins, such as immunoglobulins and albumin, can incorporated 
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into α-granules via pinocytosis [159].  Exploration of endocytosis in platelets will unveil 
a pathway, fusion machinery, and connections to exocytosis.  Our observation that 
platelets from syntaxin-2/4 double KO mice have lower levels of fibrinogen (Figure 3-13) 
supports the notion that there is an endocytosis defect caused by the loss of these two 
syntaxins.  This indicates that syntaxin-2 and -4 may be more important in platelet 
endocytosis than in exocytosis.  Thus the syntaxin-2 and -4 double KO mouse models 
will be an ideal tool to study platelet endocytosis.  It will also be interesting to determine 
whether both pathways share common SNARE proteins.  If they have common SNAREs, 
what other factors coordinate the equilibrium between the two different pathways.  Given 
syntaxin-11 was discovered as an endosomal trafficking t-SNARE [37], we expect that 
syntaxin-11 may be involved in the late stage of endocytosis pathway, for example the 
fusion between late endosome with lysosome.  Alternatively, identification of the tissue 
specific factors that direct syntaxin usage in endocytosis or exocytosis will not only be an 
important biological concept, but may also lead to the discovery of a new therapeutic 
target for cardiovascular diseases.  
 
Hemostasis and Thrombosis  
Platelets play a vital role in hemostasis upon vascular injury.  Damage to 
endothelial cells causes the exposure of agonists, such as collagen and vWF, which 
initiate platelet adhesion and activation.  Activated platelets release granule contents from 
three different types of granules.  Each granule type carries specific molecules that 
promote thrombus formation.  Dense granules contain serotonin, ATP, ADP, and 
calcium, which are important for vascular contraction and thrombogenesis [1, 13].  α-
granules contain many kinds of factors, such as PDGF, VEGF, chemokines, adhesive 
molecules (eg. vWF and fibrinogen), and coagulation factors (eg. Factor v).  These 
factors are not only important for clot stabilization but also play a role in wound repair.  
The released cargo from lysosomes is thought to be involved in fibrinolysis [1, 5].  
Although platelet secretion is essential for hemostasis and thrombosis, little is known 
about the regulatory elements that control it.  Platelet secretory machinery contains three 
core SNAREs and more than four regulatory proteins that control when, where, and how 
SNARE complexes assemble upon stimulation [5, 13, 47, 48, 50, 64].  Deficiency of the 
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primary t-SNARE or v-SNARE results in bleeding problems.  For example, VAMP-8 
null mice form smaller and delayed thrombus [13, 46] while syntaxin-11 and Munc18b 
deficient patients have severe bleeding problems [160].  Loss of regulatory proteins, such 
as Munc18b [50], Munc13-4 [48], and tomosyn-1 [Chapter 4], causes prolonged bleeding 
time and impairs thrombosis formation.  Future studies on how these regulatory proteins 
affect hemostasis and thrombosis beyond the regulation of SNARE complex formation 
might lead to new drug discovery to control thrombosis without damage to normal 
hemostasis. 
 
The Platelet Secretion in FLH Diagnosis 
Hemophagocytic lymphohistiocytosis (HLH) is a rare immune disorder 
characterized by proliferation of cells of the mononuclear phagocyte system (histiocytes) 
and hyperinflammation [161-163].  The typical clinical features include fever, 
hepatosplenomegaly, lymphadenopathy, jaundice, rash, and laboratory findings of 
lymphocytosis, histiocytosis and hemophagocytosis.  This clinical syndrome comprises 
the primary (genetic) HLH and secondary (acquired) HLH.  The genetic HLH can be 
classified as FHL and immune deficient associated HLH, such as Griscelli syndrome 2 
(GS-2), X-linked proliferative syndrome (XLP), Chediak-Higashi syndrome (CHS) 
according to the newest classification [161].  Acquired HLH appears as a severe 
complication of certain virus infection, such as Epstein–Barr virus, of autoimmune 
diseases [161].   
Five FHL (1-5) have been categorized.  FHL1 is associated with a potential gene 
locus (9q21.3-q22) with unidentified specific gene [164].  The perforin gene (PFR1) 
mutations at 10q21-22 locus were described to be the first causative gene for FHL2 
[165].  Perforin is essential for T-cell function and is released from secretory granules 
and is required for delivering granzyme to induce apoptotic death of target cells.  This 
pore-former plays a critical role in maintaining immune homeostasis [166].  Recently 
genes mutated in Munc13-4 (FHL3), Syntaxin-11 (FHL4), and Munc18b (FHL5) have 
been shown to be involved in cytotoxic granule exocytosis from CTL and NK cells [89, 
167, 168].  Concomitantly these gene are also critical for platelet exocytosis and 
deficiency of these proteins cause granule release defects [48, 50] and Chapter 4.  
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Detection of perforin, Munc13-4, syntaxin-11, and Munc18b expression in NK cells with 
FACS or western blotting analysis are reliable methods to screen for FHL2-5.  However, 
these analyses are not available to some patients with extremely reduced NK cell 
numbers.  Compared to NK and CTL, platelets are more abundant.  There are clinically 
established tools to analyze platelet function, such as aggregometry and electron 
microscopy.  Platelet function analysis is a practicable and reliable method to diagnose at 
least FHL3-5.  Combination of platelet function analysis will also provide suggestions for 
the cause of other genetic HLH.  However, it may not apply for acquired HLH. 
Although a consensus set of criteria for diagnosis of HLH was established in 2004 
by the Histiocyte Society and was revised in 2007 [163], diagnosis of HLH is still 
difficult since most criteria are not specific for HLH.  In reality, HLH patients may be 
missed because some initial symptoms are rather nondescript [161], may be disguised as 
a normal infection, or may overlap with some immune deficient disorders.  It is critical to 
find reliable methods to screen early HLH in order to initiate life-saving therapy.   
Based on our study of FHL4 patients with mutations in the syntaxin-11 gene, the 
extent of the platelet secretion defect may be determined by the loss of syntaxin-11.  It 
seems promising that the simple FACS analysis of the intra-platelet syntaxin-11 level 
could be used as a primary screen of patients with bleeding problems to exclude the 
possibility of FHL4 or severe FHL5 cases.  A small amount of whole blood is required 
for the FACS analysis.  Murata et al. [169] have shown that FACS analysis of 
intraplatelet Munc13-4 protein is a sensitive and reliable method to screen for FHL3.  
Here we propose that FACS analysis of platelets may be a good way to rapidly screen for 
three isotypes of FHL: 3, 4, and 5.  This technique is easy to combine with the analysis of 
P-selectin exposure allowing determination of whether there is a secretion defect from α-
granules upon thrombin stimulation.  In addition, almost all medical centers have the 
facility to perform the platelet aggregation and ATP release from dense granules using 
lumi-aggregometry.  Thus analysis of platelets from suspected FHL patients is a simple 
and reliable way to assist in the diagnosis of FHL subtypes and other associated HLH.  If 
platelet function analysis is normal, at least FHL3-5 can be excluded.  Analysis of CTL 
functions, genetic testing, and screening for primary immunodeficiencies such as XLP 
and CHS should be followed.   
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Finally, western blotting analysis of protein level of Munc13-4, Munc18b, 
syntaxin-11, and Rab27 in platelets can confirm the above FACS analysis for FHL 
diagnosis.  Munc13-4 is a 120 kDa cytosolic protein and is expressed much more 
abundantly in platelets than in peripheral blood mononuclear cells (PBMCs) [169].  
Mun18b, a 67 kDa cytosolic protein, is extensively expressed in platelets.  Syntaxin-11 is 
a 35 kDa membrane associated protein.  The maximal platelet number required for 
detection of syntaxin-11 is around 5 × 105, which means around 0.5 µL normal whole 
blood are needed.  Since the different sizes of these proteins are enough to be separated 
from SDS-PAGE, western blotting would be a good method to determine which protein 
is missing.  Although it takes around 6 hours, the results are accurate and reliable.  The 
same membrane could also be probed for Rab27a, which would further provide 
information for screening other genetic causes of HLH.  No more than 1 mL of whole 
blood is required to for western blotting analysis.   
 
Summary 
The work presented here, for the first time, gives a picture of how syntaxin-11 and 
tomosyn-1 are used to mediate platelet exocytosis.  Syntaxin-11 is the primary t-SNARE 
required for platelet exocytosis while syntaxin-2/4 may play a secondary role in the 
absence of syntaxin-11 but not as efficiently as syntaxin-11.  Although the precise 
mechanism of syntaxin-11 function in platelet exocytosis, we can clearly pinpoint that 
syntaxin-11 is an important, core element of the secretory machinery.  The work 
presented elucidates a complete picture of the core secretory machinery in term of which 
isoforms of t- or v-SNARE are required for platelet secretion.  Syntaxin-11, SNAP-23, 
and VAMP-8 are the functional SNARE proteins for platelet exocytosis.  In addition to 
the core SNARE secretory machinery components, a novel syntaxin-binding protein in 
platelets, tomosyn-1 was shown to be required for platelet secretion.  Tomosyn-1 is 
associated with the functional t-SNARE complex, syntaxin-11/SNAP-23 heterodimers.  
Future work will focus on how granule secretion is regulated and how the core machinery 
is coupled to the platelet signaling cascades that are activated by agonists.  The answers 
to these questions will yield a better understanding of the control mechanism of platelet 
exocytosis and give directions for pharmaceutical design.  
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Table 3Table 5-1.  SNAREs and Their Regulators in Human and Murine Platelets 
Table 5-1. SNAREs and Their Regulators in Human and Murine Platelets 
t-SNAREs 
Molecules/Platelet* 
Human Murine 
VAMP-2† <806 7,629 ± 89 
VAMP-3† 4,588 ± 658 3,080 ± 10 
VAMP-7† 3,766 ± 696 2,712 ± 230 
VAMP-8† 6,590 ± 370 8,360 ± 110 
SNAP-23 19,374 ± 5384 5,363 ± 798 
Syntaxin-2 1,579 ± 429 1,766 ± 121 
Syntaxin-4 9,633 ± 75 1,625 ± 184 
Syntaxin-7 3,861 ± 564 3,707 ± 372 
Syntaxin-11 51,717 ± 5459 46,966 ± 5516 
Munc13-4# ND 318 ± 47 
Tomosyn-1 1029  ± 80 1152 ± 46 
 
ND indicates not determined. 
*Number of molecules per platelet was calculated using the molecular weight for VAMP-
2 (13 kDa), VAMP-3 (11 kDa), VAMP-7 (25 kDa), VAMP-8 (12 kDa), SNAP-23 (23 
kDa), Syntaxin-2 (33 kDa), Syntaxin-4 (34 kDa), Syntaxin-7 (30 kDa), Syntaxin-11 (33 
kDa), Munc13-4 (125 kDa), Tomosyn-1 (128 kDa). 
#From Ren at al.[48] 
†From Graham at al. [13] 
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Figure 0-1Figure 5-1.  A Model of Platelet Secretory Machinery 
Figure 5-1. A Model of Platelet Secretory Machinery.  Platelet exocytosis is mediated 
by SNAREs and their regulatory proteins upon physiological stimulation.  The core 
SNARE machinery includes v-SNARE (VAMP) on vesicle membrane and t-SNAREs 
(syntaxin-type and SNAP-25-type) on target membrane.  The primary SNAREs required 
for platelet secretion are VAMP-8 (in blue), syntaxin-11 (in red), and SNAP-23 (in 
green) in platelets.  Munc13-4 (in blue), Munc18b (in purple), tomosyn-1 (in cyan) are 
required for regulation of vesicle priming, probably facilitating fusogenic SNARE 
complex formation, thus leading to membrane fusion and releasing granule contents upon 
stimulation.   
 
 
 
 
 
 
 
 
 
 
Copyright © Shaojing Ye 2012  
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Abbrieviations 
  
5-HT  serotonin (5-hydroxytryptamine) 
ADP adenosine biphosphate  
ATP adenosine triphosphate  
BCA bicinchoninic acid  
β-TG β-thromboglobulin 
DAG diacylglycerol 
DMP dimethyl pimelimidate 
ECF  enhanced chemi-fluorescence 
EGF epidermal growth factor  
ELISA enzyme-linked immunosorbent assay  
FACS fluorescent-activated cell sorting 
FBS fetal bovine serum  
GST Glutathione S-transferase  
FHL3 familial hemophagocytic lymphohistiocytosis type 3  
FHL4 familial hemophagocytic lymphohistiocytosis type 4 
FHL5 familial hemophagocytic lymphohistiocytosis type 5  
FITC fluorescein isothiocyanate 
HPS Hermansky-Pudlak syndrome  
HRP horseradish peroxidase  
HUVEC human umbilical vein endothelial cell  
IP immunoprecipitation 
IP3 inositol tri-phosphate 
IPTG isopropyl-beta-D-thiogalactopyranoside 
LAMP lysosomal associated membrane protein  
LDL low density lipoprotein  
lgl legthal ginat lavea  
LTP long term potential  
MBP maltose binding protein  
MHD munc homolog domain 
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MI myocardial infarction 
MVB multivesicular body 
NK Natural Killer  
NSF N-ethylmaleimide sensitive factor  
OCS Open Canalicular System  
PAGE polyacrylamide gel electrophoresis 
PAR Protease-activated receptor 
PE platelet extract  
PF4 platelet factor IV  
PGI2 prostaglandin I2  
PI3P phosphatidyl inositol tri-phosphate  
PKA protein kinase A 
PKC protein kinase C 
PMA phorbol 12-myristate 13-acetate  
PMSF phenylmethanesulphonylfluoride 
PRP platelet rich plasma  
PVDF polyvinylidene fluoride  
RRP ready releasable pool  
RT room temperature 
SLO streptolysin-O  
Slp synaptotagmin like protein 
SNAP-23 synaptosome-associated protein of 23 kDa 
SNAP-25 synaptosome-associated protein of 25 kDa 
SNARE soluble N-ethylmaleimide-sensitive fusion protein attachment 
protein receptor 
SNP single nucleotide polymorphism  
SPD Storage pool disease 
TCA tricholoracetic acid  
TF tissue factor 
TGN trans-Golgi network  
TIRF total internal reflection fluorescence 
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VEGF vascular endothelial growth factor 
VAMP vesicle associated membrane proteins 
vWF von Willebrand factor  
WPB Weibel-Palade body 
Wt wild-type  
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